Document:

Exhibit 10.6

 

CONFIDENTIAL TREATMENT REQUESTED

UNDER 17 C.F.R. §§ 200.80(b)4, AND 240.24b-2

 

DRUG
DEVELOPMENT AND LICENSE OPTION AGREEMENT

 

BETWEEN

 

ELI
LILLY AND COMPANY

 

AND

 

ISIS
PHARMACEUTICALS, INC.

 

December 2,
2009

 

 

CONFIDENTIAL TREATMENT REQUESTED

UNDER 17 C.F.R. §§ 200.80(b)4, AND 240.24b-2

 

DRUG
DEVELOPMENT AND LICENSE OPTION AGREEMENT

 

THIS DRUG DEVELOPMENT AND
LICENSE OPTION AGREEMENT (the “Agreement”)
executed on December 2, 2009 (the “Effective Date”),
by and between ELI LILLY AND COMPANY, a
corporation organized and existing under the laws of Indiana and its Affiliates
(together, “Lilly”), and ISIS PHARMACEUTICALS, INC., a corporation organized and
existing under the laws of Delaware and its Affiliates (together, “Isis”).

 

RECITALS

 

A.                                   Lilly and Isis
are parties to the Second Amended and Restated Collaboration Agreement dated August 5,
2005 (the “Collaboration Agreement”) to
identify, characterize and/or develop antisense oligonucleotides that modulate
the expression of biological molecules and to characterize the effect of such
modulation to validate gene targets for drug discovery, including antisense
drug discovery;

 

B.                                     Under the
Collaboration Agreement, the Parties conducted research and development on ASO
Compounds directed against eIF-4E, which resulted in the development of the
Product by Lilly;

 

C.                                     Lilly now
wishes to return the eIF-4E Program, including the Product, to Isis so that
Isis may continue developing the Product and the eIF-4E Program;

 

D.                                    In return, Isis
will pay Lilly a technology transfer fee and royalties on the Product and will
grant Lilly an option to later re-acquire a license to the eIF-4E Program,
including the Product on certain pre-defined terms.

 

E.                                      Except for the
return of the eIF-4E Program and the Product to Isis and related matters, this
Agreement is not intended to modify or amend the Collaboration Agreement, which
shall continue in effect following the execution of this Agreement.

 

1

 

CONFIDENTIAL TREATMENT REQUESTED

UNDER 17 C.F.R. §§ 200.80(b)4, AND 240.24b-2

 

AGREEMENT

 

NOW, THEREFORE, in
consideration of the mutual covenants contained in this Agreement, the Parties
agree as follows:

 

ARTICLE 1

 

DEFINITIONS; AMENDMENT AND RESTATEMENT

 

1.1                                 Definitions.  Capitalized terms used in this Agreement,
whether in the singular or plural, have the meanings set forth in
Schedule 1.1 which is attached hereto and made part of this Agreement, or
as otherwise specifically defined in this Agreement.

 

ARTICLE 2

 

TERMINATION OF LILLY’S RIGHTS IN
PRODUCT; TECHNOLOGY TRANSFER

 

2.1                                 Termination.  Lilly’s license and other rights under the
Collaboration Agreement with respect to the eIF-4E Program and the Product are
hereby terminated,
and all rights granted to Lilly under the Collaboration Agreement with respect
to the eIF-4E Program and to the Product are returned to Isis.  Except as specifically stated in this
Agreement: (i) the Collaboration Agreement and any license granted to
Lilly thereunder with respect to any ASO Compounds or ASO Products, in each
case that are not the Product or part of the eIF-4E Program, will remain in
full force and effect, and (ii) neither Lilly nor Isis will have any
further obligation with respect to the eIF4E Program or the Product.

 

2.2                                 Patent Assignment. Lilly hereby assigns and transfers, to
Isis, all of Lilly’s rights, title, and interests in and to the Lilly Product
Patents.  Simultaneously with the
execution of this Agreement, Lilly will execute and deliver a confirmatory
assignment relating to all Lilly Product Patents, in the form of the assignment
attached hereto as Schedule D.

 

2.3                                 Transfer of Records. Lilly and Isis will, promptly following
the Effective Date, agree to and complete an appropriate process for transfer
of information under Lilly’s control (subject to receipt of any necessary Third
Party consents) relating to the eIF-4E Program and the Product that will
include, to the extent practicable and reasonably useful to Isis,  (a) all batch records related to the
Product, including but not limited to corresponding release data; (b) toxicity
and pharmacokinetic data and reports related to the Product; (c) pharmacology
data and reports related to the Product; (d) Product characterization
data, (e) Product stability data; (f) any other records, including,
but not limited to, raw data or interim or final reports, related to the
Product; and (h) all Regulatory Documents, in each case that are in the
possession of Lilly or its Affiliates, or, to the extent Lilly controls the
same, any Third Party engaged by Lilly or any of its Affiliates.  Lilly will use its good faith efforts to
complete such transfer within [***] days following the Effective Date.  Lilly may retain copies of all such materials
for archival purposes.

 

2

 

CONFIDENTIAL TREATMENT REQUESTED

UNDER 17 C.F.R. §§ 200.80(b)4, AND 240.24b-2

 

ARTICLE 3

 

DEVELOPMENT AND
COMMERCIALIZATION; REPORTING

 

3.1                                 Phase I Study. 
Lilly, [***], will use its commercially reasonable efforts to promptly
complete the Ongoing Phase I Study, including but not limited to completing
patient follow-up, data collection, data analyses, summary reports and final
reports.  Lilly will transfer to Isis the
results generated under the Ongoing Phase I Study promptly after they become
available to Lilly from the Third Party vendor assembling such data and
reports, including, but not limited to, raw data, interim and final reports in
a manner consistent with Section 2.3. 
Lilly will use its good faith efforts to (i) send Isis the raw data
collected by Lilly (in the format collected by Lilly) from such Phase I Study
within [***] days following the locking of the primary database for such study,
and (ii) send Isis the clinical summary reports for such Phase I Study
within [***] days following the locking of the primary database for such study.
Except for as provided in Article 4, Lilly shall have no obligation to
conduct any other development activities with respect to the eIF-4E Program or
the Product.

 

3.2                                 Development and Commercialization.

 

3.2.1                        Except for Lilly’s obligation to complete
the Ongoing Phase I Study as set forth in Section 3.1 above, Isis will be
solely responsible (without obligation except as set forth in Section 3.2.2)
for all development and commercialization activities relating to the Product
and the eIF-4E Program; provided, Isis
will not be required to assume any contracts or obligations Lilly has with a
Third Party related to the Product. Within [***] days following the Effective
Date, Isis shall notify Lilly of any Third Party contracts Isis desires to
assume.  Lilly will use its good faith
efforts to assist Isis in assuming such contracts, but will not be obligated to
pay any money or incur any continuing obligation under such contracts.  Lilly shall be free to terminate any contract
that Isis does not assume. Lilly will cooperate with Isis to assign (or
otherwise transfer responsibility) under any Regulatory Document that is
necessary for Isis to conduct the activities described in this Section 3.2;
provided, Lilly will use its good faith efforts to transfer to Isis ownership
of the IND for the Product by [***]. Thereafter, Isis will have the sole right
and responsibility for the preparation of any regulatory filings required in
order to conduct clinical trials on the Product in the Territory, together with
the preparation of suitable applications for marketing approval in the
Territory and will be the owner and party of record of all such regulatory
filings.  All protocols for clinical
trials conducted by Isis prior to the exercise or expiration of the Lilly
option provided for in Section 5.1 shall be approved by the applicable
Institutional Review Board and submitted to the applicable Regulatory
Authority.

 

3.2.2                        Isis will use its commercially reasonable
efforts to conduct at [***]; provided, Isis
may discontinue such development (and will not be required to conduct [***] for
the Product) if at any time Isis in good faith believes that continuing such
development (i) is not warranted because the Product has not demonstrated
[***], or (ii) would pose an unacceptable risk or threat of harm in
humans; or (iii) would violate any applicable law, ethical principles, or
principles of scientific integrity.

 

3

 

CONFIDENTIAL TREATMENT REQUESTED

UNDER 17 C.F.R. §§ 200.80(b)4, AND 240.24b-2

 

3.3                                 Progress Reports. 
Isis will provide Lilly with [***] written reports describing in
reasonable detail the research, development and commercialization activities by
Isis for the Product conducted in the previous [***]. In addition, Isis will
provide Lilly a copy of the final study report for any clinical studies of the
Product within [***] days of the date the same becomes available to Isis.

 

3.4                                 Compliance.  All studies done under this Agreement will be
carried out in compliance with any applicable laws, regulations, or guidelines
governing the conduct of research at the site where such studies are being
conducted.  All animals involved in
studies under this Agreement will be provided humane care and treatment in
accordance with generally acceptable current veterinary practices.

 

ARTICLE 4

 

MANUFACTURING AND SUPPLY

 

4.1                                 Supply of Existing Material.   To the extent the same is available to Lilly
from its existing supplies of manufactured material, Lilly will
supply Isis with up to [***] of the existing API for the Product which was  produced in accordance with cGMP
and is located at Lilly’s facilities as of the Effective Date (“Lilly API”).  Isis agrees to purchase the Lilly API, on the
terms set forth in this ARTICLE 4.  Lilly
will endeavor to [***] on or before [***] (the “[***]”).  Lilly will perform the [***] in accordance
with the [***] attached hereto as Schedule E (the “[***]”).  Lilly will use good faith efforts to update
the [***] within [***] days of the Effective Date to include a [***] timeline
for the [***], including a [***].  Lilly
will update Isis, every [***] (or on a [***] basis if mutually agreed by the
Parties’ quality groups) regarding Lilly’s progress in performing the [***],
and Lilly will immediately notify Isis if Lilly decides to [***].  Notwithstanding the foregoing, Isis, at its
election, will not be required to purchase the material from Lilly if (i) Lilly
has not [***], or if Lilly notifies Isis that Lilly [***], which Lilly may do
if Lilly in good faith concludes that [***]; or (ii) less than [***] grams
of API for the Product is [***]. Lilly makes no representation or warranty that
any particular quantity of the Lilly API will be available or that any of Lilly
API will [***].

 

4.2                                 Transfer
of other Information.  Lilly
will also use its good faith efforts to provide any existing information and
documentation on such Lilly API within Lilly’s control (and subject to receipt
of any necessary Third Party consents) that is requested by Isis and that is
required by, or useful to, regulatory authorities at [***] to Isis, including,
but not limited to: summaries of [***] and all [***] records for the Lilly API,
the information specified in the [***], as well as Lilly’s [***] for the
Product; provided, however, that Lilly will not
be required to create any such documentation for Isis, unless otherwise agreed
by the Parties.  Lilly will also use its
good faith efforts to assist Isis in obtaining information controlled by the
manufacturer (the “Lilly CMO”) of the Lilly
API; and in obtaining the right to [***] of the Lilly CMO.  Except as explicitly provided as part of the
[***], Isis acknowledges that the Lilly API is provided “AS IS,” without any
warranty of any kind, 

 

4

 

CONFIDENTIAL TREATMENT REQUESTED

UNDER 17 C.F.R. §§ 200.80(b)4, AND 240.24b-2

 

express or implied,
including any warranty of merchantability or fitness for a particular purpose.

 

4.3                                 Lilly
API Price.  Isis will
pay Lilly US$[***] per gram (inclusive of all shipping, freight and other
delivery charges, the “API Price”)
for the Lilly API; provided, that
if [***] does not occur by [***], then the API Price will automatically [***]
at the rate of [***] per gram for each [***] day period between the date of the
[***] and the [***].  In addition, if
Lilly does not complete the [***] by [***], then Isis will have the rights
further set forth in [***] of this Agreement and, if applicable [***] of the Form License
Agreement.

 

4.4                                 [***].  If, in Isis’ reasonable opinion, differences
in the [***] in the Lilly API cause Isis to [***], Isis may [***] the [***] of
the [***] against the [***] of the [***]. 
Additionally, if Isis reasonably believes it is necessary to [***] the
[***] to comply with applicable law or satisfy the requirements of any
Regulatory Authority, and such [***] consents to the same, Isis may also offset
[***] of each [***] against the [***] of the [***].  If Isis is entitled to an [***] under this Section 4.4,
but the [***] amount of the [***] for the [***] is less than the amount Isis is
[***] to [***] under this Section 4.4, then, at Isis’ written election,
Lilly will [***] to Isis an [***]of the [***] Isis [***] that is equal to the
[***]. In no event, however, will Lilly be obligated to [***] an [***] greater
than $[***].  Isis will provide Lilly
with reasonable documentation regarding any [***] Isis [***] under this Section 4.4.

 

4.5.          Isis Manufacturing Arrangements. 
Isis shall include in any agreement between Isis and a Third
Party relating to manufacturing process development or manufacture of Product
appropriate provisions to ensure that Isis retains ownership of and access to
all manufacturing know-how or other intellectual property, with the right to transfer
the same to Lilly without cost to Lilly in the event Lilly exercises its option
to acquire rights to the Product.  Isis
shall ensure that any such agreements, to the extent they would extend beyond
the date on which Lilly may exercise its option, are [***] at [***] by Lilly
without [***], and do not contain any terms that would [***] Lilly’s efforts to
manufacture Product following exercise of the Lilly option.

 

ARTICLE 5

 

LILLY OPTION

 

5.1                                 Grant
of Option.  Subject to
the terms and conditions of this Agreement, Isis hereby grants to Lilly an
exclusive (except as permitted by Section 6.1) option to obtain an
exclusive, royalty-bearing license, to develop, make, use, import, offer for
sale and sell the Product, and the ASO Compounds in the eIF4-E Program on the
terms and conditions set forth in the form of license agreement attached hereto
as Schedule A (the “Form License
Agreement”).  During the
term of Lilly’s option under this Section 5.1, Isis shall not grant any
rights in the Product, the ASO Compounds or the eIF4-E Program to any other
person that would be inconsistent with Lilly’s right to exercise such option.

 

5

 

CONFIDENTIAL TREATMENT REQUESTED

UNDER 17 C.F.R. §§ 200.80(b)4, AND 240.24b-2

 

5.2                                 Exercise
of Option.

 

5.2.1              Lilly’s option under Section 5.1
with respect to Products that would require Lilly to pay a license fee and
milestones at Tier 1 Rates under the Form License Agreement is exercisable
at any time before the earlier of (a) [***] for the Product; and (b) the
[***], in accordance with ARTICLE 6 below. 
Lilly’s option under Section 5.1 that would require Lilly to pay a
license fee and milestones at Tier 2 Rates or Tier 3 Rates under the Form License
Agreement is exercisable after Isis has [***] of its planned [***] for the
Product, but before the earlier of (y) the [***] for the Product; and (z) the
[***], in accordance with ARTICLE 6 below. 
Isis will provide Lilly at least [***] days advance written notice of
the Phase III Study Initiation for the Product. 
Isis will provide Lilly with written notice promptly following the date
Isis has [***] of its planned [***] for the Product.

 

5.2.2              Prior to exercising its
option, Lilly may, upon [***] days prior notice to Isis, have access to all
available information regarding the Product, and the eIF-4E Program and access
to Isis personnel so that Lilly conduct a reasonable and customary due
diligence investigation; provided, such diligence is part of Lilly’s good faith
consideration of whether to exercise its option, and such diligence has been
approved in accordance with Lilly’s normal due diligence sanction
procedures.  Lilly may exercise the
option granted pursuant to this ARTICLE 5 by providing written notice to Isis
prior to the option’s expiration.  The
date that Isis timely receives such notice will be deemed the “Option Exercise Notice Date.”  The Form License Agreement will be
deemed granted to Lilly on the Option Exercise Notice Date.

 

5.3                                 Automatic
Termination.  Except as set
forth in Section 5.4 below, If Lilly fails to timely exercise its option
prior to the earlier of (a) the [***] for the Product; and (b) the
[***], in accordance with ARTICLE 6 below, then the option granted under this
ARTICLE 5 will automatically expire and terminate.

 

5.4           Substitute Option.  In
the event (i) Isis discontinues development of Product [***], (ii) Lilly
has not previously exercised its option with respect to Product, and (iii) within
[***] years after the date on which Isis discontinues development of Product,
Isis initiates human clinical trials of any other ASO Compound targeting the
eIF-4E mechanism, Lilly shall have the option to acquire a license to such
other ASO Compound upon the same terms as were applicable to Lilly’s option to
acquire the Product.

 

ARTICLE 6

LILLY RIGHT OF FIRST NEGOTIATION

 

6.1                                 Notwithstanding
Section 5.1 above, once (a) Isis has publicly disclosed the data or a
summary of the results of [***] for the Product; and (b) Isis has complied
with the terms and conditions of the Lilly Right of First Negotiation set forth
below in this ARTICLE 6, then Isis may execute a license with a development and
commercialization partner for the Product and the eIF-4E Program.

 

6

 

CONFIDENTIAL TREATMENT REQUESTED

UNDER 17 C.F.R. §§ 200.80(b)4, AND 240.24b-2

 

6.2                                 Lilly’s Right of First Negotiation. 
Isis hereby grants to Lilly a right of first negotiation (the “Lilly Right of First Negotiation”)
to obtain from Isis an exclusive, worldwide, license to develop and
commercialize the eIF4-E Program, including the Product according to the
provisions set forth in this ARTICLE 6.

 

6.3                                 Once
Isis has publicly disclosed the data or a summary of the results [***] for the
Product, and if Isis intends to [***] of the Product, Isis will so notify Lilly in
writing (the “Isis Notification”).  The Isis Notification will include summaries
of preclinical, toxicological and available clinical data and patent
information of the level of detail included in a Clinical Investigators Brochure.  All information contained in the Isis
Notification or provided pursuant to the due diligence investigation
contemplated by the next sentence will be considered Confidential Information
of Isis and subject to ARTICLE 8 and will be used by Lilly solely for the
purpose of evaluating its interest in exercising its rights under this ARTICLE
6. After receipt of the Isis
Notification, Lilly may, upon [***] days prior notice to
Isis, have access to [***] available information regarding the Product and access
to Isis personnel so that Lilly conduct a customary due diligence
investigation.

 

6.4                                 Within [***] days after receipt of the
Isis Notification (the “Lilly Response Period”),
Lilly will either (i) notify Isis that Lilly is interested in the Product,
including a written proposal of the terms that Lilly intends to form the basis
of a final agreement for the development and commercialization of the Product
(a “Lilly Expression of Interest”); or (ii) exercise
its Product option to the extent permitted under ARTICLE 5 above; or (iii) notify
Isis that Lilly has no interest in the development and commercialization of the
Product.

 

6.5                                 If Lilly provides Isis with a Lilly
Expression of Interest prior to the termination of the Lilly Response Period,
then the Parties will negotiate exclusively in good faith reasonable terms that
are intended to form the basis of a final agreement for a period of up
to [***] days from the date of Lilly’s Expression of Interest.

 

6.6                                 If, (i) Lilly fails to provide Isis
with a Lilly Expression of Interest or exercise its option prior to the
termination of the Lilly Response Period; or (ii) Lilly notifies Isis that
Lilly has no interest in the development and commercialization of the Product;
or (iii) despite good faith negotiations, Lilly and Isis are unable to
reach an agreement by the [***] day following Isis’ receipt of a Lilly
Expression of Interest; then, in each case, Isis will thereafter be free to
develop the Product on its own or execute a license with an alternative
partners with respect to the development and commercialization of the Product; provided, however, that in the event of (iii) of this Section 6.6,
then Lilly shall have a period of [***] days following the [***] day in which
to exercise its option.  If during such
period Lilly does not exercise its option, then Isis may, subject to Section 6.9,  seek an alternative partner, and where Isis
intends to execute a license with an alternative partner, the following
provisions will apply:

 

6.6.1                              milestone
payments and upfront license fees offered by any Third Party and accepted by
Isis for the Product must exceed (on a net present value basis) those set forth
in the Lilly’s last written proposal by [***] percent ([***]%).  The discount rate for the net present value
calculation will be the prime rate published in the Wall Street Journal (print
or Internet addition) at the time of negotiation plus [***] percent
([***]%).  For the 

 

7

 

CONFIDENTIAL TREATMENT REQUESTED

UNDER 17 C.F.R. §§ 200.80(b)4, AND 240.24b-2

 

purpose of calculating net
present value under this Section 6.6 the following timing definitions will
apply: (i) Phase III Study Initiation will be considered to begin [***]
years after the [***] Study Initiation; (ii) Registration Submission will
be considered to occur [***] years from Phase III Study Initiation; and (iii) First
Commercial Sale will be considered to occur [***] year after Registration
submission.

 

6.6.2                              Royalty rates
offered by any Third Party must equal or exceed [***]% multiplied by the
royalty rate set forth in the last written terms offered by Lilly.

 

6.6.3.                           All other terms and conditions of the
third party offer, taken as a whole, are not materially worse than those terms
and conditions offered by Lilly.

 

6.7                                 Isis will [***] the terms of any such
proposed Third Party agreement to [***], and in the event that Lilly in good
faith disputes that such terms meet the requirements of Section 6.6, then
an independent Third Party with the requisite expertise, selected by the
Parties, will make such determination. 
The expense of such independent Third Party will be shared equally by
the Parties.  In the event that any Third
Party terms include non-monetary consideration (e.g., licensing of patent
rights), then such independent Third Party will value such non-monetary
consideration as well as any other terms offered by such Third Party and decide
whether as a whole the Third Party offer exceeds the Lilly offer as set forth
above.

 

6.8                                 If a Third Party offer for the Isis
Product exceeds the last written terms offered by Lilly by the guidelines
outlined in Section 6.6 and is accepted by Isis, Lilly will still be
entitled to receive from Isis the running royalty in accordance with Section 7.2
below.  .

 

6.9                                 If Lilly provides Isis with a timely Lilly
Expression of Interest,
pursuant to Section 6.5, but Isis does not enter into an agreement with
Lilly or reach a mutually agreed-upon term sheet that represents a [***] from a
Third Party approved by an officer of the company of such Third Party with
respect to the development and commercialization of the Product pursuant to the
provisions of Section 6.6 on or before the date Isis publicly announces
[***] or a [***] of [***] of a [***] for the Product (i.e. where Isis has not previously
publicly announced any [***] from such [***]), then the Lilly Right of First
Negotiation with respect to such Product will be revived.  For purposes of clarity, if the Lilly Right
of First Negotiation is not revived under this Section 6.9 because there
was a mutually agreed-upon term sheet that represents a [***] from a Third
Party approved by an officer of the company of such Third Party, then, if the
transaction contemplated by such term sheet is later abandoned by Isis and such
Third Party, then the Lilly Right of First Negotiation will be revived
following the date of such abandonment.

 

6.10                           Notwithstanding the other provisions of
this ARTICLE 6, the Lilly Right of First Negotiation will automatically expire
and terminate upon the exercise or expiration of Lilly’s option under ARTICLE
5.

 

8

 

CONFIDENTIAL TREATMENT REQUESTED

UNDER 17 C.F.R. §§ 200.80(b)4, AND 240.24b-2

 

ARTICLE 7

PAYMENTS AND ACCOUNTING

 

7.1                                 Technology Access Fee.  In consideration for the patent assignment
and technology transfer set forth in Sections 2.2 and 2.3 above, Isis will pay
Lilly $[***] within 5 business days following the Effective Date.

 

7.2                                 Royalties.  Isis will pay to Lilly a royalty equal to
[***]% of the Net Sales of the Product by Isis, its Affiliates or Licensees, on
a country-by-country basis from the date of the First Commercial Sale of the
Product in such country until the expiration of the last to expire claim within
the Product Patents that Covers the [***] of [***] or [***] of [***] of such
Product in such country.  Notwithstanding
the foregoing, if Lilly does not complete the [***] by [***], then Isis will
not be required to pay royalties on the Net Sales of the Product by Isis its
Affiliates or Licensees that occur during the first [***] months following the
First Commercial Sale of the Product.

 

7.3                                 Third Party Royalty Obligations.  Isis shall be responsible for payment of all
third party royalty and other financial obligations with respect to sales of
Product under any present or future license arrangements, unless such
obligations were created by Lilly.

 

7.4                                 Accounting Reports; Payment of Royalty.  Isis (including its Affiliates) and its
Licensees under the Product Patents will keep complete and accurate books and
records which may be necessary to ascertain properly and to verify the payments
owed hereunder.  Isis will make royalty
payments to Lilly for Products sold by Isis, its Affiliates and Licensees
during the Calendar Quarter within ninety (90) days of the last day of that
Calendar Quarter.  Each royalty payment
will be accompanied by a written report for that Calendar Quarter showing the
Net Sales of the Product sold by Isis, worldwide during the quarterly reporting
period and the calculation of the royalties payable under this Agreement.

 

7.5                                 Audits.  Upon Lilly’s written request, and not more
than once in each Calendar Year, Isis will permit Lilly’s independent certified
public accountant to have access during normal business hours to such of Isis’
records as may be reasonably necessary to verify the accuracy of the royalty
reports hereunder for the current year and the preceding [***] years prior to
the date of such request.  Lilly will
submit an audit plan, including audit scope, to Isis for Isis’ approval, which
will not be unreasonably withheld, prior to audit implementation.  The independent certified public accountants
will keep confidential any information obtained during such inspection and will
report to Lilly only the amounts of Net Sales and royalties due and
payable.  Upon the expiration of [***]
years following the end of any Calendar Year, the calculation of royalties
payable with respect to such year will be binding and conclusive upon Lilly,
and Isis and its Affiliates and Licensees will be released from any liability
or accountability with respect to royalties for such year.  If such accounting firm concludes that
additional royalties were owed, or that Isis overpaid royalties, during such
period, Isis will pay the additional royalties, or Lilly will return any
overpaid royalties, within ninety (90) days of the date Lilly delivers to Isis
such accounting firm’s written report. 
The fees charged by such accounting firm will be paid by Lilly unless
the additional royalties owed by Isis exceed [***] percent ([***]%) of the
royalties paid for the royalty period subject to the audit, in which case Isis
will pay the reasonable fees of the accounting firm.  Isis will include in each license granted by
it under the Product Patents a provision requiring the Licensee to make [***]
to Isis, to [***] and [***] records of sales made pursuant to such license and
to [***] to such records by a mutually agreed upon [***] to the same extent

 

9

 

CONFIDENTIAL TREATMENT REQUESTED

UNDER 17 C.F.R. §§ 200.80(b)4, AND 240.24b-2

 

required of Isis under this
Agreement.  Lilly will treat all
financial information subject to review under this Section 7.5 or under
any license agreement in accordance with the confidentiality provisions of this
Agreement, and will cause its accounting firm to enter into an acceptable
confidentiality agreement with Isis obligating such firm to retain all such
financial information in confidence pursuant to such confidentiality agreement.

 

7.6                                 Payment.  All payments to Lilly under this Agreement
will be made in United States Dollars by bank wire transfer in next day
available funds to such bank account in the United States designated in writing
by Lilly from time to time. Isis will pay a late payment service charge of
[***]% per month (or the highest amount allowed by law, if lower than [***]%)
on all past-due amounts owed by Isis under this Agreement.

 

7.7                                 Income Tax Withholding.  Lilly will be responsible for its own tax
liabilities resulting from the payments received from Isis under this
Agreement.  If laws, rules or
regulations require withholding of income taxes or other taxes imposed upon
payments set forth in this ARTICLE 7, Isis will make such withholding
payments as required and subtract such withholding payments from the payments
set forth in this ARTICLE 7.  Isis will
submit appropriate proof of payment of the withholding taxes to Lilly within a
reasonable period of time.

 

ARTICLE 8

 

CONFIDENTIALITY

 

8.1                                 Nondisclosure and Nonuse Obligations.  All Confidential Information disclosed by one
Party to the other Party hereunder will be maintained in confidence and will
not be disclosed to any Third Party or used for any purpose except as expressly
permitted herein without the prior written consent of the other Party.

 

8.2                                 Permitted Disclosure of Confidential Information.  Notwithstanding Section 8.1, a Party may
disclose Confidential Information of the other Party as follows:

 

8.2.1                        to appropriate U.S. and/or foreign tax
authorities, appropriate patent agencies in order to obtain Patent Rights
pursuant to this Agreement, appropriate Regulatory Authorities to gain approval
to conduct clinical trials or to market Products pursuant to this Agreement,
but such disclosure, may be only to the extent reasonably necessary to obtain
such Patent Rights, authorizations or approvals;

 

8.2.2                        if required by any governmental authority
other than under Section 8.2.1, provided that prior to such disclosure,
the Party subject to the request for such disclosure (the “Notifying
Party”) promptly notifies the other Party of such requirement so
that such other Party may seek a protective order or other appropriate remedy;
and provided, further, that in the event
that no such protective order or other remedy is obtained, or that such other
Party waives compliance with this ARTICLE 8, the Notifying Party will
furnish only that portion of the other Party’s Confidential Information that it
is advised by counsel it is legally required to furnish and will exercise all
reasonable efforts to obtain reasonable assurance that 

 

10

 

CONFIDENTIAL TREATMENT REQUESTED

UNDER 17 C.F.R. §§ 200.80(b)4, AND 240.24b-2

 

confidential treatment
will be accorded the other Party’s Confidential Information so furnished;

 

8.2.3                        by a Party to its permitted Licensees,
agents, consultants, Affiliates and/or other Third Parties for the research and
development, manufacturing and/or marketing of the Product (or for such Parties
to determine their interest in performing such activities) in accordance with
this Agreement on the condition that such Affiliates and Third Parties agree to
be bound by the confidentiality and non-use obligations contained in this
Agreement; or

 

8.2.4                        if required to be disclosed by law or
court order, provided that notice is promptly delivered to the non-disclosing
Party in order to provide an opportunity to challenge or limit the disclosure
obligations.

 

ARTICLE 9

 

DISCLAIMERS, REPRESENTATIONS,
WARRANTIES AND INDEMNIFICATIONS

 

9.1                                 Lilly Representations and Warranties.  Lilly represents and warrants to Isis as
follows:

 

9.1.1                        Corporate Existence and
Authority.  As of the Effective Date, Lilly:  (a) is a corporation duly organized,
validly existing and in good standing under the laws of the state in which it
is incorporated; (b) has full corporate power and authority and the legal
right to own and operate its property and assets and to carry on its business
as it is now being conducted and as contemplated in this Agreement, including
the right to grant the patent assignments and transfer the technology
hereunder; (c) has the corporate power and authority and the legal right
to enter into this Agreement and perform its obligations hereunder; (d) has
taken all necessary corporate action on its part required to authorize the
execution and delivery of the Agreement and the performance of its obligations
hereunder; and (e) has delivered an Agreement that has been duly executed
and constitutes a legal, valid, binding obligation of Lilly and is enforceable
against it in accordance with its terms;

 

9.1.2                        Patents, Prior Art. 
As of the Effective Date and to the best of Lilly’ knowledge, it has the
sufficient legal and/or beneficial title and ownership under the Lilly Product
Patents as is necessary to grant the patent assignments to Isis pursuant to
this Agreement;

 

9.1.3                        Absence of Litigation,
Infringement, Misappropriation.  As of the
Effective Date and to the best of Lilly’ knowledge, there is no pending
litigation against Lilly (nor has Lilly received any written communication)
which alleges that Lilly’ activities in developing the Product have or would
infringe or misappropriate any intellectual property rights of any Third Party;

 

9.1.4                        Third Party Obligations. 
As of the Effective Date, Lilly is not a party to an agreement with a
Third Party that requires the payment of any royalty or other financial
obligations with respect to sales of Product;

 

11

 

CONFIDENTIAL TREATMENT REQUESTED

UNDER 17 C.F.R. §§ 200.80(b)4, AND 240.24b-2

 

9.1.5                        Compliance with Laws. 
In carrying out its work under this Agreement, all Lilly work will be
carried out in compliance with any applicable laws including, without
limitation, federal, state, or local laws, regulations, or guidelines governing
the work at the site where such work is being conducted.  Moreover, Lilly will carry out all work under
this Agreement in accordance with current Good Laboratory Practices, Good
Clinical Practices, and Good Manufacturing Practices, if applicable based on
the specific work to be conducted;

 

9.1.6                        No Debarment. 
Lilly will comply at all times with the provisions of the Generic Drug
Enforcement Act of 1992 and will upon request certify in writing to Isis that
none of its employees nor any person who developed the Product on Lilly’s
behalf have been debarred under the provisions of such Act;

 

9.1.7                        Lilly Patents. 
To the best of Lilly’ knowledge, Lilly does not control any Patent
(other than the Lilly Product Patents) that would be infringed by making, using
or selling the Product in any country.

 

9.1.8                        No Warranty of Validity or Non-Infringement.
Notwithstanding any provision of this Agreement to the contrary, Lilly makes no
representation or warranty that any of the Lilly Product Patents is valid or
that development or sale of the Product would not infringe the rights of any
other person.

 

9.2                                 Isis Representations and Warranties. 
Isis represents and warrants to Lilly as follows:

 

9.2.1                        Corporate Existence and Authority. 
As of the Effective Date, Isis:  (a) is
a corporation duly organized, validly existing and in good standing under the
laws of the state in which it is incorporated; (b) has full corporate
power and authority and the legal right to own and operate its property and
assets and to carry on its business as it is now being conducted and as
contemplated in this Agreement; (c) has the corporate power and authority
and the legal right to enter into this Agreement and perform its obligations
hereunder; (d) has taken all necessary corporate action on its part
required to authorize the execution and delivery of the Agreement and the
performance of its obligations hereunder; and (e) has delivered an
Agreement that has been duly executed and constitutes a legal, valid, binding
obligation of Isis and is enforceable against it in accordance with its terms;

 

9.2.2                        Employee Obligations. 
All Isis personnel who will conduct research under this Agreement have
legal obligations requiring assignment to Isis of all inventions made in the
course of and as a result of their association with Isis and obligating the
individual to maintain as confidential the confidential information of Isis, as
well as the confidential information of Lilly which Isis may receive;

 

9.2.3                        Compliance with Laws. 
In carrying out its work under this Agreement, all Isis work will be
carried out in compliance with any applicable laws including, without
limitation, federal, state, or local laws, regulations, or guidelines governing
the work at the site where such work is being conducted.  Moreover, Isis will develop and commercialize
the Product under this Agreement in accordance with current Good Laboratory
Practices, Good 

 

12

 

CONFIDENTIAL TREATMENT REQUESTED

UNDER 17 C.F.R. §§ 200.80(b)4, AND 240.24b-2

 

Clinical Practices, Good Manufacturing Practices, if
applicable based on the specific work to be conducted;

 

9.2.4                        No Debarment. 
Isis will comply at all times with the provisions of the Generic Drug
Enforcement Act of 1992 and will upon request certify in writing to Lilly that
none of its employees nor any person providing services to Isis in connection
with the development or commercialization of the Product have been debarred
under the provisions of such Act; and

 

9.2.5                        Licenses. 
Isis has not taken nor will it take any action which would, in Isis’s
good faith judgment, interfere with any obligations of Isis set forth in this
Agreement, including but not limited to the obligation to grant Lilly the
licenses and options described in ARTICLEs 5 and 6.

 

9.3                                 Disclaimer.  EXCEPT AS EXPRESSLY SET FORTH IN THIS
AGREEMENT, NEITHER PARTY MAKES ANY REPRESENTATION OR WARRANTY TO THE OTHER
PARTY OF ANY KIND, EXPRESS OR IMPLIED, INCLUDING, WITHOUT LIMITATION, ANY
WARRANTY OF NON-INFRINGEMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR
PURPOSE.  Without limiting the generality
of the foregoing, each Party expressly does not warrant (a) the success of
any Product; or (b) the safety for any purpose of the technology it provides
hereunder.

 

9.4                                 Responsibility and Control.  Lilly and Isis will each be solely
responsible for the safety of their respective employees, agents, licensees or
(sub)licensees with respect to efforts employed under this Agreement and each
will hold the other harmless with regard to any liability for damages or
personal injuries resulting from acts of its respective employees, agents, or
(sub)licensees in accordance with the indemnification provision set forth in
Sections 9.5 through
9.7.

 

9.5                                 Lilly’ Right to Indemnification.  Isis will indemnify each of Lilly, its
Affiliates, permitted successors and assigns, and the directors, officers,
employees, agents and counsel thereof (the “Lilly Indemnitees”),
and defend and hold each Lilly Indemnitee harmless from and against any and all
liabilities, damages, losses, settlements, claims, actions, suits, penalties,
fines, costs or expenses (including, without limitation reasonable attorneys’
fees) (any of the foregoing, “Damages”)
incurred by or asserted against any Lilly Indemnitee of whatever kind or
nature, including, without limitation, any claim or liability based upon
negligence, warranty, strict liability, or violation of government regulation
but only to the extent arising from or occurring as a result of a claim or
demand made by a Third Party (a “Third Party Claim”)
against any Lilly Indemnitee arising because of: (a) breach of any
representation or warranty made by Isis pursuant to this ARTICLE 9; (b) any
material breach of this Agreement by Isis; (c) the manufacture, use,
handling, storage, sale or other disposition of the Product that is sold or
provided by Isis, its Affiliates, agents or Licensee; and/or (d) violation
of the trade secrets of any Third Party by Isis; except,
in each such case in subparagraphs (a) through (d) above, to the
extent that such Damages are finally determined to have resulted from the
negligence or misconduct of an Lilly Indemnitee, or the breach of any
representation or warranty under Section 9.1 by Lilly.

 

13

 

CONFIDENTIAL TREATMENT REQUESTED

UNDER 17 C.F.R. §§ 200.80(b)4, AND 240.24b-2

 

9.6                                 Isis’s Right to Indemnification.  Lilly will indemnify each of Isis, its
Affiliates, Licensees, successors and assigns, and the directors, officers,
employees, agents and counsel thereof (the “Isis Indemnitees”),
and defend and hold each Isis Indemnitee harmless from and against any and all
Damages incurred by or asserted against any Isis Indemnitee of whatever kind or
nature, including, without limitation, any claim or liability based upon
negligence, warranty, strict liability, violation of government regulation but
only to the extent arising from or occurring as a result of a Third Party Claim
against any Isis Indemnitee arising because of: (a) breach of any
representation or warranty made by Lilly pursuant to this Article 9; (b) any
material breach of this Agreement by Lilly; and/or (c)  violation of the
trade secrets of any Third Party by Lilly; except, in each such case, in
subparagraphs (a) through (c) above, to the extent that such Damages
are finally determined to have resulted from the negligence or misconduct of a
Isis Indemnitee, or the breach of any representation or warranty under Section 9.2
by Isis.

 

9.7                                 Indemnification Procedures.  Promptly after a Party entitled to
indemnification under Section 9.5 or 9.6 (an “Indemnitee”)
receives notice of any pending or threatened claim against it (an “Action”), such Indemnitee will give
written notice to the Party to whom the Indemnitee is entitled to look for
indemnification pursuant to Section 9.5 or 9.6, as applicable (the “Indemnifying Party”), of the
commencement thereof, provided that
the failure so to notify the Indemnifying Party will not relieve it of any
liability that it may have to any Indemnitee hereunder, except to the extent
the Indemnifying Party demonstrates that it is prejudiced thereby.  In case any Action that is subject to
indemnification under this ARTICLE 9, will be brought against an
Indemnitee and it will give written notice to the Indemnifying Party of the
commencement thereof, the Indemnifying Party will be entitled to participate
therein and, if it so desires, to assume the defense thereof with counsel
reasonably satisfactory to such Indemnitee and, after notice from the Indemnifying
Party to the Indemnitee of its election to assume the defense thereof, the
Indemnifying Party will not be liable to such Indemnitee under this
ARTICLE 9 for any fees of other counsel or any other expenses, in each
case subsequently incurred by such Indemnitee in connection with the defense
thereof, other than reasonable costs of investigation.  Notwithstanding an Indemnifying Party’s
election to assume the defense of any such Action that is subject to
indemnification under this ARTICLE 9, the Indemnitee will have the right
to employ separate counsel and to participate in the defense of such Action,
and the Indemnifying Party will bear the reasonable fees, costs and expenses of
such separate counsel if:  (i) the
use of counsel chosen by the Indemnifying Party to represent the Indemnitee
would present such counsel with a conflict of interest; or (ii) the actual
or potential defendants in, or targets of, any such Action include both the
Indemnifying Party and the Indemnitee, and the Indemnitee will have reasonably
concluded that there may be legal defenses available to it which are different
from or additional to those available to the Indemnifying Party (in which case
the Indemnifying Party will not have the right to assume the defense of such
Action on the Indemnitee’s behalf); or (iii) the Indemnifying Party will
not have employed counsel satisfactory to the Indemnitee to represent the
Indemnitee within a reasonable time after notice of the institution of such
Action; or (iv) the Indemnifying Party will authorize the Indemnitee to
employ separate counsel at the Indemnifying Party’s expense.  If an Indemnifying Party assumes the defense
of such Action, no compromise or settlement thereof may be effected by the
Indemnifying Party without the Indemnitee’s written consent, which consent will
not be unreasonably withheld or delayed, unless (1) there 

 

14

 

CONFIDENTIAL TREATMENT REQUESTED

UNDER 17 C.F.R. §§ 200.80(b)4, AND 240.24b-2

 

is no finding or admission
of any violation of law or any violation of the rights of any other Party and
no effect on any other claims that may be made against the Indemnitee and (2) the
sole relief provided is monetary damages that are paid in full by the
Indemnifying Party.

 

ARTICLE 10

 

INTELLECTUAL PROPERTY

 

10.1                           Patent Filing and Prosecution.  Isis (at its own expense) will be responsible
for preparing, filing, prosecuting, maintaining and taking such other actions
as are reasonably necessary or appropriate with respect to the Product
Patents.  Isis will keep Lilly
continuously informed of all significant matters relating to the preparation,
filing, prosecution and maintenance of the Product Patents. In the event Isis
proposes to abandon the prosecution or maintenance of any Product Patent, it
shall notify Lilly at least [***] days in advance and allow Lilly to assume the
prosecution and maintenance of such patent at Lilly’s expense.

 

10.2                           Patent Term Extensions.  The Parties will cooperate with each other in
gaining patent term extension wherever applicable to any Product.  The Party selling such Product will determine
which patents will be extended.  All
filings for such extension will be made by the Party to whom the patent is
assigned; provided, however, that in the event
that the Party to whom the patent is assigned elects not to file for an
extension, such Party will (i) inform the other Party of its intention not
to file; (ii) grant the other Party the right to file for such extension;
and (iii) cooperate as necessary to assist the other Party in filing such
extension.

 

10.3                           Notice of Certification.  Isis and Lilly each will immediately upon
receiving notice give notice to the other of any certification filed under the
U.S. “Drug Price Competition and Patent Term Restoration Act of 1984” claiming
that (a) Product Patent Covering the Product, is invalid or that any
infringement will not arise from the manufacture, use, sale, offer for sale or
import of any product by a Third Party.

 

10.4                           Notice of Infringement Claim.  If the development or commercialization of a
Product under this Agreement results in a claim against a Party for patent
infringement or for inducing or contributing to patent infringement (“Infringement Claim”), the Party
first having notice of an Infringement Claim will promptly notify the other in
writing.  The notice will set forth the
facts of the Infringement Claim in reasonable detail.

 

10.5                           Responsibilities. 
Isis will have the sole right to control any defense of any Infringement
Claim involving alleged infringement of Third Party rights by Isis’ activities
at its own expense and by counsel of its own choice, and Lilly will have the
right, at its own expense, to be represented in any such action by counsel of
its own choice.  Lilly will have the sole
right to control any defense of any Infringement Claim involving alleged
infringement of Third Party rights by Lilly’s activities at its own expense and
by counsel of its own choice, and Isis will have the right, at its own expense,
to be represented in any such action by counsel of its own choice.  Notwithstanding the foregoing, if the claim
involves an allegation of a violation of the trade secret rights of a Third
Party, the Party accused of such 

 

15

 

CONFIDENTIAL TREATMENT REQUESTED

UNDER 17 C.F.R. §§ 200.80(b)4, AND 240.24b-2

 

violation will have the
obligation to defend against such claim and will indemnify the other Party
against all costs associated with such claim in accordance with Sections 9.5
through 9.7, as applicable.  Lilly will
not settle any patent infringement litigation under this Section 10.5
relating to any Product Patents without Isis’ consent.  Isis will not settle any patent infringement
litigation under this Section 10.5 relating to any Product Patents without
Lilly’s consent, if such settlement would materially impair the rights granted
to Lilly under Section 5.1, or would impose an obligation on Lilly.  Each Party will also keep the other Party
continually informed of all significant matters relating to Infringement Claims
of Third Parties.

 

10.6                           Infringement Claims Against Third Parties.

 

10.6.1                  Notice of Infringement. 
If any Product Patent is infringed or misappropriated, as the case may
be, by a Third Party, the Party to this Agreement first having knowledge of
such infringement or misappropriation, will promptly notify the other in
writing.  The notice will set forth the
facts of such infringement or misappropriation in reasonable detail.  Isis will have the primary right, but not the
obligation, to institute, prosecute, and control any action or proceeding with
respect to infringement or misappropriation of such Product Patent by its own
counsel.  Lilly will have the right, at
its own expense, to be represented in such action by its own counsel.  Except as otherwise agreed to by the Parties
in writing as part of a cost-sharing arrangement, any recovery realized as a
result of such litigation, after reimbursement of any litigation expenses of
Lilly and Isis, will be retained by Isis, except that any recovery realized by
Isis as a result of such litigation, after reimbursement of the Parties’
litigation expenses, will, to the extent attributable to [***] or be treated as
[***] of Products by Isis.

 

10.6.2                  Expenses of Bringing Infringement
Action.  Isis will bear the costs and expenses of all
infringement or misappropriation actions asserted against a Third Party on
Product Patents.

 

ARTICLE 11

 

TERM AND TERMINATION

 

11.1                           Term of Agreement.  This Agreement will commence on the Effective
Date and will continue until no payments are due or are capable of becoming due
hereunder, unless the Agreement is terminated earlier. All licenses granted
hereunder that are in effect at expiration of this Agreement will be deemed
fully paid-up and perpetual, except as provided otherwise by this Agreement.

 

11.2                           Termination for Breach.  Either Party may terminate this Agreement by
notice to the other Party at any time during the term of this Agreement if the
other Party is in breach of any material obligations hereunder and has not
cured such breach within [***] days after notice requesting cure of the breach
or such longer period of time as is required to cure such breach as long as the
breaching Party is proceeding in good faith to cure; provided,
however, that in any case when a breach is alleged regarding the
payment of money hereunder, the time period will be [***] days and undisputed
amounts must be paid prior to 

 

16

 

CONFIDENTIAL TREATMENT REQUESTED

UNDER 17 C.F.R. §§ 200.80(b)4, AND 240.24b-2

 

such
time to avoid breach.  Upon material
breach by a Party of its obligations hereunder, if the non-breaching Party
decides not to terminate this Agreement, such Party will have the right to
[***] any [***] it may incur as a result of curing such breach [***] the
amounts [***] to the [***] for the performance of [***].  Further, to the extent that a Party prevails
in a lawsuit brought against the other Party for material breach of this
Agreement, such prevailing Party will be entitled to collect from the other
Party reasonable attorneys’ fees and legal costs incurred in connection with
such law suit. If the non-breaching Party terminates this Agreement under Section 11.2
following material breach by the breaching Party, the breaching Party will
return to the non-breaching Party all of the non-breaching Party’s Confidential
Information and all materials received from the non-breaching Party during the
Agreement, and the breaching Party will cease all use of the non-breaching Party’s
Confidential Information and materials received from the non-breaching Party
for any purpose except as provided in Sections 11.6, and except that the
breaching Party may (1) keep a copy of all documents for record keeping
purposes only and (2) keep and use any Confidential Information and
materials received from the non-breaching Party that are necessary for the
breaching Party to exercise those of its rights and fulfill those of its
obligations that survive the termination of this Agreement.

 

11.3                           Termination Upon Insolvency.  Either Party may terminate this Agreement
upon notice to the other should the other Party become insolvent or file or
consent to the filing of a petition under any bankruptcy or insolvency law or
have any such petition filed against it which has not been stayed within sixty
(60) days of such filing.  During the
term of this Agreement, all rights and options or licenses granted under or
pursuant to this Agreement by Isis or Lilly are, and will otherwise be deemed
to be, for purposes of Section 365(n) of the U.S. Bankruptcy Code,
licenses of right to “intellectual property” as defined under Section 101
of the U.S. Bankruptcy Code.  The Parties
agree that, during the term of this Agreement, the Parties, as licensees of
such rights under this Agreement, will retain and may fully exercise all of
their rights and elections under the U.S. Bankruptcy Code.  The Parties further agree that, in the event
of the commencement of a bankruptcy proceeding-by or against either Party under
the U.S. Bankruptcy Code, the Party hereto that is not a party to such
proceeding will be entitled to a complete duplicate of (or complete access to,
as appropriate) any such intellectual property and all embodiments of such
intellectual property, and same, if not already in their possession, will be
promptly delivered to them (i) upon any such commencement of a bankruptcy
proceeding upon their written request therefor, unless the Party subject to
such proceeding elects to continue to perform all of its obligations under this
Agreement; or (ii) if not delivered under (i) above, following the
rejection of this Agreement by or on behalf of the Party subject to such
proceeding upon written request therefor by the non-subject Party.

 

11.4                           Effect of Termination Due to Isis Breach or
Insolvency.  If Lilly
terminates the Agreement based on material breach by or insolvency of Isis,
then:

 

11.4.1                  Solely in the event Isis materially breaches its
obligation under [***] (or termination by Lilly under Section 11.3 before
Isis has met its obligation under [***]), the option granted by Isis to Lilly
pursuant to ARTICLE 5 prior to such termination, will survive, but the [***]
and the amount of each [***] that would otherwise be payable under 

 

17

 

CONFIDENTIAL TREATMENT REQUESTED

UNDER 17 C.F.R. §§ 200.80(b)4, AND 240.24b-2

 

the Form License
Agreement upon exercise of the option shall be reduced by [***] percent
([***]%);

 

11.4.2                  Isis’s payment obligations set forth in ARTICLE 7
will continue; provided, however, that the
amounts of the payments will be increased to reflect the nature of Isis’s
breach and the damages caused thereby by amounts to be agreed upon by the
Parties or, if the Parties are unable to reach agreement, by an independent
Third Party with the requisite expertise selected by the Parties, the expense
of which will be borne by Isis;

 

11.4.3                  Any license granted by Isis to Third Party under the
Product Patent Rights will continue in full force and effect but the right to
collect and receive the royalties under ARTICLE 7 will be assigned by Isis to
Lilly, and Isis will provide Lilly with complete and accurate copies of the
relevant portions of the license agreement within thirty (30) days following
the effective date of such termination;

 

11.5                           Effect of Termination Due to Lilly Breach or
Insolvency.  If Isis
terminates the Agreement based on material breach by or insolvency of Lilly,
then:

 

11.5.1                  The assignment and technology transfer granted by
Lilly to Isis pursuant to Sections 2.2 and 2.3 will survive;

 

11.5.2                  Lilly’s option and Right of First Negotiation granted
by Isis pursuant to ARTICLE 5 and 6 will terminate;

 

11.5.3                  Isis’ payment obligations set forth in ARTICLE 7
will continue, provided, however, that the
amounts of the payments will be decreased to reflect the nature of Lilly’s
breach and the damages caused thereby by amounts to be agreed upon by the
Parties or, if the Parties are unable to reach agreement, by an independent
Third Party with the requisite expertise selected by the Parties, the expense
of which will be borne by Lilly;

 

11.6                           Accrued Rights/Surviving Obligations.  Except as expressly provided in this
Agreement, expiration or termination of this Agreement will not relieve the
Parties of any obligation that accrued prior to such expiration or termination,
and Isis will be obligated to pay and will pay to Lilly, within [***] days of
such expiration or termination, all payments and royalties due or accrued
pursuant to the terms of ARTICLE 7. 
Upon expiration or early termination of this Agreement, all rights and
obligations of the Parties will cease, except as follows:

 

11.6.1                  The obligations to pay royalties and other sums
accruing hereunder up to the date of termination or expiration will survive;

 

11.6.2                  The obligations of confidentiality set forth in
ARTICLE 8 will survive any expiration or termination of this Agreement for a
period of five (5) years;

 

11.6.3                  The obligations for record keeping and accounting
reports set forth in ARTICLE 7 will survive for so long as Products are
sold.  At such time after termination or
expiration of this Agreement when sales or other dispositions of Products have
ceased, Isis will render a final report along with any royalty payment due;

 

18

 

CONFIDENTIAL TREATMENT REQUESTED

UNDER 17 C.F.R. §§ 200.80(b)4, AND 240.24b-2

 

11.6.4                  The termination under Section 2.1 will survive
any termination or expiration of the Agreement;

 

11.6.5                  Lilly and Isis’ rights to inspect books and records as
described in ARTICLE 7 will survive;

 

11.6.6                  The obligations of defense and indemnity set forth in
ARTICLE 9 will survive;

 

11.6.7                  Any cause of action or claim of Lilly or Isis accrued
or to accrue because of any breach or default by the other Party hereunder will
survive; and

 

11.6.8                  All other terms, provisions, representations, rights
and obligations contained in this Agreement that are intended to survive as
specifically set forth elsewhere in this Agreement will survive.

 

11.7                           Limitation of Liability.  No Party will be liable to another for
indirect, incidental, consequential or special damages, including but not
limited to lost profits, arising from or relating to any breach of this
Agreement, regardless of any notice of the possibility of such damages.  Nothing in this Section is intended to
limit or restrict the indemnification rights or obligations of any Party under
ARTICLE 9.

 

ARTICLE 12

 

PUBLICITY

 

12.1                           Press Release.  Upon execution of this Agreement, the Parties
shall issue a joint press release announcing the existence of this Agreement in
a form and substance agreed to in writing by the Parties.

 

12.2                           Disclosure of Agreement.  Neither Party to this Agreement may release
any information to any Third Party regarding the terms or existence of this
Agreement or the reasons for any termination hereof, without the prior written
consent of the other Party.  Without
limitation, this prohibition applies to press releases, educational and
scientific conferences, quarterly investor updates, promotional materials,
governmental filings and discussions with public officials, the media, security
analysts and investors.  However, this
provision does not apply to any disclosures regarding this Agreement or related
information to regulatory agencies such as the FDA or Federal Trade Commission
and/or Department of Justice for such disclosures which may be required by law,
including requests for a copy of this Agreement or related information by tax
authorities.  If any Party to this
Agreement determines a release of information regarding the existence or terms
of this Agreement is required by law (including releases a may be required to
be filed through the Securities Exchange Commission or other government
agency), that Party will notify the other Party as soon as practicable and give
as much detail as possible in relation to the disclosure required.  The Parties will then cooperate with respect
to determining what information should actually be released.  The Parties hereby agree that release of a
press release upon complete execution of this Agreement is appropriate and such
press release will be mutually agreed upon by the Parties.

 

19

 

CONFIDENTIAL TREATMENT REQUESTED

UNDER 17 C.F.R. §§ 200.80(b)4, AND 240.24b-2

 

12.3         Use of Names, Logos or Symbols.  No Party hereto will use the name,
trademarks, logos, physical likeness, employee names or owner symbol of any
other Party for any purpose, including, without limitation, private or public
securities placements, without the prior written consent of the affected Party,
such consent not to be unreasonably withheld or delayed so long as such use of
name is limited to objective statements of fact, rather than for endorsement
purposes.  Nothing contained herein will
be construed as granting either Party any rights or license to use any of the
other Party’s trademarks or tradenames without separate, express written
permission of the owner of such trademark or tradename.

 

12.4         Publication. Lilly shall have the right
to publish the results of the Ongoing Phase I Study; provided,
Lilly will coordinate such publication with Isis, including giving Isis at
least 5 Business Days in advance of such proposed public disclosure to review
and comment on such publication. Isis may publish, present or otherwise
disclose results regarding the Product to the public at its sole discretion; provided, however, so long as Lilly’s option under ARTICLE 5
has not expired or terminated, Isis will share with Lilly any press release or
other similar public communication made by Isis that is related to a Product’s
efficacy or safety data and/or results at least 5 Business Days in advance of
such proposed public disclosure.  Unless
Lilly exercises its option under ARTICLE 5, Lilly will not publicly present or
otherwise disclose results regarding the Product without obtaining Isis’ prior
written consent, such consent not to be unreasonably withheld.

 

ARTICLE 13

 

MISCELLANEOUS

 

13.1         Force Majeure.  No Party will be held liable or responsible
to the other Party nor be deemed to have defaulted under or breached the
Agreement for failure or delay in fulfilling or performing any term of the
Agreement (except payment obligations) when such failure or delay is caused by
or results from causes beyond the reasonable control of the affected Party
including, but not limited to, fire, flood, earthquake, embargo, war, acts of
war or terrorism (whether war be declared or not), insurrection, riot, civil
commotion, strike, lockout or other labor disturbance, act of God or act,
omission or delay in acting by any governmental authority or the other
Party.  The affected Party will notify
the other Party of such force majeure circumstances as soon as reasonably
practical.

 

13.2         Assignment.  This Agreement may not be assigned or
otherwise transferred, nor, except as expressly provided hereunder, may any
right or obligations hereunder be assigned or transferred, by a Party without
the written consent of the other Party; provided, however,
that either Party may, without such consent, assign the Agreement and its
rights and obligations hereunder to (i) any wholly-owned subsidiary in a
manner such that the assignor (if it continues as a separate entity) will remain
liable and responsible for the performance and observance of all its duties and
obligations hereunder; and (ii)  to any successor by merger or sale of
substantially all of its business unit to which this Agreement relates, or in
the event of its merger or consolidation or change in control or similar
transaction.  Lilly may also assign or
transfer its rights to receive fees, royalties and milestones under this
Agreement (but no liabilities) without Isis consent, to a Third Party in
connection with a payment factoring transaction. This Agreement will be binding
upon the permitted successors 

 

20

 

CONFIDENTIAL TREATMENT REQUESTED

UNDER 17 C.F.R. §§ 200.80(b)4, AND 240.24b-2

 

and
permitted assigns of the Parties.  Any
assignment not in accordance with this Section 13.2 will be void.

 

13.3         Severability.  In the event that any of the provisions
contained in this Agreement are held invalid, illegal or unenforceable in any
respect, the validity, legality and enforceability of the remaining provisions
contained herein will not in any way be affected or impaired thereby, unless
the absence of the invalidated provision(s) adversely affect the
substantive rights of the Parties.  The
Parties will replace the invalid, illegal or unenforceable provision(s) with
valid, legal and enforceable provision(s), which, insofar as practical,
implement the purposes of this Agreement.

 

13.4         Notices.  All notices or other communications which are
required or permitted hereunder will be in writing and deemed to be effective (a) on
the date of delivery if delivered in person and written confirmation of
delivery is provided; or (b) on the date sent by facsimile or other
electronic transmission, provided such receipt is verified; or (c) on the
day following date of deposit with an overnight courier if a receipt confirming
delivery by overnight courier is provided; or (d) three days after mailing
if mailed by first-class certified mail, postage paid, to the respective
addresses given below, or to another address as it will designate by written
notice given to the other Party.

 

if to Isis, to:

 

Isis Pharmaceuticals, Inc.

1896 Rutherford Road

Carlsbad, CA 92008

Attention:          Chief Operating
Officer

 

with a copy to:

 

Attention:          General Counsel

 

if to Lilly, to:

 

Eli Lilly and Company

Lilly Corporate Center

Indianapolis, IN 46285

Attention:          Group Vice
President, Lilly Research Laboratories

 

with a copy to:

 

Attention:          General Patent
Counsel

 

13.5         Dispute Resolution.  In the event of any controversy or claim
arising from or relating to any provision of this Agreement, or any term or
condition hereof, or the performance by a Party of its obligations hereunder,
or its construction or its actual or alleged breach, the Parties will try to
settle their differences amicably between themselves.

 

21

 

CONFIDENTIAL TREATMENT REQUESTED

UNDER 17 C.F.R. §§ 200.80(b)4, AND 240.24b-2

 

13.6         Choice of Law.  This Agreement will be governed by and
construed in accordance with the laws of the State of New York and the United
States without reference to any rules of conflict of laws.

 

13.7         Entire Agreement.  This Agreement (including all Schedules
hereto), constitute the entire agreement between the Parties with respect to the
subject matter hereof, and supersedes all previous arrangement with respect to
the subject matter hereof, whether written or oral.  Any amendment or modification to this
Agreement will be made in writing signed by both Parties.

 

13.8         Headings.  The captions to the several Articles and
Sections hereof are not a part of the Agreement, but are merely guides or
labels to assist in locating and reading the several Articles and Sections
hereof.

 

13.9         Independent Contractors.  It is expressly agreed that the Parties will
be independent contractors and that the relationship between the Parties will
not constitute a partnership, joint venture or agency.  No Party will have the authority to make any
statements, representations or commitments of any kind, or to take any action,
which will be binding on the other Parties, without the prior consent of such
other Parties.

 

13.10       Further Actions.  Each Party agrees to execute, acknowledge and
deliver such further instruments, and to do all such other acts, as may be necessary
or appropriate in order to carry out the purposes and intent of the Agreement.

 

13.11       Waiver.  The waiver by a Party hereto of any right
hereunder or the failure to perform or of a breach by another Party will not be
deemed a waiver of any other right hereunder or of any other breach or failure
by said other Party whether of a similar nature or otherwise.

 

13.12       Jointly Prepared.  This Agreement has been prepared jointly and
will not be strictly construed against either Party.

 

13.13       Counterparts.  This Agreement may be executed in two or more
counterparts, each of which will be deemed an original, but all of which
together will constitute one and the same instrument.

 

[THIS
SPACE INTENTIONALLY LEFT BLANK]

 

22

 

CONFIDENTIAL TREATMENT REQUESTED

UNDER 17 C.F.R. §§ 200.80(b)4, AND 240.24b-2

 

IN WITNESS WHEREOF, the Parties
have executed this Agreement as of the Effective Date.

 

 

	
  ELI LILLY AND COMPANY

  	
   

  	
  ISIS PHARMACEUTICALS, INC.

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
  By:

  	
  /s/ Steven Paul

  	
   

  	
  By:

  	
  /s/ B. Lynne Parshall

  
	
  Dr. Steven
  Paul

  	
   

  	
  B. Lynne Parshall

  
	
  Executive Vice
  President

  	
   

  	
  Chief Operating Officer and

  
	
  LRL

  	
   

  	
  Chief Financial Officer

  
					

 

 

[SIGNATURE PAGE TO
DEVELOPMENT AND LICENSE AGREEMENT]

 

 

CONFIDENTIAL TREATMENT REQUESTED

UNDER 17 C.F.R. §§ 200.80(b)4, AND 240.24b-2

 

List of
Schedules

 

	
  Schedule 1.1

  	
  Definitions

  
	
   

  	
   

  
	
  Schedule A

  	
  Form of License Agreement

  
	
   

  	
   

  
	
  Schedule B

  	
  Lilly Product Patents as of the Effective Date

  
	
   

  	
   

  
	
  Schedule C

  	
  Isis Product Patents as of the Effective Date

  
	
   

  	
   

  
	
  Schedule D

  	
  Form of Patent Assignment

  
	
   

  	
   

  
	
  Schedule
  E

  	
  [***]
  Plan

  

 

 

CONFIDENTIAL TREATMENT REQUESTED

UNDER 17 C.F.R. §§ 200.80(b)4, AND 240.24b-2

 

SCHEDULE
1.1

 

DEFINITIONS

 

“Affiliate” means any person, organization, corporation
or other business entity that controls, directly or indirectly, the power to
direct, or cause the direction of, the management and policies of another
person, organization, corporation or entity, whether through the ownership of
voting securities or by contract or court order or otherwise.  For purposes of this definition, an entity
will be deemed to control another entity if it owns or controls, directly or
indirectly, at least fifty percent (50%) of the outstanding stock or other
voting rights entitled to elect directors or their equivalent of such other
entity.  Regulus Therapeutics Inc., will
not be considered an Affiliate of Isis.

 

“ASO Compound” means an
[***].

 

“Calendar Quarter” will mean the respective
three month periods ending on March 31, June 30, September 30,
or December 31 for so long as the Agreement is in effect.

 

“Calendar Year” will mean each
successive twelve month period commencing on January 1 and ending on December 31
for so long as the Agreement is in effect.

 

“cGMP” means U.S.
current Good Manufacturing Practices regulations.

 

“Collaboration Agreement” has the meaning set forth
in Recital A of this Agreement.

 

“Confidential Information” means any and
all inventions, know-any, and data and will include, without limitation,
information relating to research and development plans, experiments, results
and plans, compounds, therapeutic leads, candidates and products, clinical and
preclinical data, trade secrets and manufacturing, marketing, financial,
regulatory, personnel and other business information and plans, all scientific,
clinical, regulatory, marketing, financial and commercial information or data,
all whether communicated in writing, orally or by any other means, and which is
provided by one Party to the other Party in connection with this Agreement.  Confidential Information will not include
information that:

 

(a)           is known by the
receiving Party at the time of its receipt, and not through a prior disclosure
by the disclosing Party, as documented by written records; or

 

(b)           is properly in
the public domain through no fault of the receiving Party; or

 

(c)           is subsequently
disclosed to the receiving Party by a Third Party who may lawfully do so and is
not under an obligation of confidentiality to the disclosing Party; or

 

(d)           is developed by
the receiving Party independently of Confidential Information received from the
other Party, as documented by written records.

 

“Control” or “Controlled” means with respect to
any intellectual property right, that the Party owns or has a license to such
intellectual property right and has the ability to grant access, 

 

1.1-1

 

CONFIDENTIAL TREATMENT REQUESTED

UNDER 17 C.F.R. §§ 200.80(b)4, AND 240.24b-2

 

a
license, or a sublicense to such intellectual property right to the other Party
as provided for in this Agreement without violating an agreement with, or
infringing any rights of, a Third Party as of the time the Party would be first
required under this Agreement to grant the other Party such access, license or
sublicense.

 

“Cover” (including variations thereof such as “Covering”, “Covered”,
and “Coverage”) means that the
manufacture, use, import, offer for sale or sale of a Product would infringe a
Valid Claim; provided, with respect to a process or manufacturing patent, that
such a Valid Claim therein effectively precludes a Third Party from
manufacturing, using, importing, offering for sale, or selling such
Product.  The determination of whether a
Product is Covered by a particular Valid Claim will be made on a
country-by-country basis.  A Valid Claim
will be deemed to provide effective preclusion hereunder where (i) there
is no competing product being marketed; or (ii) if a product is being
marketed by a competitor, it infringes the Valid Claim (including any period in
which, and provided that, the Valid Claim is being litigated).

 

“Effective Date” has the
meaning given to it in the preamble of this Agreement.

 

“eIF-4E” means
eukaryotic initiation factor-4E (Entrez Gene ID: 1977).

 

“eIF-4E Program” means [***] eIF-4E [***] eIF-4E [***] eIF-4E Program.

 

“FDA” means the United States Food and Drug
Administration or any successor agency having the administrative authority to
regulate the approval for marketing of new human pharmaceutical or biological
therapeutic products in the United States.

 

“First Commercial Sale” means with
respect to any Product the first sale to a Third Party by Isis, its Affiliates
or Licensees under the Product Patent. 
First Commercial Sale will not include transfer of reasonable quantities
of any free samples of a Product or reasonable quantities of Product solely for
development purposes, such as for use in experimental studies or clinical
trials.

 

“[***]” means (1) the
[***] of the Lilly API by Lilly’s [***], including but not limited to (i) a
[***] containing the [***] for each lot of Lilly API, and [***] that each such
lot of Lilly API [***] to the applicable [***] set forth in the [***] of the
[***] for the Product; (ii) a [***] of [***] that the Lilly API was made
[***] and the process defined in the [***] for the Lilly API; and (iii) copies
of documents detailing any [***] from any [***] then in effect, in each case
such documents to be delivered to Isis’ VP, Development Chemistry and
Manufacturing; and (2) shipment of the Lilly API to Isis’ VP, Development
Chemistry and Manufacturing in accordance with applicable product
specifications for the Lilly API.

 

“IND” means an
Investigational New Drug application as defined in 21 C.F.R. 312 and any
versions thereof governing the FDA as may be amended from time to time.

 

“Initiate” means with respect to a clinical study, the dosing of the first patient
in such study.

 

“Institutional Review
Board” means an Institutional Review Board as defined in
21 C.F.R. 56 as may be amended from time to time, or its applicable foreign equivalent.

 

1.1-2

 

CONFIDENTIAL TREATMENT REQUESTED

UNDER 17 C.F.R. §§ 200.80(b)4, AND 240.24b-2

 

“Isis Product Patents” means the
Patent Rights listed on Schedule C, and all Patent Rights issuing therefrom.

 

“Know-How” means all
tangible or intangible know-how, inventions (whether patentable or not),
discoveries, processes, formulas, data, clinical and preclinical results,
non-patented inventions, trade secrets, and any physical, chemical, or
biological material or any replication of any such material in whole or in
part.

 

“Licensee” means a Third
Party to which Isis has granted a license under the Product Patents to develop
and commercialize the Product.

 

“Lilly Product Patents” means the
Patent Rights listed on Schedule B, and all Patent Rights issuing therefrom.

 

“Lilly Right of First Negotiation” has the meaning set forth
in Section 6.2.

 

“Major Market Country” means the United States,
Japan, Germany, the United Kingdom, France, Spain or Italy.

 

“NDA” means a new drug application or other application
filed with the FDA to obtain approval for marketing a Product in the United
States, or any future equivalent process.

 

“Net Sales” means, with respect to a Product, the gross
amount invoiced by a Party, its Affiliates or Licensees thereof to unrelated
Third Parties, excluding any Licensee, for the Product, less:

 

(a)           Trade, quantity
and cash discounts allowed;

 

(b)           Commissions,
discounts, refunds, rebates, chargebacks, retroactive price adjustments, and
any other allowances which effectively reduce the net selling price;

 

(c)           Product returns
and allowances;

 

(d)           That portion of
the value associated with the cost of the drug delivery systems;

 

(e)           Any tax imposed
on the production, sale, delivery or use of the Product, including, without
limitation, sales, use, excise or value added taxes;

 

(f)            Allowance for
distribution expenses; and

 

(g)           Any other
similar and customary deductions.

 

Net Sales will be calculated
in U.S. Dollars.  Such amounts will be
determined from the books and records of a Party, its Affiliate or Licensee,
maintained in accordance with U.S. Generally Accepted Accounting Principles or,
in the case of Licensees, such similar accounting principles, consistently
applied.  Each Party further agrees in determining
such amounts, it will use its then current standard procedures and methodology,
including its then current standard 

 

1.1-3

 

CONFIDENTIAL TREATMENT REQUESTED

UNDER 17 C.F.R. §§ 200.80(b)4, AND 240.24b-2

 

exchange
rate methodology for the translation of foreign currency sales into U.S.
Dollars or, in the case of Licensees, such similar methodology, consistently
applied.

 

Net Sales excludes:

 

(i)            The transfer of
reasonable and customary quantities of free samples of Product(s) and the
transfer of Product(s) as clinical trial materials, other than for
subsequent resale;

 

(ii)           Sales or
transfers of Product(s) among a Party and its Affiliates unless the
receiving Party is the consumer or user of the Product(s); and

 

(ii)           Use by a Party
or its Affiliates or Licensees of Product for any use connected with the
securing of regulatory approval or validating of a manufacturing process or the
obtaining of other necessary marketing approvals for Product (unless such
Product is subsequently sold).

 

In the event that the
Product(s) is sold as part of a Combination Product (where “Combination Product” means any
pharmaceutical product which comprises the Product(s) and at least one
other active compound(s) and/or ingredients), the Net Sales of the
Product(s), for the purposes of determining royalty payments, will be
determined by multiplying the Net Sales of Combination Product (as defined in
the standard Net Sales definition) by the fraction, A / (A+B) where A is the weighted
average sale price of the Product(s) when sold separately in finished
form, and B is the weighted average sale price of the other product(s) sold
separately in finished form.

 

In the event that the
weighted average sale price of the Product(s) can be determined but the
weighted average sale price of the other product(s) cannot be determined,
Net Sales for purposes of determining royalty payments will be calculated by
multiplying the Net Sales of the Combination Product by the fraction A / C
where A is the weighted average sale price of the Product(s) when sold
separately in finished form and C is the weighted average selling price of the
Combination Product.  In the event that
the weighted average sale price of the other product(s) can be determined but
the weighted average sale price of the Product cannot be determined, Net Sales
for purposes of determining royalty payments will be calculated by multiplying
the Net Sales of the Combination Product by the following formula:  one (1) minus B / C where B is the
weighted average sale price of the other product(s) when sold separately
in finished form and C is the weighted average selling price of the Combination
Product.  In the event that the weighted
average sale price of both the Product(s) and the other product(s) in
the Combination Product cannot be determined, the Parties will attempt to agree
on an appropriate weighted average sale price of both the Product(s) and
the other product(s) in the Combination Product, and lacking such
agreement the Net Sales of the Product(s) will be deemed to be equal to
fifty percent (50%) of the Net Sales of the Combination Product.

 

The weighted average sale
price for a Product, other product(s), or Combination Product will be
calculated once each Calendar Year and such price will be used during all
applicable royalty reporting periods for the entire Calendar Year.  When determining the weighted average sale
price of a Product, other product(s), or Combination Product, the weighted
average sale price will be calculated by dividing the sales dollars (translated
into U.S. Dollars) by the units of active ingredient sold during the twelve
(12) months (or the number of months sold in a partial 

 

1.1-4

 

CONFIDENTIAL TREATMENT REQUESTED

UNDER 17 C.F.R. §§ 200.80(b)4, AND 240.24b-2

 

Calendar
Year) for the respective Product(s), other product(s), or Combination
Product.  In the initial Calendar Year, a
forecasted weighted average sale price will be used for Product(s), other
product(s), or Combination Product.  Any
over or under payment due to a difference between forecasted and actual
weighted average sale prices will be paid or credited in the first royalty
payment of the following Calendar Year.

 

“Ongoing Phase I Study” means the Lilly
Phase I clinical study of the Product, which study is identified internally by
the code [***].

 

“Patent Rights” means: (a) patent
applications (including provisional applications and applications for
certificates of invention); (b) any patents issuing from such patent
applications (including certificates of invention); (c) all patents and
patent applications based on, corresponding to, or claiming the priority date(s) of
any of the foregoing; (d) any reissues, substitutions, confirmations,
registrations, validations, re-examinations, additions, continuations,
continued prosecutions, continuations-in-part, or divisions of or to any of the
foregoing; and (e) term extension or other governmental action which
provide exclusive rights beyond the original patent expiration date.

 

“Phase II Study” means a human clinical trial conducted on a series of
patients with the same type of cancer, in each case where the protocol for such
phase II study was approved by the applicable Institutional Review Board.

 

“Phase II Study Initiation” means the dosing of the first patient in the first human clinical
trial conducted on a series of patients with the same type and stage of cancer.

 

“Phase III Study
Initiation”  means
the dosing of the first patient in the first human clinical trial conducted in
patients and designed to establish Product safety and efficacy and required to
obtain clinical registration of a product with health regulatory authorities
such as the FDA.

 

“Product” means (i) the
compound known as LY2275796; and (ii) any preparation in final form for
sale by prescription, over-the-counter or any other method for any indication,
including human or animal use, which contains LY2275796.

 

“Product Patents” means the Isis
Product Patents and the Lilly Product Patents.

 

“Registration” means (a) in the
United States, approval by the FDA of an NDA, or similar application for
marketing approval, and satisfaction of any related applicable FDA registration
and notification requirements (if any); and (b) in any Major Market Country
other than the United States, approval by regulatory authorities having
jurisdiction over such country of a single application or set of applications
comparable to an NDA and satisfaction of any related applicable regulatory and
notification requirements, if any, together with any other approval necessary
to make and sell pharmaceuticals and medical devices commercially in such
country.

 

“Registration Submission” means (a) in
the United States, acceptance by the FDA of the filing of an NDA, or similar
application for marketing approval, for the Product, and (b) in any Major
Market Country other than the United States, the filing with the applicable
Regulatory

 

1.1-5

 

CONFIDENTIAL TREATMENT REQUESTED

UNDER 17 C.F.R. §§ 200.80(b)4, AND 240.24b-2

 

Authorities
having jurisdiction over such country of a single application or set of
applications comparable to an NDA for the Product.

 

“Regulatory Authority” means any applicable
government entities regulating or otherwise exercising authority with respect
to the development and commercialization of the Product.

 

“Regulatory Documentation”  means all applications, registrations,
licenses, authorizations and approvals (including all regulatory approvals),
all correspondence submitted to or received from Regulatory Authorities
(including minutes and official contact reports relating to any communications
with any Regulatory Authority), all supporting documents and all clinical studies
and tests, including the manufacturing batch records, relating to the Product,
and all data contained in any of the foregoing, including all regulatory drug
lists, advertising and promotion documents, adverse event files and complaint
files.

 

“Territory” means the
entire world.

 

“Third Party” means any
Party other than Isis or Lilly and their respective Affiliates.

 

“Valid Claim” means any
claim in an issued and unexpired patent which has not been held unenforceable,
unpatentable or invalid by a decision of a court or other governmental agency
of competent jurisdiction following exhaustion of all possible appeal processes
and which has not been admitted to be invalid or unenforceable through reissue,
reexamination or disclaimer, or otherwise.

 

1.1-6

 

CONFIDENTIAL TREATMENT REQUESTED

UNDER 17 C.F.R. §§ 200.80(b)4, AND 240.24b-2

 

Schedule A

 

Form of License Agreement

 

 

CONFIDENTIAL TREATMENT REQUESTED

UNDER 17 C.F.R. §§ 200.80(b)4, AND 240.24b-2

 

Schedule B

 

Lilly Product Patents as of the Effective Date

 

[***]

 

 

CONFIDENTIAL TREATMENT REQUESTED

UNDER 17 C.F.R. §§ 200.80(b)4, AND 240.24b-2

 

Schedule C

 

Isis Product Patents as of the Effective Date

 

[***]

 

 

CONFIDENTIAL TREATMENT REQUESTED

UNDER 17 C.F.R. §§ 200.80(b)4, AND 240.24b-2

 

Schedule D

 

Form of Patent Assignment

 

WHEREAS, Eli Lilly and Company (“Assignor”), a Indiana corporation with
an address of Lilly Corporate Center, Indianapolis, IN 46285, is the owner of
all rights, title, and interests in and to the patents and patent applications
shown on the attached Exhibit 1 (the “Patents”); and

 

WHEREAS, Isis Pharmaceuticals, Inc. (“Assignee”), a Delaware
corporation with an address of 1896 Rutherford Road, Carlsbad, California
92008, desires to acquire the entire right, title, and interest in and to the
Patents and all the inventions and discoveries disclosed in the Patents (the “Inventions”);

 

NOW THEREFORE, be it known that effective as of
[    ], 2009, for good and valuable consideration, the receipt
and sufficiency of which are hereby acknowledged, Assignor hereby sells,
assigns, transfers, and sets over unto Assignee (1) the entire right,
title, and interest in all countries throughout the world in and to said
Patents and Inventions, including any renewals, revivals, reissues,
reexaminations, extensions, continuations, continuations-in-part, and divisions
of said Patents and any substitute applications therefor; (2) the entire
right to file patent applications (“New Applications”) in the name of Assignee
or its designee, or in the name of Assignor at Assignee’s or its designee’s
election, on the aforesaid Inventions in all countries of the world; (3) the
entire right, title, and interest in and to any patent which issued and may
issue on the Inventions in any country, and any renewals, revivals, reissues,
reexaminations, and extensions thereof, and any patents of confirmation,
registration, and importation of the same; (4) the right to sue and
recover for, and the right to profits or damages due or accrued in connection
with, any and all past, present, or future infringements of the Patents and
Inventions; and (5) the entire right, title, and interest in all
convention and treaty rights of all kinds, including without limitation all
rights of priority in any country of the world, in and to the above Patents and
Inventions;

 

AND, Assignor hereby authorizes and requests the competent authorities
to grant and to issue any and all patents on the Inventions throughout the
world to Assignee, its successors, or assigns, whose rights, title, and
interests in such patents are the same as would have been held and enjoyed by
Assignor had this assignment, sale, and transfer not been made.

 

[Remainder of Page Left
Blank]

 

 

CONFIDENTIAL TREATMENT REQUESTED

UNDER 17 C.F.R. §§ 200.80(b)4, AND 240.24b-2

 

Schedule E

 

[***]

 

 

 

FORM OF LICENSE AGREEMENT
UNDER DEVELOPMENT AND LICENSE AGREEMENT DATED DECEMBER 2, 2009

 

CONFIDENTIAL
TREATMENT REQUESTED

UNDER 17 C.F.R. §§
200.80(b)4, AND 240.24b-2

 

 

DEVELOPMENT
AND LICENSE AGREEMENT

 

 

BETWEEN

 

 

ELI
LILLY AND COMPANY

 

 

AND

 

 

ISIS
PHARMACEUTICALS, INC.

 

 

 

 

DEVELOPMENT
AND LICENSE AGREEMENT

 

THIS DEVELOPMENT AND
LICENSE AGREEMENT (the “Agreement”)
executed on
              
(the “Effective Date”), by and between ELI LILLY AND COMPANY, a corporation organized and existing
under the laws of Indiana and its Affiliates (together “Lilly”),
and ISIS PHARMACEUTICALS, INC., a
corporation organized and existing under the laws of Delaware, and its
affiliates (together “Isis”).

 

RECITALS

 

A.            Isis and Lilly
have collaborated to discover and develop the Product;

 

B.            Lilly has
expertise in the research, manufacturing, development, distribution and sale of
pharmaceutical products for human and animal use;

 

C.            Isis and Lilly
are parties to the Drug Development and License Option Agreement dated December 2,
2009 (the “License Option Agreement”)
pursuant to which Isis granted Lilly the option to acquire the Product;

 

D.            On
                      
(the “Option Exercise Date”) Lilly
exercised its option under the License Option Agreement; and

 

E.             Lilly wishes to
obtain, and Isis wishes to grant, an exclusive license to enable Lilly to
develop and commercialize the Product on its own.

 

AGREEMENT

 

NOW, THEREFORE, in
consideration of the mutual covenants contained in this Agreement, the Parties
agree as follows:

 

ARTICLE 1

DEFINITIONS; OPTION AGREEMENT TERMINATED

 

1.1           Definitions.  Capitalized terms used in this Agreement,
whether in the singular or plural, have the meanings set forth in
Schedule 1.1 which is attached hereto and made part of this Agreement, or as
otherwise specifically defined in this Agreement.

 

1.2           Termination of Option Agreement.  The License Option Agreement is hereby
terminated and replaced by this Agreement in its entirety.  For purposes of clarification,
such termination and replacement will not negate the effect of Section 2.1
of the License Option Agreement.

 

1

 

ARTICLE 2

PRODUCT DEVELOPMENT AND COMMERCIALIZTION

 

2.1           Development and Commercialization.  As soon as practicable after the Effective
Date, the parties will mutually agree upon and implement a commercially
reasonable transition plan pursuant to which further development and
commercialization activities will be transitioned from Isis to Lilly. The
transition plan will provide for transfer to Lilly of relevant data and
records, ownership of regulatory filings, and transition of Third Party
arrangements (e.g., manufacturing, CRO and similar agreements), and a process
for sharing class specific safety data related to the Product. Isis will not be
entitled to any compensation or reimbursement for the costs of the first [***]
hours of its personnel incurred in transitioning activities to Lilly. Lilly
will reimburse Isis for its reasonable direct Third Party costs incurred in
connection with transition activities. 
If Isis and Lilly agree that Isis will continue some of the development
of the Product, Isis and Lilly will agree upon a plan and budget to reimburse
Isis for such development activities. 
Following transition of activities to Lilly, Lilly will be solely
responsible for all development and commercialization of the Product, including
toxicology, clinical development (including taking over and becoming the IND
sponsor of all clinical trials that are ongoing as of the Effective Date),
regulatory, manufacturing and commercialization efforts, except as agreed
otherwise by the Parties.  Lilly and its
Sublicensees will have the sole right and responsibility for the preparation of
any regulatory filings required in order to conduct clinical trials on Product
in the Territory, together with the preparation of suitable applications for
marketing approval in the Territory and will be the owner and party of record
of all such regulatory filings.  Isis
will cooperate with Lilly, at Lilly’s expense, as Lilly reasonably requires in
preparing such regulatory filings including, without limitation, any and all
data contained therein.

 

ARTICLE 3

PRODUCT LICENSE

 

3.1           Grant of License.  Subject to the terms and conditions of this
Agreement, Isis hereby grants to Lilly an exclusive, royalty-bearing license,
including the right to sublicense, under the Isis Technology solely to develop,
make, use, import, offer for sale and sell Products in the Territory.

 

3.2           Diligence and Reporting.  In order to maintain the license granted to
Lilly under Section 3.1 above, Lilly must maintain an Active Program on
the Product, and as long as Lilly has an Active Program on the Product Isis
will not conduct any research on its own or with a Third Party on eIF-4E or any
ASO Compound directed to eIF-4E.  In the
event that there is a material, uncured breach of the foregoing diligence
obligation by Lilly with respect to the Product, Isis may terminate this
Agreement for Lilly breach pursuant to Section 8.5.  Lilly will provide Isis with annual written
reports that include a description of the research, development and
commercialization activities by Lilly on the Product.  Lilly will provide prompt written 

 

2

 

notice to Isis when it ceases to have an Active Program on the Product
and thereafter such license will terminate. 
Within [***] months of such notice from Lilly, or within [***] months of
termination of this Agreement by Isis pursuant to this Section 3.2 or Section 8.2,
Isis will provide written notice to Lilly if it desires to develop a Product
and whether it desires to receive from Lilly summary reports on completed
IND-enabling toxicology studies and completed clinical trials for the Product.  Lilly will provide such summary reports
promptly after receiving such notice from Isis. 
If Isis fails to provide such notice within such [***] month period
Lilly will have no obligation to provide such summary reports to Isis.  For purposes of clarity, if Isis fails to
request such summary reports from Lilly for a Product as described above in
this Section 3.2, Isis may still develop a Product.

 

3.3           No Implied
Licenses.  Except as
expressly provided otherwise herein, neither Party hereto will be deemed by
this Agreement to have been granted any license or other rights to the other
Party’s intellectual property rights including any Third Party patent rights.

 

3.4           Negative
Covenant of Isis.  Isis
hereby agrees that, for so long as Lilly’s exclusive license under Section 3.1
is in effect, Isis will not (a) pursue research, development or
commercialization of [***] to eIF-4E outside this Agreement, either on its own
or for a Third Party, or (b) grant or assign to any Third Party any rights
to [***] to eIF-4E.

 

ARTICLE 4

PAYMENTS AND ACCOUNTING

 

4.1           Payment Tiers.  The license fee and milestones payable by
Lilly to Isis under this Agreement will depend upon whether Isis has Initiated
certain Phase II Studies for the Product for certain market types by the Option
Exercise Date as follows:

 

4.1.1        If, by the Option Exercise Date, Isis has Initiated
either (i) at least [***] Phase II Study of the Product in at least [***],
or (ii) [***] or more Phase II Studies of the Product in at least [***],
then Lilly will pay Isis the license fee and milestones set forth in this
ARTICLE 4 at the “Tier 1
Rates”.

 

4.1.2        If, by the Option Exercise Date, Isis has Initiated
[***] or more Phase II Studies of the Product in only [***], then Lilly will
pay Isis the license fee and milestones set forth in this ARTICLE 4 at the “Tier 2 Rates”.

 

4.1.3        If, by the Option Exercise Date, Isis has only
Initiated Phase II Studies of the Product in [***], then Lilly will pay Isis
the license fee and milestones set forth in this ARTICLE 4 at the “Tier 3 Rates”.

 

4.1.4        Lilly will pay Isis a license fee and milestones
based on the single highest payment tier set forth in this Section 4.1
that Isis has qualified for with the Product. 
For purposes of clarification, the payment tiers above will be set
regardless of the outcome of any Phase II Study referenced above.

 

3

 

4.2           License Fees.

 

4.2.1        Depending on which payment tier applies as
determined under Section 4.1 above, Lilly will pay Isis a one-time,
non-refundable, non-creditable fee in accordance with the table below, payable
within 30 days following the Effective Date.

 

	
   

  	
   

  	
  Tier 1 Rates

  	
   

  	
  Tier 2 Rates

  	
   

  	
  Tier 3 Rates

  	
   

  
	
  Applicable License Fee:

  	
   

  	
  $

  	
  [***]

  	
   

  	
  $

  	
  [***]

  	
   

  	
  $

  	
  [***]

  	
   

  
											

 

4.2.2        In addition, if Lilly did not complete the [***] by
[***], as set forth in ARTICLE 4 of the License Option Agreement, then Lilly
will pay Isis an additional one-time, non-refundable, non-creditable fee of
$[***], payable within 60 days following the Effective Date.

 

4.3           Milestone Payments.  Depending on which payment tier applies as
determined under Section 4.1 above, Lilly will pay to Isis the following
milestone payments for a Product within 30 days after the first achievement by
Lilly, its Affiliates or Sublicensees of each of the following events in the
first Major Market Country:

 

	
   

  	
   

  	
  Milestone Payment

  	
   

  
	
  Milestone Event

  	
   

  	
  Tier 1 Rates

  	
   

  	
  Tier 2 Rates

  	
   

  	
  Tier 3 Rates

  	
   

  
	
  [***]

  	
   

  	
  $

  	
  [***]

  	
   

  	
  $

  	
  [***]

  	
   

  	
  $

  	
  [***]

  	
   

  
	
  [***]

  	
   

  	
  $

  	
  [***]

  	
   

  	
  $

  	
  [***]

  	
   

  	
  $

  	
  [***]

  	
   

  
	
  [***]

  	
   

  	
  $

  	
  [***]

  	
   

  	
  $

  	
  [***]

  	
   

  	
  $

  	
  [***]

  	
   

  
	
  [***]

  	
   

  	
  [***]

  	
   

  	
  $

  	
  [***]

  	
   

  	
  $

  	
  [***]

  	
   

  
	
  [***]

  	
   

  	
  [***]

  	
   

  	
  [***]

  	
   

  	
  $

  	
  [***]

  	
   

  
	
  Total:

  	
   

  	
  $

  	
  [***]

  	
   

  	
  $

  	
  [***]

  	
   

  	
  $

  	
  [***]

  	
   

  

 

Each
milestone payment set forth above is only payable once, even if more than one
Product achieves the same milestone.

 

4.4           Royalties.  Lilly will pay to Isis the following
royalties on a country-by-country basis from the date of the First Commercial
Sale of a Product in each such country until the later of (i) the
expiration of the last to expire Isis Patent Right that includes a Valid Claim
that Covers such Product; and (ii) [***] years from the First Commercial
Sale:

 

4

 

	
  Worldwide Annual Net Sales of the Product

  	
   

  	
  Royalty Rate

  	
   

  
	
  On the portion of Net
  Sales from US$[***] to less than US$[***]

  	
   

  	
  [***]

  	
  %

  
	
  On the portion of Net
  Sales from US$[***] to less than US$[***]

  	
   

  	
  [***]

  	
  %

  
	
  On the portion of Net
  Sales equal to or more than US$[***]

  	
   

  	
  [***]

  	
  %

  

 

4.5           Pass Through Royalties.  With respect to Products, Isis will be
responsible for paying the pass through royalties or other compensation payable
by Isis under (i) the [***], (ii) the [***] and (iii) except as
provided under Section 4.6.2, any other agreement executed by Isis under
which agreement Isis has agreed to pay a Third Party royalties based upon sales
of the Product.

 

4.6           Access to Third Party Rights.

 

4.6.1        Third Party Licenses.  If, after the Effective Date access to a
Third Party’s intellectual property rights becomes necessary to make, use,
import, or offer to sell, or sell a Product in the Territory, Lilly will have
the right to acquire such access.  [***] percent
([***]%) of the acquisition cost paid by Lilly (i.e.,
all consideration paid by Lilly in connection with such acquisition including,
without limitation up-front payments, milestones payments and royalties)
applicable to such Product will be credited against future royalties owed to
Isis by Lilly under this Agreement for a Product.  Except as the Parties may otherwise agree in
writing, under no circumstance will Lilly acquisitions of Third Party
intellectual property rights under the provisions of this Section 4.5.1
result in a reduction of Net Royalties payable to Isis under this Agreement by
more than [***] ([***]%) percent of the royalty otherwise due to Isis.

 

4.6.2        Oral Preparation, Formulation or
Delivery Technology.  Any oral
preparation, formulation or delivery technology that is applicable to the
Product that is obtained by Isis from any Affiliate or Third Party, including
[***], will be made available to Lilly, at Lilly’s discretion, for use at a
cost (including royalties, milestones and other payments) that is no greater
than the [***] payable by Isis to such Third Party.  Any oral preparation, formulation or delivery
technology developed by Isis during the term of the Agreement that is
applicable to the Products will be made available to Lilly hereunder as Isis
Technology.

 

4.6.3        Royalty Obligations.  Except as otherwise provided in this
Agreement both Parties acknowledge and agree that each is solely responsible
for any and all royalty obligations that have accrued or may accrue in the
future with respect to any agreements and/or arrangement that such Party may
have agreed to prior to the Effective Date. 
Except as otherwise provided in this Agreement, any Third Party
technology acquired by Isis that is applicable to the Product will be made available
to Lilly at the cost (including royalties, milestones and other payments)
payable by Isis to such Third Party.

 

5

 

4.7           Compulsory License.  If in any country a Third Party obtains a
Compulsory License to sell a Product, then Lilly or Isis, respectively, will
promptly notify the other Party.  If the
royalty rate payable by the grantee of the Compulsory License is less than the
then-current royalty rate paid under this Agreement, then the royalty rate,
payable under this Agreement with respect to such Product, will be reduced to
such lower rate in the subject country for so long as sales are made pursuant
to the Compulsory License; provided, however,
that in no event will the Net Royalty to Isis fall below [***] percent
([***]%).

 

4.8           Inflation.  The increments of annual Net Sales tiers set
forth in Sections 4.3 will be adjusted on a Calendar Year basis commencing
January 1, [***] (and on January 1 of each year thereafter during the
term of this Agreement) by an amount equal to the percentage change, if any, in
the CPI for the preceding year.

 

4.9           Accounting Reports; Payment of Royalty.  Lilly (including its Affiliates) and its
Sublicensees will keep complete and accurate books and records which may be necessary
to ascertain properly and to verify the payments owed hereunder.  To the extent Lilly has prepared such
information for its own purposes, if requested in writing by Isis, Lilly will
provide to Isis [***] ([***]) days after the end of each Calendar Quarter a
written report with Lilly’s good faith estimate of Lilly’s Net Sales accrued in
the preceding Calendar Quarter and the royalties payable thereon.  Lilly will make royalty payments to Isis for
Products sold by Lilly, its Affiliates and Sublicensees during the Calendar
Quarter within [***] ([***]) days of the last day of that Calendar
Quarter.  Each royalty payment will be
accompanied by a written report for that Calendar Quarter showing the Net Sales
of the Products sold by Lilly, its Affiliates and Sublicensees worldwide during
the quarterly reporting period and the calculation of the royalties payable
under this Agreement.

 

4.10         Audits.  Upon Isis’ written request, and not more than
once in each Calendar Year, Lilly will permit Lilly’s independent certified
public accountant to have access during normal business hours to such of Lilly’s
records as may be reasonably necessary to verify the accuracy of the royalty
reports hereunder for the current year and the preceding [***] ([***]) years
prior to the date of such request.  Isis
will submit an audit plan, including audit scope, to Lilly for Lilly’s
approval, which will not be unreasonably withheld, prior to audit
implementation.  The independent
certified public accountants will keep confidential any information obtained
during such inspection and will report to Isis only the amounts of Net Sales
and royalties due and payable.  Upon the
expiration of [***] ([***]) years following the end of any Calendar Year, the
calculation of royalties payable with respect to such year will be binding and
conclusive upon Isis, and Lilly and its Affiliates and Sublicensees will be
released from any liability or accountability with respect to royalties for
such year.  If such accounting firm
concludes that additional royalties were owed, or that Lilly overpaid
royalties, during such period, Lilly will pay the additional royalties, or Isis
will return any overpaid royalties, within [***] ([***]) days of the date Isis
delivers to Lilly such accounting firm’s written report.  The fees charged by such accounting firm will
be paid by Lilly unless the additional royalties owed by Lilly exceed [***] percent ([***]%)
of the royalties paid for the royalty period subject to the audit, in which
case Lilly will pay the reasonable fees of the accounting firm.  Lilly will include in each sublicense granted
by it pursuant to this Agreement a provision requiring the Sublicensee to make
reports to Lilly, to keep and maintain records of sales made pursuant to such
sublicense and to grant access to such records by a mutually agreed upon
independent accountant to the 

 

6

 

same extent required of Lilly under this Agreement.  Lilly will treat all financial information
subject to review under this Section 4.10 or under any sublicense
agreement in accordance with the confidentiality provisions of this Agreement,
and will cause its accounting firm to enter into an acceptable confidentiality
agreement with Lilly obligating it to retain all such financial information in
confidence pursuant to such confidentiality agreement.

 

4.11         Payment.  All payments to Isis under this Agreement
will be made in United States Dollars by bank wire transfer in next day
available funds to such bank account in the United States designated in writing
by Isis from time to time. Lilly will pay a late payment service charge of
[***]% per month (or the highest amount allowed by law, if lower than [***]%)
on all past-due amounts owed by such Party under this Agreement.

 

4.12         Income Tax Withholding.  Each Party will be responsible for its own
tax liabilities resulting from the payments received from the other Party under
this Agreement.  If laws, rules or
regulations require withholding of income taxes or other taxes imposed upon payments
set forth in this ARTICLE 4, the paying Party will make such withholding
payments as required and subtract such withholding payments from the payments
set forth in this ARTICLE 4.  The
paying Party will submit appropriate proof of payment of the withholding taxes
to the other Party within a reasonable period of time.

 

ARTICLE 5

CONFIDENTIALITY

 

5.1           Nondisclosure and Nonuse Obligations.  All Confidential Information disclosed by one
Party to the other Party hereunder will be maintained in confidence and will
not be disclosed to any Third Party or used for any purpose except as expressly
permitted herein without the prior written consent of the other Party.

 

5.2           Permitted Disclosure of Confidential Information.  Notwithstanding Section 5, a Party may disclose
Confidential Information of the other Party as follows:

 

5.2.1        to appropriate
U.S. and/or foreign tax authorities, appropriate patent agencies in order to
obtain Patent Rights pursuant to this Agreement, appropriate regulatory
authorities to gain approval to conduct clinical trials or to market Products
pursuant to this Agreement, but such disclosure, may be only to the extent
reasonably necessary to obtain such Patent Rights or authorizations;

 

5.2.2        if required by
any governmental authority other than under Section 5.2.1, provided that
prior to such disclosure, the Party subject to the request for such disclosure
(the “Notifying Party”) promptly notifies
the other Party of such requirement so that such other Party may seek a
protective order or other appropriate remedy; and provided,
further, that in the event that no such protective order or other
remedy is obtained, or that such other Party waives compliance with this
ARTICLE 5, the Notifying Party will furnish only that portion of the other
Party’s Confidential Information that it is advised by counsel it is legally
required to furnish and will exercise all reasonable efforts to obtain
reasonable assurance that confidential treatment will be accorded the other
Party’s Confidential Information so furnished;

 

7

 

5.2.3        by a Party to
its permitted Sublicensees, agents, consultants, Affiliates and/or other Third
Parties for the research and development, manufacturing and/or marketing of
Products (or for such Parties to determine their interest in performing such
activities) in accordance with this Agreement on the condition that such
Affiliates and Third Parties agree to be bound by the confidentiality and
non-use obligations contained in this Agreement; or

 

5.2.4        if required to
be disclosed by law or court order, provided that notice is promptly delivered
to the non-disclosing Party in order to provide an opportunity to challenge or
limit the disclosure obligations.

 

ARTICLE 6

DISCLAIMERS, REPRESENTATIONS,
WARRANTIES AND INDEMNIFICATIONS

 

6.1           Isis Representations and Warranties.  Isis represents and warrants to Lilly as
follows:

 

6.1.1        Corporate Existence and
Authority.  As of the
Option Exercise Date, Isis:  (a) is
a corporation duly organized, validly existing and in good standing under the
laws of the state in which it is incorporated, (b) has full corporate
power and authority and the legal right to own and operate its property and
assets and to carry on its business as it is now being conducted and as
contemplated in this Agreement, including the right to grant the options to
license and licenses granted hereunder, (c) has the corporate power and
authority and the legal right to enter into this Agreement and perform its
obligations hereunder, (d) has taken all necessary corporate action on its
part required to authorize the execution and delivery of the Agreement and the
performance of its obligations hereunder, and (e) has delivered an
Agreement that has been duly executed and constitutes a legal, valid, binding
obligation of Isis and is enforceable against it in accordance with its terms;

 

6.1.2        Patents, Prior Art.  As of the Option Exercise Date and to the
best of Isis’ knowledge, it has the sufficient legal and/or beneficial title
and ownership under the Isis Technology as is necessary to fulfill its
obligations under this Agreement and to grant the licenses and options to
license to Lilly pursuant to this Agreement. 
Isis is not aware of any communications alleging that it has violated
or, by conducting its business as currently proposed under this Agreement, would
violate any of the intellectual property rights of any Third Party;

 

6.1.3        Absence of Litigation,
Infringement, Misappropriation.  As of the Option Exercise Date and to the
best of Isis’ knowledge, there is no pending or threatened litigation (and Isis
has not received any communication relating thereto) which alleges that Isis’
activities in developing the Product infringe or misappropriate any
intellectual property rights of any Third Party.  To the best of Isis’ knowledge, there is no
material unauthorized use, infringement or misappropriation of any of its
intellectual property rights that are the subject of the licenses or options to
license granted hereunder;

 

6.1.4        Upstream Licenses.   True and correct copies of the Upstream
Licenses have previously been provided to Lilly by Isis. The Upstream Licenses
are in full force and effect as of the Effective Date, and Isis is not in
material breach of any of the provisions of any 

 

8

 

of the Upstream Licenses, nor does there exist any condition that, to the
knowledge of Isis, with passage of time or sending of notice would constitute a
material breach by Isis of any of the provisions of the Upstream Licenses, nor
is Isis aware of any material breach of the Upstream Licenses by any other
party thereto.  Isis has not waived any
material rights under any Upstream Licenses. 
Isis will not amend or terminate any Upstream License or waive any
rights under any Upstream License during the term of this Agreement without the
prior written consent of Lilly.  Isis will fulfill all
of its material obligations under the Upstream Licenses and otherwise comply
with the terms thereof, and, notwithstanding any other provisions of this
Agreement to the contrary, will be solely responsible for and pay when due any
payments due under the Upstream Licenses. Isis shall exercise its rights under
the Upstream Licenses in a manner consistent with the intent and terms of this
Agreement.

 

6.1.5        Full Disclosures.  Isis has provided Lilly with all information
that Lilly has requested for deciding the merits of entering into this
Agreement and all information reasonably useful or necessary to enable Lilly to
make an informed decision regarding entering into this Agreement;

 

6.1.6        Employee Obligations.  All Isis employees who will conduct research
under this Agreement have legal obligations requiring assignment to Isis of all
inventions made in the course of and as a result of their association with Isis
and obligating the individual to maintain as confidential the Confidential
Information of Isis, as well as the Confidential Information of Lilly which
Isis may receive;

 

6.1.7        No Debarment.  Isis will comply at all times with the
provisions of the Generic Drug Enforcement Act of 1992 and will upon request
certify in writing to Lilly that none of its employees nor any person providing
services to Isis in connection with this Agreement have been debarred under the
provisions of such Act; and

 

6.1.8        Licenses.  Isis has not taken nor will it take any
action which would, in Isis’ good faith judgment, interfere with any
obligations of Isis set forth in this Agreement, including but not limited to
the licenses granted by Isis to Lilly under ARTICLE 3.

 

6.2           Lilly Representations and Warranties.  Lilly represents and warrants to Isis as
follows:

 

6.2.1        Corporate Existence and
Authority.  As of the
Effective Date, Lilly:  (a) is a
corporation duly organized, validly existing and in good standing under the
laws of the state in which it is incorporated, (b) has full corporate
power and authority and the legal right to own and operate its property and
assets and to carry on its business as it is now being conducted and as
contemplated in this Agreement, including the right to grant the options to
license and licenses granted hereunder, (c) has the corporate power and
authority and the legal right to enter into this Agreement and perform its
obligations hereunder, (d) has taken all necessary corporate action on its
part required to authorize the execution and delivery of the Agreement and the
performance of its obligations hereunder, and (e) has delivered an
Agreement that has been duly 

 

9

 

executed and constitutes a legal, valid, binding obligation of Lilly
and is enforceable against it in accordance with its terms;

 

6.2.2        Employee Obligations.  All Lilly personnel who will conduct research
or development under this Agreement have legal obligations requiring assignment
to Lilly of all inventions made in the course of and as a result of their
association with Lilly and obligating the individual to maintain as
confidential the confidential information of Lilly, as well as the confidential
information of Isis which Lilly may receive;

 

6.2.3        Compliance with Laws.  In carrying out its work under this
Agreement, all Lilly work will be carried out in compliance with any applicable
laws including, without limitation, federal, state, or local laws, regulations,
or guidelines governing the work at the site where such work is being
conducted.  Moreover, Lilly will carry
out all work under this Agreement in accordance with current Good Laboratory
Practices, Good Clinical Practices, Good Manufacturing Practices, if applicable
based on the specific work to be conducted; and

 

6.2.4        No Debarment.  Lilly will comply at all times with the
provisions of the Generic Drug Enforcement Act of 1992 and will upon request
certify in writing to Isis that none of its employees nor any person providing
services to Lilly in connection with this Agreement have been debarred under
the provisions of such Act.

 

6.3           Disclaimer.  EXCEPT AS EXPRESSLY SET FORTH IN THIS
AGREEMENT, NEITHER PARTY MAKES ANY REPRESENTATION OR WARRANTY TO THE OTHER
PARTY OF ANY KIND, EXPRESS OR IMPLIED, INCLUDING, WITHOUT LIMITATION, ANY
WARRANTY OF NON-INFRINGEMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR
PURPOSE.  Without limiting the generality
of the foregoing, each Party expressly does not warrant (a) the success of
any Product or (b) the safety for any purpose of the technology it
provides hereunder.

 

6.4           Responsibility and Control.  Lilly and Isis will each be solely
responsible for the safety of their respective employees, agents, licensees or
Sublicensees with respect to efforts employed under this Agreement and each will
hold the other harmless with regard to any liability for damages or personal
injuries resulting from acts of its respective employees, agents, licensees or
Sublicensees.

 

6.5           Isis’ Right to Indemnification.  Lilly will indemnify each of Isis, its
Affiliates, Sublicensees, permitted successors and assigns, and the directors,
officers, employees, agents and counsel thereof (the “Isis
Indemnitees”), and defend and hold each Isis Indemnitee harmless
from and against any and all liabilities, damages, losses, settlements, claims,
actions, suits, penalties, fines, costs or expenses (including, without
limitation reasonable attorneys’ fees) (any of the foregoing, “Damages”) incurred by or asserted
against any Isis Indemnitee of whatever kind or nature, including, without
limitation, any claim or liability based upon negligence, warranty, strict
liability, or violation of government regulation but only to the extent arising
from or occurring as a result of a claim or demand made by a Third Party (a “Third Party Claim”) against any
Isis Indemnitee arising because of: (a) breach of any representation or
warranty made by Lilly pursuant to this ARTICLE 6; (b) any material
breach of this Agreement by Lilly; (c) the manufacture, use, handling,
storage, sale or other disposition of a Product that is 

 

10

 

sold or provided by Lilly, its Affiliates, agents or Sublicensees;
and/or (d) violation of the trade secrets of any Third Party by Lilly;
except, in each such case in subparagraphs (a) through (d) above, to
the extent that such Damages are finally determined to have resulted from the
negligence or misconduct of an Isis Indemnitee, or the breach of any
representation or warranty under Section 6.1 by Isis.

 

6.6           Lilly’s Right to Indemnification.  Isis will indemnify each of Lilly, its
Affiliates, Sublicensees, successors and assigns, and the directors, officers,
employees, agents and counsel thereof (the “Lilly Indemnitees”),
and defend and hold each Lilly Indemnitee harmless from and against any and all
Damages incurred by or asserted against any Lilly Indemnitee of whatever kind
or nature, including, without limitation, any claim or liability based upon
negligence, warranty, strict liability, violation of government regulation but
only to the extent arising from or occurring as a result of a Third Party Claim
against any Lilly Indemnitee arising because of: (a) breach of any
representation or warranty made by Isis pursuant to this ARTICLE 6;  (b) any material breach of this Agreement
by Isis; (c) the manufacture, use, handling, storage, sale or other
disposition of a Product that is sold or provided by Isis, its Affiliates,
agents or Sublicensees; (d) violation of the trade secrets of any Third
Party by Isis and/or (e) any Third Party Claim that any Isis Technology
should not have been disclosed or made available to Lilly; except, in each such
case, in subparagraphs (a) through (e) above, to the extent that such
Damages are finally determined to have resulted from the negligence or misconduct
of a Lilly Indemnitee, or the breach of any representation or warranty under Section 6.2
by Lilly.

 

6.7           Indemnification Procedures.  Promptly after a Party entitled to
indemnification under Section 6.5 or 6.6 (an “Indemnitee”)
receives notice of any pending or threatened claim against it (an “Action”), such Indemnitee will give
written notice to the Party to whom the Indemnitee is entitled to look for
indemnification pursuant to Section 6.5 or 6.6, as applicable (the “Indemnifying Party”), of the commencement
thereof, provided that the failure so to notify the Indemnifying Party will not
relieve it of any liability that it may have to any Indemnitee hereunder,
except to the extent the Indemnifying Party demonstrates that it is prejudiced
thereby.  In case any Action that is
subject to indemnification under this ARTICLE 6, will be brought against
an Indemnitee and it will give written notice to the Indemnifying Party of the
commencement thereof, the Indemnifying Party will be entitled to participate therein
and, if it so desires, to assume the defense thereof with counsel reasonably
satisfactory to such Indemnitee and, after notice from the Indemnifying Party
to the Indemnitee of its election to assume the defense thereof, the
Indemnifying Party will not be liable to such Indemnitee under this
ARTICLE 6 for any fees of other counsel or any other expenses, in each
case subsequently incurred by such Indemnitee in connection with the defense
thereof, other than reasonable costs of investigation.  Notwithstanding an Indemnifying Party’s
election to assume the defense of any such Action that is subject to
indemnification under this ARTICLE 6, the Indemnitee will have the right
to employ separate counsel and to participate in the defense of such Action,
and the Indemnifying Party will bear the reasonable fees, costs and expenses of
such separate counsel if:  (i) the
use of counsel chosen by the Indemnifying Party to represent the Indemnitee
would present such counsel with a conflict of interest; (ii) the actual or
potential defendants in, or targets of, any such Action include both the
Indemnifying Party and the Indemnitee, and the Indemnitee will have reasonably
concluded that there may be legal defenses available to it which are different
from or additional to those available to the Indemnifying Party (in which case
the 

 

11

 

Indemnifying Party will not have the right to assume the defense of
such Action on the Indemnitee’s behalf); (iii) the Indemnifying Party will
not have employed counsel satisfactory to the Indemnitee to represent the
Indemnitee within a reasonable time after notice of the institution of such
Action; or (iv) the Indemnifying Party will authorize the Indemnitee to
employ separate counsel at the Indemnifying Party’s expense.  If an Indemnifying Party assumes the defense
of such Action, no compromise or settlement thereof may be effected by the
Indemnifying Party without the Indemnitee’s written consent, which consent will
not be unreasonably withheld or delayed, unless (1) there is no finding or
admission of any violation of law or any violation of the rights of any other
Party and no effect on any other claims that may be made against the Indemnitee
and (2) the sole relief provided is monetary damages that are paid in full
by the Indemnifying Party.

 

ARTICLE 7

INTELLECTUAL PROPERTY

 

7.1           Patent Filing and Prosecution.  Except as provided in Section 7.2, Isis
will be responsible for preparing, filing, prosecuting, maintaining and taking
such other actions as are reasonably necessary or appropriate with respect to
the Isis Patent Rights.

 

7.2           Lilly at its own expense,
will prepare, file, prosecute and/or maintain the Isis ASO Compound Patent
Rights that are exclusively licensed by Lilly pursuant to Section 3.1.  In the event of termination under Section 3.2
or 8.5, or upon written agreement of the Parties, such responsibility and
expense for preparation, filing, prosecuting and maintenance will revert back
to Isis.  Lilly may use in-house patent
counsel or outside patent counsel that is acceptable to Isis for the filing,
prosecution and maintenance of Isis ASO Compound Patent Rights for which Lilly
assumes responsibility for under this Section 7.2.  Isis will promptly transfer the subject
patent files to Lilly and will execute such documents and perform such acts as
may be reasonably necessary for Lilly to take control of such patent filing,
prosecution and maintenance and will provide all necessary assistance in the
prosecution and maintenance thereof. 
Lilly will, in a timely manner, provide Isis with copies of all draft
applications, responses and other substantive papers relating to the filing,
prosecution and maintenance (including the verification of all fees and
annuities) of such Isis ASO Compound Patent Rights and will provide Isis with
an opportunity to comment on any draft applications, responses or amendments at
least [***] days prior to filing and to the extent practicable incorporate such
comments.  Isis
hereby acknowledges a possible conflict of interest between Lilly and Isis
relating to the Isis ASO Compound Patent Rights for which Lilly assumes
responsibility for filing, prosecution and maintenance under this Section 7.2.  So long as Lilly complies with provisions of
this Section 7.2, Isis hereby grants Lilly and Lilly’s patent counsel a
conflict waiver, to the limited extent of any conflict of interest arising from
the fact that (a) Lilly has the right to prepare, file, prosecute and
maintain the Isis ASO Compound Patent Rights pursuant to this Section 7.2
and (b) Isis owns or Controls such Patent Rights.  Isis and Lilly will discuss in good faith
assignment of any ASO Compound Patent Rights to Lilly.

 

7.3           Election Not to File, Prosecute or Maintain.  If Lilly elects to discontinue prosecution or
maintenance of any Isis ASO Compound Patent Right for which Lilly assumes
responsibility for filing, prosecution and maintenance (or that is assigned to
Lilly) under Section

 

12

 

7.2, then Lilly will give [***] days advance written notice to Isis of
any decision to cease preparation, filing, prosecution and maintenance of that
Patent Right (a “Discontinued Patent”); provided, however, that abandonment of a patent application
in favor of a continuation or a continuation-in-part thereof will not
constitute discontinuance of the patent application.  In such case, Isis may elect at its sole
discretion to continue preparation, filing, prosecution or maintenance of the Discontinued
Patent at its sole expense, and Isis will own any such patent application and
patents maturing therefrom and be solely responsible for all costs, and Lilly
will have a non-exclusive, worldwide, royalty-bearing (under Section 4.3)
license to continue to practice such Discontinued Patent, including the right
to sublicense solely to develop, make, use, import, offer for sale and sell a
Product, in accordance with the terms of Section 3.1. Lilly will execute
such documents and perform such acts as may be reasonably necessary for Isis to
file or to continue prosecution or maintenance, including assigning ownership
of such patents and inventions to Isis. 
Discontinuance may be on a country-by-country basis or for a patent
application or patent series in total.

 

7.4           Costs and Expenses.  Lilly will bear its own costs and expenses in
filing, prosecuting, maintaining and extending the Isis ASO Patent Rights.  Isis will bear its own costs and expenses in
filing, prosecuting, maintaining and extending the Isis Core Technology Patent
Rights and the Isis Manufacturing Patent Rights.

 

7.5           Patent Term Extensions.  The Parties will cooperate with each other in
gaining patent term extension wherever applicable to any Product.  The Party selling such Product will determine
which patents will be extended.  All
filings for such extension will be made by the Party selling such Product; provided, however, that in the event that the Party to
selling such Product elects not to file for an extension, such Party will (i) inform
the other Party of its intention not to file, (ii) grant the other Party
the right to file for such extension, and (iii) cooperate as necessary to
assist the other Party in filing such extension.

 

7.6           Notice of Certification.  Isis and Lilly each will immediately upon
receiving notice give notice to the other of any certification filed under the
U.S. “Drug Price Competition and Patent Term Restoration Act of 1984” claiming
that an Isis Patent Right Covering a Product being developed or commercialized
by Lilly hereunder is invalid or that any infringement will not arise from the
manufacture, use, sale, offer for sale or import of any product by a Third
Party.  If permitted under Section 7.2
and Lilly decides not to bring infringement proceedings against the entity
making such a certification with respect to a Isis Patent Right Covering a
Product being developed or commercialized by Lilly hereunder, Lilly will give
notice to Isis of its decision not to bring suit within twenty-one (21) days
after receipt of notice of such certification. 
Isis may then, but is not required to, bring suit against the entity
that filed the certification.  Any suit
by Lilly or Isis will either be in the name of Lilly or in the name of Isis, or
jointly by Lilly and Isis, as may be required by law.  For this purpose, the Party not bringing suit
will execute such legal papers necessary for the prosecution of such suit as
may be reasonably requested by the Party bringing suit.  Any costs incurred or benefits received as a
result of proceeding under this Section 7.6 will be paid or received
entirely by the Party who pursued the action.

 

7.7           Notice of Infringement Claim.  If the practice of a license granted to a
Party under this Agreement results in a claim against a Party for patent
infringement or for inducing or contributing to patent infringement (“Infringement Claim”), the Party
first having notice of an

 

13

 

Infringement Claim will promptly notify the other in writing.  The notice will set forth the facts of the
Infringement Claim in reasonable detail.

 

7.8           Responsibilities.  Isis will have the sole right to control any
defense of any Infringement Claim involving alleged infringement of Third Party
rights by Isis’ activities at its own expense and by counsel of its own choice,
and Lilly will have the right, at its own expense, to be represented in any
such action by counsel of its own choice. 
Lilly will have the sole right to control any defense of any
Infringement Claim involving alleged infringement of Third Party rights by
Lilly’s activities at its own expense and by counsel of its own choice, and
Isis will have the right, at its own expense, to be represented in any such
action by counsel of its own choice. 
Notwithstanding the foregoing, if the claim involves an allegation of a
violation of the trade secret rights of a Third Party, the Party accused of
such violation will have the obligation to defend against such claim and will
indemnify the other Party against all costs associated with such claim (in
accordance with Sections 6.5 through 6.7). 
Neither Party will have the right to settle any patent infringement
litigation under this Section 7.8 relating to any Patent Rights owned by
or exclusively licensed to the other Party hereunder without the consent of
such other Party.  Each Party will also
keep the other Party continually informed of all significant matters relating
to Infringement Claims of Third Parties.

 

7.9           Infringement Claims Against Third Parties.

 

7.9.1        Protection
Against Infringement.  Isis
and Lilly each agree to take reasonable actions to protect their respective
patents and technology from infringement and from unauthorized possession or
use.

 

7.9.2        Notice
of Infringement.  If any Isis
ASO Compound Patent Right licensed by Isis to Lilly under this Agreement is
infringed or misappropriated, as the case may be, by a Third Party, the Party
to this Agreement first having knowledge of such infringement or
misappropriation, will promptly notify the other in writing.  The notice will set forth the facts of such infringement
or misappropriation in reasonable detail. 
In such case, Lilly will have the primary right, but not the obligation,
to institute, prosecute, and control any action or proceeding with respect to
infringement or misappropriation of such Isis ASO Compound Patent Right by its
own counsel.  The other Party will have
the right, at its own expense, to be represented in such action by its own
counsel.  Except as otherwise agreed to
by the Parties as part of a cost-sharing arrangement, any recovery realized as
a result of such litigation, after reimbursement of any litigation expenses of
Isis and Lilly, will be retained by the Party that brought and controlled such
litigation for purposes of this Agreement, except that any recovery realized by
Lilly as a result of such litigation, after reimbursement of the Parties’
litigation expenses, will, to the extent [***] to [***], be treated as [***] of
[***] by Lilly.

 

7.9.3        Expenses
of Bringing Infringement Action.  Subject to Section 7.9.2, Lilly will
bear the costs and expenses of all infringement or misappropriation actions
brought by Lilly under this Agreement. 
Subject to Section 7.9.2, 
Isis will bear the costs and expenses of all infringement or
misappropriation actions brought by Isis under this Agreement.

 

7.9.4        Lilly’s
Failure to Institute, Prosecute and Control.  If Lilly fails to institute, prosecute, and
control such action or prosecution within a period of [***] days after

 

14

 

receiving
notice of the infringement, Isis, subject to the prior rights of any Third
Party, will have the right to bring and control any such action by counsel of
its own choice, and Lilly will have the right, at its own expense, to be
represented in any such action by counsel of its own choice. Except as
otherwise agreed to by the Parties as part of a cost-sharing arrangement, any
recovery realized as a result of such litigation, after reimbursement of 100%
of any litigation expenses of Isis and 100% of any litigation expenses of Lilly
(including the costs and expenses incurred by Lilly in providing reasonable
assistance to Isis), will be shared [***] by the Parties.  No settlement or consent judgment or other
voluntary final disposition of a suit under this Section 7.9.4 may be entered
into without the joint consent of Isis and Lilly (which consent will not be
unreasonably withheld or delayed).

 

7.9.5        Settlement
Approval.  Neither
Party will settle any such proceeding under this Section 7.9 without the
approval of the other Party, which approval will not be unreasonably withheld
or delayed.

 

ARTICLE 8

TERM AND TERMINATION

 

8.1           Term of Agreement.  This Agreement will commence on the Effective
Date and will continue until no payments are due or are capable of becoming due
hereunder, unless the Agreement is terminated earlier in accordance with this
ARTICLE 8. All licenses granted hereunder that are in effect at expiration of
this Agreement will be deemed fully paid-up and perpetual (as more specifically
described in 8.6.1 below), except as provided otherwise by this Agreement.

 

8.2           Termination for Breach.  Either Party may terminate this Agreement by
notice to the other Party at any time during the term of this Agreement if the
other Party is in breach of any material obligations hereunder and has not
cured such breach within ninety (90) days after notice requesting cure of the
breach or such longer period of time as is required to cure such breach as long
as the breaching Party is proceeding in good faith to cure; provided, however, that in any case when a breach is alleged
regarding the payment of money hereunder, the time period will be thirty (30)
days and undisputed amounts must be paid prior to such time to avoid
breach.  Upon material breach by a Party
of its obligations hereunder, if such Party decides not to terminate this
Agreement, such Party will have the right to offset any costs it may incur as a
result of curing such breach against the amounts payable to the breaching Party
for the performance of such obligations. 
Further, to the extent that a Party prevails in a lawsuit brought
against the other Party for material breach of this Agreement, such prevailing
Party will be entitled to collect from the other Party reasonable attorneys’
fees and legal costs incurred in connection with such law suit. If the
non-breaching Party terminates this Agreement under Section 8.2 following
material breach by the breaching Party, the breaching Party will return to the
non-Breaching Party all of the non-breaching Party’s Confidential Information
and all materials received from the non-breaching Party during the Agreement,
and the breaching Party will cease all use of the non-breaching Party’s
Confidential Information and materials received from the non-breaching Party
for any purpose except as provided in Section 8.7, and except that the
breaching Party may (1) keep a copy of all documents for record keeping
purposes only and (2) keep and use any Confidential Information and
materials received from the non-breaching

 

15

 

Party that are necessary for the breaching Party to exercise those of
its rights and fulfill those of its obligations that survive the termination of
this Agreement.

 

8.3           Termination
Upon Insolvency. 
Either Party may terminate this Agreement upon notice to the other
should the other Party become insolvent or file or consent to the filing of a
petition under any bankruptcy or insolvency law or have any such petition filed
against it which has not been stayed within sixty (60) days of such filing.  During the term of this Agreement, all rights
and licenses granted under or pursuant to this Agreement by Isis or Lilly are,
and will otherwise be deemed to be, for purposes of Section 365(n) of
the U.S. Bankruptcy Code, licenses of right to “intellectual property” as
defined under Section 101 of the U.S. Bankruptcy Code.  The Parties agree that, during the term of
this Agreement, the Parties, as licensees of such rights under this Agreement,
will retain and may fully exercise all of their rights and elections under the
U.S. Bankruptcy Code.  The Parties
further agree that, in the event of the commencement of a bankruptcy
proceeding-by or against either Party under the U.S. Bankruptcy Code, the Party
hereto that is not a party to such proceeding will be entitled to a complete
duplicate of (or complete access to, as appropriate) any such intellectual
property and all embodiments of such intellectual property, and same, if not
already in their possession, will be promptly delivered to them (i) upon
any such commencement of a bankruptcy proceeding upon their written request
therefor, unless the Party subject to such proceeding elects to continue to
perform all of its obligations under this Agreement, or (ii) if not
delivered under (i) above, following the rejection of this Agreement by or
on behalf of the Party subject to such proceeding upon written request therefor
by the non-subject Party.

 

8.4           Termination
at Will by Lilly. 
Lilly shall have the right to terminate this Agreement at will upon 90
days written notice to Isis.

 

8.5           Effect
of Termination Due to Lilly Breach, Insolvency or at Will.  If Isis terminates the Agreement based on
material breach by or insolvency of Lilly, or if Lilly terminates this
agreement at will pursuant to Section 8.4, then:

 

8.5.1        the licenses granted
by Isis to Lilly pursuant to Section 3.1 will terminate, and Lilly will
stop making and selling such Product;

 

8.5.2        any sublicense
granted by either Party to any Sublicensee under a license hereunder that
terminates as a result of termination of this Agreement by Isis pursuant to Section 8.2
or 8.3 will continue in full force and effect but will be assigned by such
Party to the other Party, and such Party will provide the other Party with
complete and accurate copies of such sublicense agreements within thirty (30)
days following the effective date of such termination; and

 

8.5.3        Lilly will promptly
re-assign any patents assigned to Lilly under this Agreement, and Lilly will
assign or otherwise transfer ownership of any regulatory filings related to the
Product.

 

8.6           Effect of Termination Due to Isis Breach or
Insolvency.  If Lilly
terminates the Agreement based on material breach by or insolvency of Isis,
then:

 

8.6.1        licenses granted by Isis to Lilly
pursuant to Section 3.1 will survive;

 

16

 

8.6.2        Lilly’s payment obligations set forth in
ARTICLE 4 will continue, provided, however,
that the amounts of the payments will be decreased to reflect the nature of
Isis’s breach and the damages caused thereby by amounts to be agreed upon by
the Parties or, if the Parties are unable to reach agreement, by an independent
Third Party with the requisite expertise selected by the Parties, the expense
of which will be borne by Isis; and

 

8.6.3        any sublicense granted by either Party
to any Sublicensee under a license hereunder that terminates as a result of
termination of this Agreement by Lilly pursuant to Section 8.2 or 8.3 will
continue in full force and effect but will be assigned by such Party to the
other Party, and such Party will provide the other Party with complete and
accurate copies of such sublicense agreements within thirty (30) days following
the effective date of such termination.

 

8.7           Accrued
Rights/Surviving Obligations. 
Except as expressly provided in this Agreement, expiration or
termination of this Agreement will not relieve the Parties of any obligation
that accrued prior to such expiration or termination, and Lilly will be
obligated to pay and will pay to Isis, within [***] days of such expiration or
termination, all payments and royalties due or accrued pursuant to the terms of
ARTICLE 4.  Upon expiration or early
termination of this Agreement, all rights and obligations of the Parties will
cease, except as follows:

 

8.7.1        In the case of expiration
of this Agreement only (and, for purposes of clarification, not in the case of
termination of this Agreement pursuant to Section 8.2 or 8.3), each of the
licenses set forth in Sections 3.1 will survive and will be deemed to be
perpetual and fully paid up, provided that all payment and other obligations
with respect to such licenses have been fulfilled;

 

8.7.2        The obligations to
pay royalties and other sums accruing hereunder up to the date of termination
or expiration will survive;

 

8.7.3        The obligations of
confidentiality set forth in ARTICLE 5 will survive;

 

8.7.4        The obligations for
record keeping and accounting reports set forth in ARTICLE 4 will survive
for so long as Products are sold.  At
such time after termination or expiration of this Agreement when sales or other
dispositions of Products have ceased, the Party selling such Product will
render a final report along with any royalty payment due;

 

8.7.5        Isis’ and Lilly’s
rights to inspect books and records as described in ARTICLE 4 will survive;

 

8.7.6        The obligations of
defense and indemnity set forth in ARTICLE 6 will survive;

 

8.7.7        Any cause of action
or claim of Isis or Lilly accrued or to accrue because of any breach or default
by the other Party hereunder will survive; and

 

17

 

8.7.8        All other terms,
provisions, representations, rights and obligations contained in this Agreement
that are intended to survive as specifically set forth elsewhere in this
Agreement will survive.

 

8.8           Limitation of Liability.  No Party will be liable to another for
indirect, incidental, consequential or special damages, including but not
limited to lost profits, arising from or relating to any breach of this
Agreement, regardless of any notice of the possibility of such damages.  Nothing in this Section is intended to
limit or restrict the indemnification rights or obligations of any Party under
ARTICLE 6.

 

ARTICLE 9

PUBLICITY

 

9.1           Press Release.  Upon execution of this Agreement, the Parties
shall issue a joint press release announcing the existence of this Agreement in
a form and substance agreed to in writing by the Parties.

 

9.2           Disclosure
of Agreement.  Neither
Party to this Agreement may release any information to any Third Party
regarding the terms or existence of this Agreement or the reasons for any
termination hereof, without the prior written consent of the other Party.  Without limitation, this prohibition applies
to press releases, educational and scientific conferences, quarterly investor
updates, promotional materials, governmental filings and discussions with
public officials, the media, security analysts and investors.  However, this provision does not apply to any
disclosures regarding this Agreement or related information to regulatory
agencies such as the FDA or Federal Trade Commission and/or Department of
Justice for such disclosures which may be required by law, including requests
for a copy of this Agreement or related information by tax authorities.  If any Party to this Agreement determines a release
of information regarding the existence or terms of this Agreement is required
by law (including releases a may be required to be filed through the Securities
Exchange Commission or other government agency), that Party will notify the
other Party as soon as practicable and give as much detail as possible in
relation to the disclosure required.  The
Parties will then cooperate with respect to determining what information should
actually be released.  The Parties hereby
agree that release of a press release upon complete execution of this Agreement
is appropriate and such press release will be mutually agreed upon by the
Parties.

 

9.3           Use of
Names, Logos or Symbols. 
No Party hereto will use the name, trademarks, logos, physical likeness,
employee names or owner symbol of any other Party for any purpose, including,
without limitation, private or public securities placements, without the prior
written consent of the affected Party, such consent not to be unreasonably
withheld or delayed so long as such use of name is limited to objective
statements of fact, rather than for endorsement purposes.  Nothing contained herein will be construed as
granting either Party any rights or license to use any of the other Party’s
trademarks or tradenames without separate, express written permission of the
owner of such trademark or tradename.

 

18

 

9.4           Publications.

 

9.4.1        On a country by country basis and only
with respect to the Major Market Countries, prior to Registration of the
Product in such country, (i) Lilly will notify (and provide as much
advance notice as possible to) Isis of any event materially related to Product
(including the Product’s efficacy, safety, clinical data or results, any
Registration Submission or Registration) so that the Parties may analyze the
need to or desirability of publicly disclosing or reporting such event; and (ii) Lilly
may publish, present or otherwise disclose results regarding the Product to the
public at its sole discretion; however, any
press release or other similar public communication by either Party related to
a Product’s efficacy, safety, clinical data or results, Registration Submission
or Registration, will be submitted to the other Party for review at least 5
Business Days in advance of such proposed public disclosure.

 

9.4.2        On a country by country basis and only
with respect to the Major Market Countries, after Registration of the Product
in such country, the appropriateness of all publications regarding development
or commercialization of the Products in such country shall be determined by
Lilly and Lilly may publish, present or otherwise disclose results regarding
the Product to the public at its sole discretion; however,
in each case Lilly will submit to Isis for review at least 5 Business Days in
advance of such proposed public disclosure, any press release or other similar
public communication related to new and materially negative information
regarding a Product’s safety, or clinical data or results.

 

9.4.3        Notwithstanding the foregoing, the contents of any
announcement or similar publicity which has been reviewed and approved by the
reviewing Party can be re-released by either Party without a requirement for
re-approval.

 

ARTICLE 10

MISCELLANEOUS

 

10.1         Further Assurances, HSR.  Each Party will duly execute and deliver such
further instruments and do and cause to be done such further acts and things,
including the filing of such assignments, agreements, documents and
instruments, as may be necessary or as the other Party may reasonably request
in connection with this Agreement in order to carry out more effectively the
provisions and purposes of this Agreement. Each of the Parties shall use its commercially
reasonable efforts to take all actions necessary or advisable under applicable
laws to consummate and make effective the transactions contemplated by this
Agreement including the taking of such reasonable actions as are necessary to
obtain any requisite approvals, consents, orders, exemptions or waivers by any
governmental authority, including filings pursuant to the Hart-Scott-Rodino
Antitrust Improvements Act of 1976, as amended (the “HSR Act”), if
required.  The Parties shall make any
necessary filings under the HSR Act as soon as practicable, but in any event
not more than fifteen (15) days following the Effective Date.  In the event the Parties conclude that a
filing under the HSR Act is necessary, no payments shall be made and no license
granted hereunder shall become effective and, except for this Section 10.1,
no time period measured from the Effective Date, shall commence until the
applicable waiting period under the HSR Act has expired or been
terminated.  In the event the applicable
waiting period has not expired or been terminated within six months of the
Effective Date, either Party shall have the option to terminate this Agreement
without liability upon written notice to the other.  Neither Party shall be obligated

 

19

 

to agree to any divestiture of assets or limitation on
its current or future businesses in connection with obtaining clearance under
the HSR Act or other requirement if the Party in good faith believes that the
same is unreasonable.

 

10.2         Force
Majeure.  No Party will
be held liable or responsible to the other Party nor be deemed to have
defaulted under or breached the Agreement for failure or delay in fulfilling or
performing any term of the Agreement (except payment obligations) when such
failure or delay is caused by or results from causes beyond the reasonable
control of the affected Party including, but not limited to, fire, flood,
earthquake, embargo, war, acts of war or terrorism (whether war be declared or
not), insurrection, riot, civil commotion, strike, lockout or other labor
disturbance, act of God or act, omission or delay in acting by any governmental
authority or the other Party.  The
affected Party will notify the other Party of such force majeure circumstances
as soon as reasonably practical.

 

10.3         Assignment.  This Agreement may not be assigned or
otherwise transferred, nor, except as expressly provided hereunder, may any
right or obligations hereunder be assigned or transferred, by a Party without
the written consent of the other Party; provided, however,
that either Party may, without such consent, (1) assign the Agreement and
its rights and obligations hereunder to (i) any wholly-owned subsidiary in
a manner such that the assignor (if it continues as a separate entity) will
remain liable and responsible for the performance and observance of all its
duties and obligations hereunder or (ii)  to any successor by merger or
sale of substantially all of its business unit to which this Agreement relates,
or in the event of its merger or consolidation or Change in Control or similar
transaction; or (2) Isis may assign or transfer its rights to receive
fees, royalties and milestones under this Agreement (but no liabilities),
without Lilly’s consent, to a Third Party in connection with a payment
factoring transaction.  This Agreement
will be binding upon the permitted successors and permitted assigns of the
Parties.  Any assignment not in
accordance with this Section 10.3 will be void.

 

10.4         Severability.  In the event that any of the provisions
contained in this Agreement are held invalid, illegal or unenforceable in any
respect, the validity, legality and enforceability of the remaining provisions
contained herein will not in any way be affected or impaired thereby, unless
the absence of the invalidated provision(s) adversely affect the
substantive rights of the Parties.  The
Parties will replace the invalid, illegal or unenforceable provision(s) with
valid, legal and enforceable provision(s), which, insofar as practical,
implement the purposes of this Agreement.

 

10.5         Notices.  All notices or other communications which are
required or permitted hereunder will be in writing and deemed to be effective (a) on
the date of delivery if delivered in person and written confirmation of
delivery is provided, (b) on the date sent by facsimile or other electronic
transmission, provided such receipt is verified, (c) on the day following
date of deposit with an overnight courier if a receipt confirming delivery by
overnight courier is provided, or (d) three days after mailing if mailed
by first-class certified mail, postage paid, to the respective addresses given
below, or to another address as it will designate by written notice given to
the other Party.

 

20

 

if to Isis, to:

 

Isis Pharmaceuticals, Inc.

1896 Rutherford Road

Carlsbad, CA 92008

Attention:          Chief Operating
Officer

Telephone:        760-931-9200

Facsimile:           760-918-3592

 

with a copy to:

 

Attention:          General Counsel

Telephone:        760-931-9200

Facsimile:           760-268-4922

 

if to Lilly, to:

 

Eli Lilly and Company

Lilly Corporate Center

Indianapolis, IN 46285

Attention:          Group Vice
President, Lilly Research Laboratories

with a copy to:

 

Attention:          General Patent
Counsel

 

10.6         Dispute Resolution.  In the event of any controversy or claim
arising from or relating to any provision of this Agreement, or any term or
condition hereof, or the performance by a Party of its obligations hereunder,
or its construction or its actual or alleged breach, the Parties will try to
settle their differences amicably between themselves.

 

10.7         Choice of Law.  This Agreement will be governed by and
construed in accordance with the laws of the State of New York and the United
States without reference to any rules of conflict of laws.

 

10.8         Entire Agreement.  This Agreement (including all Schedules
hereto), constitute the entire agreement between the Parties with respect to
the subject matter hereof, and supersedes all previous arrangement with respect
to the subject matter hereof, whether written or oral.  Any amendment or modification to this
Agreement will be made in writing signed by both Parties.

 

10.9         Headings.  The captions to the several Articles and
Sections hereof are not a part of the Agreement, but are merely guides or
labels to assist in locating and reading the several Articles and Sections hereof.

 

10.10       Independent Contractors.  It is expressly agreed that the Parties will
be independent contractors and that the relationship between the Parties will
not constitute a partnership, joint venture or agency.  No Party will have the authority to make any
statements, 

 

21

 

representations or commitments of any kind, or to take any action,
which will be binding on the other Parties, without the prior consent of such
other Parties.

 

10.11       Further Actions.  Each Party agrees to execute, acknowledge and
deliver such further instruments, and to do all such other acts, as may be
necessary or appropriate in order to carry out the purposes and intent of the
Agreement.

 

10.12       Waiver.  The waiver by a Party hereto of any right
hereunder or the failure to perform or of a breach by another Party will not be
deemed a waiver of any other right hereunder or of any other breach or failure
by said other Party whether of a similar nature or otherwise.

 

10.13       Jointly Prepared.  This Agreement has been prepared jointly and
will not be strictly construed against either Party.

 

10.14       Counterparts.  This Agreement may be executed in two or more
counterparts, each of which will be deemed an original, but all of which
together will constitute one and the same instrument.

 

[THIS
SPACE INTENTIONALLY LEFT BLANK]

 

22

 

IN WITNESS WHEREOF, the Parties
have executed this Agreement as of the Effective Date.

 

 

	
  ELI LILLY AND COMPANY

  	
   

  	
  ISIS PHARMACEUTICALS, INC.

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
  By:

  	
   

  	
   

  	
  By:

  	
   

  
	
   

  	
   

  	
  B. Lynne Parshall

  
	
   

  	
   

  	
  Chief Operating Officer and

  
	
   

  	
   

  	
  Chief Financial Officer

  
					

 

 

[SIGNATURE PAGE TO
DEVELOPMENT AND LICENSE AGREEMENT]

 

 

List of
Schedules

 

Schedule
1.1              Definitions

 

Schedule A               Isis ASO Compound Patent
Rights as of the Effective Date

 

Schedule
B                Isis Manufacturing Patent
Rights as of the Effective Date

 

Schedule
C                Isis Core Technology Patent
Rights as of the Effective Date

 

 

SCHEDULE
1.1

 

DEFINITIONS

 

“Active Program” means with respect to a
Product, any [***], of a Product. 
Without limitation of the generality of the foregoing, for purposes of
clarification, research, development and commercialization efforts with respect
to a Product will be deemed reasonable if Lilly’s research and development
efforts with respect to such Product are reasonably comparable with other
products in Lilly’s portfolio at a similar stage of development, of similar
market potential, and presenting similar development or commercialization
challenges.

 

“Affiliate” means any
person, organization, corporation or other business entity that controls,
directly or indirectly, the power to direct, or cause the direction of, the
management and policies of another person, organization, corporation or entity,
whether through the ownership of voting securities or by contract or court
order or otherwise.  For purposes of this
definition, an entity will be deemed to control another entity if it owns or
controls, directly or indirectly, at least fifty percent (50%) of the
outstanding stock or other voting rights entitled to elect directors or their
equivalent of such other entity.  Regulus
Therapeutics Inc. will not be considered an Affiliate of Isis.

 

“ASO Compound” means an [***].

 

“ASO Field” means the
development, manufacture and sale of ASO Products for all uses.

 

“Calendar Quarter” will mean the respective
three month periods ending on March 31, June 30, September 30,
or December 31 for so long as the Agreement is in effect.

 

“Calendar Year” will mean each
successive twelve month period commencing on January 1 and ending on December 31
for so long as the Agreement is in effect.

 

“Change in Control” means any of the following
events:  (i) the acquisition by any
Person or group, other than a Person or group controlling such Party as of the
Effective Date, of “beneficial ownership” (as defined in Rule 13d-3 under
the United States Securities Exchange Act of 1934, as amended), directly or
indirectly, of fifty percent (50%) or more of the shares of such Party’s
capital stock the holders of which have general voting power under ordinary
circumstances to elect at least a majority of such Party’s Board of Directors
or equivalent body (the “Board of Directors”)
(the “Voting Stock”); (ii) the first
day of which less than two-thirds of the total membership of such Party’s Board
of Directors will be Continuing Directors (as such term is defined below); (iii) the
approval by the shareholders of such Party of a merger, share exchange,
reorganization, consolidation or similar transaction of such Party (a “Transaction”), other than a
Transaction which would result in the Voting Stock of such Party outstanding
immediately prior thereto continuing to represent (either by remaining
outstanding or by being converted into voting securities of the surviving
entity) more than fifty percent (50%) of the Voting Stock of such Party or such
surviving entity immediately after such Transaction; or (iv) approval by
the shareholders of such Party of a complete liquidation of such Party or a
sale or disposition of all or substantially all of the assets of such
Party.  For purposes of this

 

1.1-1

 

definition,
“Continuing Directors” means individuals serving as of the Second Restatement
Date hereof on such Party’s Board of Directors and any individuals elected
after the date hereof whose election or nomination was approved by at least a
majority of the Continuing Directors serving at the time.

 

“Compulsory License” means, in the case of
Product, a compulsory license under the a Party’s technology obtained by a
Third Party through the order, decree or grant of a governmental authority
having competent jurisdiction, authorizing such Third Party to manufacture,
use, sell, offer for sale or import such Product in a particular country.

 

“Confidential Information” means any and
all inventions, know-any, and data and will include, without limitation,
information relating to research and development plans, experiments, results
and plans, compounds, therapeutic leads, candidates and products, clinical and
preclinical data, trade secrets and manufacturing, marketing, financial,
regulatory, personnel and other business information and plans, all scientific,
clinical, regulatory, marketing, financial and commercial information or data,
all whether communicated in writing, orally or by any other means, and which is
provided by one Party to the other Party in connection with this Agreement.  Confidential Information will not include
information that:

 

(a)           is known by the
receiving Party at the time of its receipt, and not through a prior disclosure
by the disclosing Party, as documented by written records;

 

(b)           is properly in
the public domain through no fault of the receiving Party;

 

(c)           is subsequently
disclosed to the receiving Party by a Third Party who may lawfully do so and is
not under an obligation of confidentiality to the disclosing Party; or

 

(d)           is developed by
the receiving Party independently of Confidential Information received from the
other Party, as documented by written records.

 

“Control” or “Controlled” means with respect to
any intellectual property right, that the Party owns or has a license to such
intellectual property right and has the ability to grant access, a license, or
a sublicense to such intellectual property right to the other Party as provided
for in this Agreement without violating an agreement with, or infringing any
rights of, a Third Party as of the time the Party would be first required under
this Agreement to grant the other Party such access, license or sublicense.

 

“Cover” (including
variations thereof such as “Covering”,
“Covered”, and “Coverage”)
means that the manufacture, use, import, offer for sale or sale of a Product
would infringe a Valid Claim; provided, with respect to a process or
manufacturing patent, that such a Valid Claim therein effectively precludes a
Third Party from manufacturing, using, importing, offering for sale, or selling
such Product.  The determination of
whether a Product is Covered by a particular Valid Claim will be made on a
country-by-country basis.  A Valid Claim
will be deemed to provide effective preclusion hereunder where (i) there
is no competing product being marketed or (ii) if a product is being
marketed by a competitor, it infringes the Valid Claim (including any period in
which, and provided that, the Valid Claim is being litigated).

 

1.1-2

 

“CPI” or “Consumer Price Index” means the
consumer price index for all urban consumer series ID CUUR0000SAO as published
from time to time by the US Bureau of Labor Statistics, where the CPI for June,
2001 was 178.

 

“Effective Date” has the meaning ascribed to
it in the preamble.

 

“eIF-4E” means
eukaryotic initiation factor-4E (Entrez Gene ID: 1977).

 

“eIF-4E Compound” means [***] of
the [***] that are [***] eIF-4E [***] eIF-4E [***].

 

“FDA” means the
United States Food and Drug Administration or any successor agency having the
administrative authority to regulate the approval for marketing of new human
pharmaceutical or biological therapeutic products in the United States.

 

“First Commercial Sale” means with
respect to any Product the first sale to a Third Party by Lilly, its Affiliates
or Sublicensees.  First Commercial Sale
will not include transfer of reasonable quantities of any free samples of a
Product or reasonable quantities of a Product solely for development purposes,
such as for use in experimental studies or clinical trials. First Commercial
Sale with respect to an Indication means the First Commercial Sale following
receipt of regulatory approval to include such Indication in the official
labeling for the Product.

 

“[***] Agreement” means that
certain agreement between [***] and [***]effective [***], and any amendments
thereto.

 

“IND” means an
Investigational New Drug application as defined in 21 C.F.R. 312 and any
versions thereof governing the FDA as may be amended from time to time.

 

“Indication” means, with
respect to a Product, such Product’s interference with a gene to affect a
specific primary endpoint of a pathophysiologic state, regardless of
etiology.  For purposes of clarity, if an
Indication was not included in a particular NDA (or any foreign counterpart or
equivalent section) for a Product but is included in a subsequent NDA (or
abbreviated NDA or supplemental NDA) for such Product, such Indication is
presumptively a separate and distinct “Indication” from all other Indications
for such Product.

 

“Initiate” means with respect to a clinical study, the initial dosing of the first
patient in such study.

 

“Institutional Review
Board” means an Institutional Review Board as defined in
21 C.F.R. 56 as may be amended from time to time, or its applicable foreign
equivalent.

 

“Isis ASO Compound Patent
Rights” means Patent Rights Controlled by Isis on or after
the Effective Date that Cover the composition of matter of a Product or the
method of using such Product per se.  A representative list of the Isis ASO
Compound Patent Rights as of the Effective Date is attached to this Agreement
as Schedule A.

 

1.1-3

 

“Isis Core Technology
Patent Rights” means Patent Rights Controlled by Isis on or after
the Effective Date that Cover the practice of Isis Standard Chemistry including
Patent Rights that Cover chemistries, motifs (patterns of arranging the
chemical building blocks of an antisense oligonucleotides) and/or cellular
mechanism of action by which an oligonucleotide promotes RNA cleavage. A
representative list of the Isis Core Technology Patent Rights that exist as of
the of this Agreement are listed in Schedule C.

 

“Isis Know-How” means all
Know-How that is either (i) Controlled by Isis as of the Effective Date or
(ii) that becomes Controlled by Isis after the Effective Date that is
reasonably necessary or useful for research, development, manufacture, use and
sale of Products.

 

“Isis Manufacturing Patent
Rights” means Patent Rights Controlled by Isis on or after
the Effective Date that Cover the practice of the Isis Standard Chemistry
Manufacturing Process.  The Isis
Manufacturing Patent Rights as of the date of this Agreement are listed in Schedule B.

 

“Isis Patent Rights” means the Isis Core
Technology Patent Rights, the Isis Manufacturing Patent Rights and Isis ASO
Compound Patent Rights.  To the extent
Isis Controls Patent Rights as of the Effective Date other than the Isis
Manufacturing Patents, Isis Core Technology Patent Rights, and the Isis ASO
Compound Patent Rights, and such Patent Rights would Cover a Product, such
Patent Rights will be included in the definition of Isis Patent Rights
automatically if they can be licensed to Lilly with no obligation (financial or
otherwise) to any Third Party with respect to a Product.  To the extent Isis Controls Patent Rights as
of the Effective Date, other than the Isis Manufacturing Patent Rights, the
Isis Core Technology Patent Rights and Isis ASO Compound Patent Rights that
would Cover a Lilly ASO Product, and such Patent Rights were acquired by Isis
from a Third Party and/or Isis has obligations (financial or otherwise) to a
Third Party in connection with the practice of such Patent Rights, such Patent
Rights will only be included in the definition of Isis Patent Rights if Isis
and Lilly negotiate an agreement to license such Patent Rights which includes (1) the
assumption by Lilly of all financial obligations of Isis arising from the grant
to Lilly and the practice by Lilly, its Affiliates of Sublicensees, of the
Patent Rights, (2) the compensation of an appropriate portion of any
acquisition costs incurred by Isis in connection with obtaining Control of such
Patent Rights, and (3) an agreement by Lilly to abide by all of the terms
of the agreement under which Isis has obtained Control of such Patent
Right.  For purposes of determining
whether a royalty is payable under Section 4.4 Isis Patent Rights will
include any Patent Right assigned to Lilly under Section 7.2.

 

“Isis Standard Chemistry” means “2 ́MOE Gapmers” or an
antisense phosphothioate oligonucleotide of [***] nucleotides wherein all of
the backbone linkages are modified by adding a sulfur at the non-bridging
oxygen (phosphorothioate) and a stretch of at least [***] consecutive
nucleotides remain unmodified (deoxy sugars) and the remaining nucleotides contain
an O ́-methyl O ́-ethyl substitution at the 2 ́ position (MOE).

 

“Isis Standard Chemistry
Manufacturing Process” means the manufacturing
process as of the [***], represented by the batch record for Isis [***].  Manufacturing for this purpose includes [***].

 

“Isis Technology” means Isis
Know-How and Isis Patent Rights.

 

1.1-4

 

“Know-How” means all tangible or intangible know-how,
inventions (whether patentable or not), discoveries, processes, formulas, data,
clinical and preclinical results, non-patented inventions, trade secrets, and
any physical, chemical, or biological material or any replication of any such
material in whole or in part.

 

“[***] Market Type(s)” means any of
[***]

 

“License Option Agreement” has the
meaning set forth in Recital C.

 

“Major Market Country” means the
[***].

 

“NDA” means a new drug application or other application
filed with the FDA to obtain approval for marketing a Product in the United
States, or any future equivalent process.

 

“Net Royalty” means the
effective royalty rate payable to a Party hereunder determined by subtracting
from the actual royalty rate set forth in Section 4.4 hereof the royalty
that such Party is required to pay to a Third Party licensor, including, without
limitation, under the [***] Agreement or the [***] Agreement.

 

“Net Sales” means, with
respect to a Product, the gross amount invoiced by a Party, its Affiliates or
Sublicensees thereof to unrelated Third Parties, excluding any Sublicensee, for
the Product, less:

 

(a)           Trade, quantity
and cash discounts allowed;

 

(b)           Commissions,
discounts, refunds, rebates, chargebacks, retroactive price adjustments, and
any other allowances which effectively reduce the net selling price;

 

(c)           Product returns
and allowances;

 

(d)           That portion of
the value associated with the cost of the drug delivery systems;

 

(e)           Any tax imposed
on the production, sale, delivery or use of the Product, including, without
limitation, sales, use, excise or value added taxes;

 

(f)            Allowance for
distribution expenses; and

 

(g)           Any other
similar and customary deductions.

 

Net Sales will be calculated
in U.S. Dollars.  Such amounts will be
determined from the books and records of a Party, its Affiliate or Sublicensee,
maintained in accordance with U.S. Generally Accepted Accounting Principles or,
in the case of Sublicensees, such similar accounting principles, consistently
applied.  Each Party further agrees in
determining such amounts, it will use its then current standard procedures and
methodology, including its then current standard exchange rate methodology for
the translation of foreign currency sales into U.S. Dollars or, in the case of
Sublicensees, such similar methodology, consistently applied.

 

Net Sales excludes:

 

1.1-5

 

(i)            The transfer of
reasonable and customary quantities of free samples of Product(s) and the
transfer of Product(s) as clinical trial materials, other than for
subsequent resale;

 

(ii)           Sales or
transfers of Product(s) among a Party and its Affiliates unless the
receiving Party is the consumer or user of the Product(s); and

 

(ii)           Use by a Party
or its Affiliates or Sublicensees of Product for any use connected with the
securing of regulatory approval or validating of a manufacturing process or the
obtaining of other necessary marketing approvals for Product (unless such
Product is subsequently sold).

 

In the event that the
Product(s) is sold as part of a Combination Product (where “Combination Product” means any
pharmaceutical product which comprises the Product(s) and at least one
other active compound(s) and/or ingredients), the Net Sales of the
Product(s), for the purposes of determining royalty payments, will be
determined by multiplying the Net Sales of Combination Product (as defined in
the standard Net Sales definition) by the fraction, A / (A+B) where A is the
weighted average sale price of the Product(s) when sold separately in
finished form, and B is the weighted average sale price of the other product(s) sold
separately in finished form.

 

In the event that the
weighted average sale price of the Product(s) can be determined but the
weighted average sale price of the other product(s) cannot be determined,
Net Sales for purposes of determining royalty payments will be calculated by
multiplying the Net Sales of the Combination Product by the fraction A / C
where A is the weighted average sale price of the Product(s) when sold
separately in finished form and C is the weighted average selling price of the
Combination Product.  In the event that
the weighted average sale price of the other product(s) can be determined
but the weighted average sale price of the Product cannot be determined, Net
Sales for purposes of determining royalty payments will be calculated by
multiplying the Net Sales of the Combination Product by the following
formula:  one (1) minus B / C where
B is the weighted average sale price of the other product(s) when sold
separately in finished form and C is the weighted average selling price of the
Combination Product.  In the event that
the weighted average sale price of both the Product(s) and the other
product(s) in the Combination Product cannot be determined, the Parties
will attempt to agree on an appropriate weighted average sale price of both the
Product(s) and the other product(s) in the Combination Product, and
lacking such agreement the Net Sales of the Product(s) will be deemed to
be equal to fifty percent (50%) of the Net Sales of the Combination Product.

 

The weighted average sale
price for a Product, other product(s), or Combination Product will be
calculated once each Calendar Year and such price will be used during all
applicable royalty reporting periods for the entire Calendar Year.  When determining the weighted average sale
price of a Product, other product(s), or Combination Product, the weighted
average sale price will be calculated by dividing the sales dollars (translated
into U.S. Dollars) by the units of active ingredient sold during the twelve
(12) months (or the number of months sold in a partial Calendar Year) for the
respective Product(s), other product(s), or Combination Product.  In the initial Calendar Year, a forecasted
weighted average sale price will be used for Product(s), other product(s), or
Combination Product.  Any over or under
payment due to a difference between 

 

1.1-6

 

forecasted
and actual weighted average sale prices will be paid or credited in the first
royalty payment of the following Calendar Year.

 

“[***] Agreement” means that
certain agreement between [***] effective [***] and all amendments thereto.

 

“Option Exercise Date” has the
meaning set forth in Recital D.

 

“Patent Rights” means: (a) patent
applications (including provisional applications and applications for certificates
of invention); (b) any patents issuing from such patent applications
(including certificates of invention); (c) all patents and patent
applications based on, corresponding to, or claiming the priority date(s) of
any of the foregoing; (d) any reissues, substitutions, confirmations,
registrations, validations, re-examinations, additions, continuations,
continued prosecutions, continuations-in-part, or divisions of or to any of the
foregoing; and (e) term extension or other governmental action which
provide exclusive rights beyond the original patent expiration date.

 

“Phase II Study”
means a human clinical trial conducted on a series of patients with the same
type of cancer, in each case where the protocol for such phase II study was
approved by the applicable Institutional Review Board.

 

“Phase III Study Initiation”  means
the dosing of the first patient in the first human clinical trial conducted in
patients and designed to establish Product safety and efficacy and required to
obtain clinical registration of a product with health regulatory authorities
such as the FDA.

 

“Product” means any
preparation in final form for sale by prescription, over-the-counter or any
other method for any indication, including human or animal use, which contains
an eIF-4E Compound.

 

“Registration” means (a) in the
United States, approval by the FDA of an NDA, or similar application for
marketing approval, and satisfaction of any related applicable FDA registration
and notification requirements (if any), and (b) in any Major Market
Country other than the United States, approval by regulatory authorities having
jurisdiction over such country of a single application or set of applications
comparable to an NDA and satisfaction of any related applicable regulatory and
notification requirements, if any, together with any other approval necessary
to make and sell pharmaceuticals and medical devices commercially in such
country.

 

“Registration Submission” means (a) in
the United States, acceptance by the FDA of the filing of an NDA, or similar
application for marketing approval, for the Product, and (b) in any Major
Market Country other than the United States, the filing with the applicable
Regulatory Authorities having jurisdiction over such country of a single
application or set of applications comparable to an NDA for the Product.

 

“RNAi Compound” means [***]

 

“[***] Market Types” means any [***]
that are not [***] Market Types.

 

1.1-7

 

“Sublicensees” means any Third Party to
which Lilly or any of its Affiliates or Isis or any of its Affiliates grants
any right to manufacture, market and sell a Product.  A Third Party who is granted only the right
to sell a Product (such as a wholesaler) will not be considered a Sublicensee.

 

“Territory” means the
entire world.

 

“Third Party” means any
Party other than Isis or Lilly and their respective Affiliates.

 

“Upstream Licenses” means those
Third Party licenses or sublicenses listed on Schedule
    .

 

“Valid Claim” means any
claim in an issued and unexpired patent which has not been held unenforceable,
unpatentable or invalid by a decision of a court or other governmental agency
of competent jurisdiction following exhaustion of all possible appeal processes
and which has not been admitted to be invalid or unenforceable through reissue,
reexamination or disclaimer, or otherwise.

 

1.1-8

 

SCHEDULE
A

 

ISIS ASO COMPOUND PATENT RIGHTS
AS OF THE EFFECTIVE DATE

 

 

SCHEDULE B

 

ISIS MANUFACTURING PATENT RIGHTS
AS OF THE EFFECTIVE DATE

 

 

SCHEDULE C

 

ISIS CORE TECHNOLOGY PATENT
RIGHTS AS OF THE EFFECTIVE DATEExhibit 10.13

 

CONFIDENTIAL
TREATMENT REQUESTED

UNDER 17 C.F.R. §§
200.80(b)4, AND 240.24b-2

 

Confidential
— Execution Version

 

AMENDED &
RESTATED LICENSE AGREEMENT

 

THIS AMENDED & RESTATED  LICENSE AGREEMENT
(the “Agreement”) is made and
entered into effective as of November 30, 2009 (the “Restatement
Date”), by and between ATLANTIC
PHARMACEUTICALS LIMITED (formerly
ATLANTIC HEALTHCARE (UK) LIMITED registered number 6025726), whose
registered office is MoFo Notices Limited, 7th Floor, City Point, One Ropemaker Street,
London EC2Y 9AW (“Atlantic”) and ISIS PHARMACEUTICALS, INC., having principal offices at 1896
Rutherford Road, Carlsbad, CA 92008 (“Isis”).
Atlantic and Isis each may be referred to herein individually as a “Party,” or collectively as the “Parties.”

 

WHEREAS, Isis and Atlantic are parties to the License
Agreement dated March 7, 2007, as amended December 6, 2007 and December 18,
2008 (as amended, the “Original Agreement”)
under which Isis, among other things, licensed to Atlantic the drug known as
Alicaforsen (also known as ISIS 2302) for Atlantic to develop and
commercialize, together with, at Atlantic’s election, the right to license
second generation ICAM-1 products;

 

WHEREAS, Isis and Atlantic now desire to amend and restate
the Original Agreement in order to, among other things, redefine and confirm as
of the Restatement Date each Party’s rights and obligations with respect to the
development, manufacture, and commercialization of Alicaforsen Products, and to
return to Isis all other rights granted to Atlantic under the Original
Agreement; and

 

NOW, THEREFORE, the Parties do hereby agree as follows:

 

ARTICLE
1 -

 

DEFINITIONS;
AMENDMENT AND RESTATEMENT; REVERSION OF RIGHTS; DATA ASSIGNMENT TO ISIS

 

Section 1.1            Definitions.

 

1.1.1       Capitalized terms used in this Agreement
and not otherwise defined herein have the meanings set forth in Appendix 1.

 

Section 1.2            Amendment and Restatement;
Reversion of Rights; Data Assignment to Isis.

 

1.2.1       Amendment and Restatement; Reversion of Rights.  Effective as of the Restatement Date,
notwithstanding anything to the contrary in the Original Agreement (i) this
Agreement restates, supersedes, and terminates the Original Agreement in its
entirety, and (ii) except as otherwise expressly provided in this
Agreement, the Original Agreement (including all licenses and other rights
granted thereunder) is deemed void ab initio.
Therefore, for the

 

1

 

avoidance of doubt, (x) any rights and licenses granted by Isis to
Atlantic under the Original Agreement and not expressly granted by Isis to
Atlantic under this Agreement (the “Reverted Rights”),
automatically revert back to Isis as of the Restatement Date as though such
licenses and rights were never granted to Atlantic under the Original
Agreement, and (y) that certain Subscription and Share Exchange Agreement
dated March 16, 2007 (the “Subscription and Share
Exchange Agreement”) will (A) be unaffected by the
termination of the Original Agreement, and (B) continue in full force and
effect in accordance with its terms. 
Atlantic agrees, at Isis’ request and expense, to execute, verify and
deliver such documents and perform such other acts (including appearances as a
witness) as Isis may reasonably request for use in applying for, obtaining,
confirming, sustaining and/or enforcing Isis’ rights relating to such Reverted
Rights.

 

1.2.2       Assignment
of Isis Data to Isis.  Effective as of the Restatement Date,
Atlantic hereby assigns to Isis all of Atlantic’s right, title and interest in
and to (i) the Isis Data, and (ii) any other Regulatory
Documentation, data, results and information related to testing and studies of
Alicaforsen (including clinical data, analytical test results and non-clinical
pharmacology and safety data) in the possession of Atlantic on the Restatement
Date, to the extent necessary for the development and commercialization of
products covered by the Reverted Rights. In the event any of the Isis Data and
any other Regulatory Documentation, data, results and information related to
testing and studies of Alicaforsen can be used for development and
commercialization of both Alicaforsen Products and products covered by the
Reverted Rights, then such data shall not be assigned by Atlantic to Isis,
however, Isis shall have a non-exclusive, royalty-free, fully-paid up,
worldwide license to use such data for products covered by the Reverted Rights.

 

ARTICLE 2 - 

ALICAFORSEN GRANT OF RIGHTS

 

Section 2.1            Alicaforsen License Grant.

 

2.1.1       Subject
to the terms and conditions of this Agreement, Isis hereby grants to Atlantic:

 

(i)            an exclusive, worldwide license under the Alicaforsen Patents and the
ICAM-1 Specific Patents solely to develop, make, have made, use, sell, offer
for sale, have sold and import Alicaforsen API and Alicaforsen Products. The
license granted to Atlantic under this Section 2.1.1(i) is
sublicensable only in connection with a license of rights to an Alicaforsen
Product to a Third Party for the continued development, manufacture and
commercialization of that Alicaforsen Product in accordance with the terms of
this Agreement; and

 

(ii)           a non-exclusive, worldwide license under the Excluded Manufacturing IP
solely to make and have made Alicaforsen API. The license granted to Atlantic
under this Section 2.1.1(ii) is sublicensable to a Third Party
for the manufacture of Alicaforsen API in accordance with the terms of this
Agreement.

 

2

 

Section 2.2            Data Transfer.

 

2.2.1       After
the Effective Date, Isis transferred and assigned to Atlantic all of Isis’
right, title and interest in and to (i) the Regulatory Documentation,
data, results and information related to testing and studies of Alicaforsen
(including clinical data, analytical test results and non-clinical pharmacology
and safety data) in the possession of Isis on the Effective Date to the extent
such data, results and/or information were necessary for the continued
development and commercialization of Alicaforsen (“Isis
Data”), and (ii) the know how which was owned by or licensed
to Isis at the Effective Date that related to the formulation of Alicaforsen
from Alicaforsen API, but excluding the
Excluded Manufacturing IP (the “Isis Manufacturing Know
How”).  As of the
Restatement Date, Atlantic will use such Isis Data and Isis Manufacturing Know
How solely to the extent necessary to manufacture, develop and/or commercialize
Alicaforsen API and/or Alicaforsen Products.

 

Section 2.3            No
Implied Licenses.  All rights in and to the Alicaforsen Patents,
the ICAM-1 Specific Patents, and the Excluded Manufacturing IP not expressly
licensed to Atlantic under Section 2.1, and any other Patents or
know-how of Isis or its Affiliates, are hereby retained by Isis or its
Affiliates. Except as expressly provided in Section 2.1, Isis will
not be deemed by estoppel or implication to have granted Atlantic any license
or other right with respect to any intellectual property of Isis. Nothing in
this Agreement will prevent Isis from practicing the Alicaforsen Patents, the
ICAM-1 Specific Patents, or the Excluded Manufacturing IP for products other
than Alicaforsen Products.

 

ARTICLE
3 - 

ATLANTIC PRODUCT DEVELOPMENT

 

Section 3.1            Development/Commercialization/Regulatory
Responsibilities.

 

3.1.1       Commercially
Reasonable Efforts. Unless
Isis exercises its reversion rights under Section 11.2,  Atlantic is fully responsible for the continued development
and commercialization of Alicaforsen Products and will use Commercially
Reasonable Efforts to develop Alicaforsen Products for all commercially
reasonable indications, including Alicaforsen Products for the treatment of
Pouchitis and to make its First Commercial Sale of an Alicaforsen Product for
the treatment of Pouchitis in the USA and Europe as soon as practicable.
Atlantic hereby assumes all regulatory responsibilities in connection with
Alicaforsen Products, including sole responsibility for all related Regulatory
Documentation and for obtaining all Regulatory Approvals. Atlantic will comply
with all Applicable Laws and the Quality Standard in connection with the
development and commercialization of Alicaforsen Products. For the avoidance of
doubt, any sublicensee that enters into a Sublicense with Atlantic will use
Commercially Reasonable Efforts in accordance with this Agreement to develop
and commercialize any Alicaforsen Products that are the subject of such
Sublicense, and Atlantic will ensure that such efforts are undertaken.

 

3.1.2       Development
Plan. Without
limiting any of the foregoing in Section 3.1.1, Atlantic will use
Commercially Reasonable Efforts to implement and perform the initial
Development Plan approved by both Atlantic and Isis as attached to this
Agreement as Appendix 4 (the “Initial Development Plan”),
which contains a Gantt chart of Atlantic’s good-faith development plan for
Alicaforsen as of the Restatement Date which supersedes all previous

 

3

 

development plans.  Atlantic may
update the Initial Development Plan within 30 days following the Restatement
Date so long as (i) any such update does not constitute a material
modification of, or addition to, the Initial Development Plan, and (ii) Atlantic
promptly provides Isis with a copy of such modified Initial Development Plan
with a summary/explanation of any modifications thereto. Following the
Restatement Date, Atlantic will use Commercially Reasonable Efforts to arrange
and participate in “advisory” meetings with the FDA and EMEA (or any other
Regulatory Authority) as soon as practicable (each, an “Advisory
Meeting”), and following each such Advisory Meeting, Atlantic
will present the information arising from such meeting(s) to the JDC to,
among other things, discuss any necessary modifications to the Development
Plan.  The Development Plan will be
updated and modified only as determined by the JDC on a periodic basis under Section 3.2.1,
including following the occurrence of any Advisory Meetings held between
Atlantic and the FDA and/or the EMEA (or any other Regulatory Authority).
Notwithstanding the foregoing, any Development Plan to be performed by one of
Atlantic’s sublicensees under a Sublicense will not require the approval of the
JDC so long as (i) such Development Plan is provided to the JDC for the
JDC’s review and comment and such sublicensee considers in good faith any
comments provided by the JDC, (ii) such Development Plan is not in
conflict with the terms and conditions of this Agreement, and (iii) such
sublicensee uses Commercially Reasonable Efforts to implement and perform such
Development Plan.

 

Section 3.2            Joint Development Committee.

 

3.2.1       To
promote the successful development of the Alicaforsen Products, the Parties
will establish a Joint Development Committee (the “JDC”),
which will be formed and will hold its first meeting within 90 days after the
Restatement Date, and will be comprised of two Isis representatives and two
Atlantic representatives (“Committee Members”).  A Party may replace any of its Committee
Member(s) by notice to the other Party. 
Each Committee Member shall be appropriately qualified and experienced in
order to make a meaningful contribution to JDC meetings.  The purpose of the JDC is to provide a forum
for the Parties to share information and knowledge on the on-going research and
development of the Alicaforsen Products, including sharing scientific direction
and data, discussing the current development and regulatory status of the
Alicaforsen Products, any Alicaforsen Product sublicensing development plans
with Third Parties, discussing regulatory or quality assurance issues in
relation to the Alicaforsen API, and reviewing, providing advice on, and
approving the Development Plan.  In
addition, at JDC meetings, Isis will apprise the JDC of any development
activities undertaken by Isis with respect to any Follow-On Products.  The JDC shall conduct its discussions in good
faith with a view to operating to the mutual benefit of the Parties and in
furtherance of the successful marketing of Alicaforsen Products. The JDC shall
meet at Isis’ corporate offices located in Carlsbad, California, USA where such
meeting is not held by video-conference or telephone conference, as often as
the Committee Members may determine but in any event not less than once per
calendar quarter.  Each JDC meeting shall
be chaired by a Committee Member nominated by Atlantic and Atlantic is
responsible for coordinating and ensuring that such communication and meetings
take place in a timely manner in accordance with this Agreement, and Isis shall
co-operate with Atlantic and will not unreasonably refuse requests for such
meetings. The JDC will strive to make decisions by majority vote, and record
such decisions in the minutes of the applicable JDC meeting. If, after good
faith discussions, the JDC is unable to decide a particular matter by majority
vote, such matter will be referred to the Executive Officers for final
resolution.  If the matter is not
resolved by the Executives Officers within 30 days, either Party may seek final
resolution of the matter in accordance with Section 14.4.

 

4

 

3.2.2       The
JDC will continue in existence for three years after the Restatement Date,
subject to extension by mutual agreement of the Parties.

 

Section 3.3            Safety Database.

 

3.3.1       Isis maintains a database that includes information
regarding the tolerability of its drug compounds, individually and as a class,
including information discovered during pre-clinical and clinical development
(the “Isis Database”).  In an effort to maximize understanding of the
safety profile and pharmacokinetics of Isis compounds, Atlantic will cooperate
in connection with populating the Isis Database. Atlantic will provide Isis
with information concerning toxicology, pharmacokinetics, safety pharmacology
study(ies), serious adverse events and other safety information related to each
Alicaforsen Product as soon as practicable following the date such information
is available to Atlantic (but not later than 30 days after Atlantic’s receipt
of such information). In addition, in connection with any reported serious
adverse event, Atlantic will provide Isis (promptly following such event and
prior to any communication with a Regulatory Authority or ethics committee) in
a mutually acceptable format, the following patient data where it is reasonably
available to Atlantic once informed of a serious adverse event and any other
data Atlantic reasonably deems relevant to the Isis Database: (a) basic
statistics (including age, race, gender, weight, height); (b) medical
history; (c) concurrent medication usage; (d) particulars of the
event (verbatim term, MedDRA term & system organ class, onset date,
resolution date, relation to Alicaforsen Product, severity/seriousness,
outcome); (e) dosing history (dates, quantity of Alicaforsen Product
administered, method of administration); (f) chemistry and hematology lab
tests; and (g) ocular pressure. Atlantic will deliver all such information
to Isis for the Isis Database to: Isis Pharmaceuticals, Inc. 1896
Rutherford Road, Carlsbad, California 92008, Attention: Chief Medical Officer
(or to such other address/contact designated in writing by Isis). For clarity,
Atlantic shall be responsible for all safety and/or pharmacovigilance matters
relating to or arising from the development and commercialization of the
Alicaforsen Products and for making all adverse event reports to the relevant
Regulatory Authorities at the times and in the manner it deems appropriate to
comply with all Applicable Laws.

 

3.3.2.      From time
to time, Isis utilizes the information in the Isis Database to conduct analyses
to keep Isis and its partners informed regarding class generic properties of
antisense oligonucleotides, including with respect to safety. As such, if and
when Isis identifies safety or other related issues that Isis reasonably
believes may be relevant to an Alicaforsen Product or the gene target, ICAM-1
(including any potential class-related toxicity), Isis will promptly inform
Atlantic of such issues and, if requested, provide the data supporting Isis’
conclusions. In addition, if Isis becomes aware of any serious adverse events
related to Alicaforsen or ICAM-1, Isis will promptly inform Atlantic. Isis will
deliver all such information to Atlantic to: Atlantic Pharmaceuticals Limited,
Maple House, Birdbrook, Halstead, CO9 4BB, UK, Attention: Chief Medical Officer
(or to such other address/contact designated in writing by Atlantic).

 

5

 

Section 3.4            Reports. Atlantic agrees to keep Isis informed
with respect to activities and progress with the further development and
commercialization of Alicaforsen Products (including with respect to the
activities of Atlantic’s Affiliates and sublicensees), and agrees to provide to
Isis and the JDC every six months a summary of such activities and progress. In
accordance with Section 3.2.1, during the period Atlantic has a
right of first negotiation under Section 4.1, Isis agrees to keep
Atlantic informed with respect to Isis’ activities and progress with the
further development and commercialization of Follow-On Products by providing a
summary of any such activities at meetings of the JDC.

 

Section 3.5            [Not used]

 

Section 3.6            Supply of Existing  Alicaforsen API.

 

3.6.1       Isis
agrees to supply Atlantic with a quantity of Alicaforsen API that is in Isis’
possession as of the Restatement Date, reasonably sufficient to obtain
Regulatory Approval for an Alicaforsen Product for Pouchitis (but not to exceed
[***] kg) in the USA or Europe [***], in accordance with a clinical trial
program set forth in the Development Plan. 
For the avoidance of doubt, the [***] kg of Alicaforsen API supplied by
Isis prior to the Restatement Date has been supplied [***].

 

3.6.2       Atlantic
and Isis agree that, to the extent available from the stocks of Alicaforsen API
in Isis’ possession as of the Restatement Date, any other quantities of
Alicaforsen API required by Atlantic for the development and commercialization
of Alicaforsen Product may be purchased from Isis in a minimum order size of
[***]kg at a cost of [***] Dollars ($[***]) per gram until such stocks have
been exhausted.  As of the Restatement
Date, Isis has approximately (i) [***] kilograms of Alicaforsen API
available for sale, and (ii) [***] kilograms of Alicaforsen API in
quarantine with the possibility of release from such quarantine if certain
qualification study(ies) are performed (e.g., a
bridging toxicology study).  Isis will
hold such Alicaforsen API in quarantine for a period of [***] ([***]) years
after the Restatement Date for the benefit of Atlantic. If Atlantic has the
necessary study(ies) performed, at Atlantic’s expense, and such Alicaforsen API
is successfully released from quarantine in accordance with cGMP, Isis will
sell such [***] kilograms of Alicaforsen API to Atlantic at a cost of [***]
Dollars ($[***]) per gram.

 

3.6.3       All
Alicaforsen API ordered by Atlantic pursuant to Section 3.6 will be
shipped by Isis to Atlantic, EXW (Incoterms 2000) Isis’ premises, to the
destination specified in writing by Atlantic. 
All transportation and insurance costs are the sole responsibility of
Atlantic.  Isis warrants that each such
amount of Alicaforsen API supplied by Isis pursuant to Section 3.6;
(i) will have been manufactured in accordance with cGMP, (ii) meets
the specification for Alicaforsen API set out in the Regulatory Documentation
existing at the Restatement Date, (iii) have at least [***] months shelf
life remaining when delivered, and will be accompanied by a certificate of
analysis.

 

Section 3.7            Product Manufacturing
Responsibility.  Except as otherwise provided in this
Agreement, Atlantic acknowledges and agrees that it is solely responsible for
the manufacturing of Alicaforsen Product and Alicaforsen API, including,
without limitation, management of the overall manufacturing strategy and
tactics, CMC work, validation activities

 

6

 

and batches, formulation, contract manufacturer
selection for finished Alicaforsen Product, associated audits, and stability
testing.  For the avoidance of doubt,
except as expressly set forth in Section 3.6.1 and Section 3.6.2
of this Agreement, neither Atlantic nor Isis will have any obligations to one
another with respect to the manufacture or supply of Alicaforsen API or
Alicaforsen Product, and Atlantic is licensed under Section 2.1.1
to make and/or have made Alicaforsen API and Alicaforsen Product itself or by a
Third Party, including, without limitation, by an Enabled CMO.

 

ARTICLE
4 - 

FOLLOW-ON PRODUCT ROFN; EXCLUSIVITY COVENANTS

 

Section 4.1            (a)   Follow-On Product ROFN.  For a period of [***] ([***]) years
following the Restatement Date, if Isis desires to (i) offer a Third Party
an exclusive license to the rights to Systemic Delivery and Enema Delivery for
a Follow-On Product (the “Follow-On Product License”),
or (ii) pursue a bona-fide offer from a Third Party for a Follow-On
Product License, then Isis will provide Atlantic with the right of first
negotiation for such Follow-On Product License by written notice to Atlantic
and will promptly deliver evaluation materials and any data reasonably relevant
to such Follow-On Product, at which time Atlantic will have [***] days to
notify Isis in writing whether Atlantic desires to obtain the Follow-On Product
License. If Atlantic provides Isis with timely written notice within such
[***]-day period that Atlantic desires to obtain the Follow-On Product License,
then Isis and Atlantic will negotiate in good faith, to conclude a written
license agreement within [***] days on commercially reasonable terms (including
Development Plan and funding commitments from Atlantic for such Follow-On
Product). If Atlantic fails to notify Isis within such [***]-day period that
Atlantic desires to obtain the Follow-On Product License or, if despite good
faith negotiations Atlantic and Isis are unable to reach agreement within [***]
days after Isis’ receipt of such notice from Atlantic, then, notwithstanding
anything to the contrary in this Agreement, (i) Isis will be free to
develop and commercialize the Follow-On Product on its own or with a Third
Party and may grant the Follow-On Product License (or grant a right to obtain
such an exclusive license) to any Third Party for any indication on economic
terms which, when taken as a whole, are no more favorable to any such Third
Party than the terms last offered under this Section 4.1 by
Atlantic to Isis, (ii) Atlantic will have no further rights to such
Follow-On Product, and (iii) Isis will have no further obligations to
Atlantic under this Agreement with respect to such Follow-On Product.

 

(b)           [***]
Standstill Period.
Notwithstanding the foregoing in Section 4.1, for a period of [***]
([***]) years following the Restatement Date (the “Standstill
Period”), Isis agrees (i) not to consummate a Follow-On
Product License with a Third Party that includes a license to develop and
commercialize a Follow-On Product intended to achieve a therapeutic effect in
the [***] (“[***]”), or (ii) if Isis
consummates such a Follow-On Product License that includes rights to develop
and commercialize a [***], such Third Party will be precluded from undertaking
development of the [***] during the Standstill Period.  For purposes of this Section 4.1(b),
a Third Party will be deemed to have initiated development of a [***] if such
Third Party initiates [***] with a Follow-On Product intended to achieve a
therapeutic effect in the [***].

 

7

 

Section 4.2            Exclusive Partner.

 

4.2.1       During the
Term of this Agreement so long as Atlantic is developing and commercializing
Alicaforsen Products in accordance with the terms of this Agreement, Isis will
not develop or commercialize itself, and will not permit or grant any license
under the Alicaforsen Patents or the ICAM-1 Specific Patents to a Third Party
to develop or commercialize, any antisense drug compound designed to directly
inhibit ICAM-1. Notwithstanding the foregoing, subject to Section 4.1,
Isis retains the right to (i) use antisense compounds modulating ICAM-1
(including Alicaforsen) or to transfer such antisense compounds to Third
Parties in each case for non-commercial target validation purposes, and (ii) use,
manufacture, research, develop, and commercialize Follow-On Products and any
other compounds to inhibit ICAM-1 other than Alicaforsen Products, covered by
any of Isis’ intellectual property (including the Reverted Rights), and such
activities will not be interpreted as a breach of this Agreement.    For the avoidance of doubt, subject to Section 4.1,
Isis shall not be prohibited in any manner from using or exploiting any Isis
intellectual property (including the Reverted Rights) with products and
compounds other than Alicaforsen Products. 
Isis’ obligations under this Section 4.2.1 will
automatically terminate in the event of a Discontinuance.

 

4.2.2       To
avoid confusion in the marketplace, during the term of this Agreement, Atlantic
agrees not to develop or commercialize any product designed to directly inhibit
ICAM-1 other than the Alicaforsen Products, and will not permit or grant any
license under the Alicaforsen Patents or ICAM-1 Specific Patents to a Third
Party to develop or commercialize any such product other than the Alicaforsen
Products.  Notwithstanding the foregoing
sentence, in the event that Atlantic’s right of first negotiation for the
Follow-On Product License under Section 4.1(a) (i) is
voluntarily terminated by Atlantic by written notice to Isis, or (ii) terminates
in accordance with Section 4.1(a) and Atlantic and Isis have
not consummated the Follow-On Product License, this Section 4.2.2
will no longer apply to Atlantic.

 

ARTICLE
5 - 

[Not used]

 

ARTICLE
6 - 

FINANCIAL PROVISIONS

 

Section 6.1            Up-Front Payment by Atlantic.

 

6.1.1       In
consideration of the licenses granted to Atlantic under the Original Agreement
and Section 2.1.1 of this Agreement, following the Effective Date,
Isis and Atlantic executed the Subscription and Share Exchange Agreement,
pursuant to which Atlantic paid an up-front license fee of $[***] to Isis which
was satisfied (in full) by the issue to Isis of [***] ordinary shares in
Atlantic’s share capital, which were immediately exchanged for [***] ordinary
shares in Atlantic Healthcare’s share capital pursuant to the terms of the
Subscription and Share Exchange Agreement; provided, however,

 

8

 

(a)  if at any time during the Anti-Dilution Protection
Period (as defined in the Subscription and Share Exchange Agreement) Atlantic
Healthcare issues any shares in the capital of Atlantic Healthcare to current
shareholders (determined by reference to the date of the Original Agreement) at
a subscription price per share of less than £[***], then Isis shall have the
right to subscribe for additional AH Shares (as defined in the Subscription and
Share Exchange Agreement) at [***] in the share capital of Atlantic Healthcare
(for which purpose all shares in Atlantic Healthcare previously issued to Isis
pursuant to the Original Agreement shall be deemed held by Isis, irrespective
of whether Isis remains the registered holder thereof) had such new shares so
issued to existing shareholders [***], as further provided for in the
Subscription and Share Exchange Agreement; and

 

(b) if at any time during the Anti-Dilution Protection
Period Atlantic Healthcare issues any shares in the capital of Atlantic
Healthcare to [***] (as defined in the Subscription and Share Exchange Agreement)
and/or [***] (as defined in the Subscription and Share Exchange Agreement)
beyond [***] shares on terms not offered to other shareholders (including
Isis), then Isis will have the right to participate on the same terms as [***]
(as the case may be) so as to maintain its pro-rata shareholding in Atlantic
Healthcare (for which purpose all shares in Atlantic Healthcare previously
issued to Isis pursuant to the Original Agreement shall be deemed held by Isis,
irrespective of whether Isis remains the registered holder thereof) as further
provided for in the Subscription and Share Exchange Agreement.

 

6.1.2  In no event
will Atlantic issue shares to Isis that exceed the Equity Cap.

 

Section 6.2            Milestone Payments by Atlantic.

 

6.2.1       Atlantic
will pay to Isis the relevant milestone payment in cash or in an equivalent
amount of Atlantic Equity Securities (subject to the written consent of
Atlantic Healthcare Limited and in accordance with the terms of the
Subscription and Share Exchange Agreement), at Atlantic’s sole discretion, not
more than 60 days after achievement by Atlantic, its Affiliates or a
sublicensee, of each of the applicable events, as follows:

 

	
  Event

  	
   

  	
  Payment*

  	
   

  
	
  [***]

  	
   

  	
  US
  $

  	
  [***]

  	
   

  
	
  [***]

  	
   

  	
  US
  $

  	
  [***]

  	
   

  

 

* In respect of the above payments, Atlantic
will be entitled to a single $[***] credit that may be applied to the first
[***]% of each milestone payment due under this Section 6.2.1 until
such credit is exhausted.  For example
only, if Atlantic achieves the [***] milestone for an Alicaforsen Product for
an indication other than [***], Atlantic may apply the $[***] credit toward the
first [***]% of the applicable $[***] milestone payment (i.e.,
[***]% of $[***] = $[***]), such that after the credit is applied Atlantic will
owe Isis a total milestone payment of $[***], and will have a remaining credit
of $[***] (i.e., $[***] - $[***] = $[***]) to apply
to the first [***]% of another milestone payment under this Agreement.

 

9

 

6.2.2 Notwithstanding
the foregoing, in no event will Atlantic issue Atlantic Equity Securities to
Isis that exceed the Equity Cap. To the extent any milestone payment of
Atlantic Equity Securities will cause Isis’ aggregate equity ownership in
Atlantic to exceed the Equity Cap, Atlantic will issue to Isis only the number
of shares that will maintain such Equity Cap, and will pay Isis the remainder
of such milestone payment in cash.  For
purposes of this Section 6.2, the term “Atlantic
Equity Securities” means (a) if Atlantic has a class of
stock (x) registered under Section 12(b) or 12(g) of the
Securities Exchange Act of 1934 and that is publicly traded on a major US
exchange such as the NYSE or NASDAQ, or (y) traded on a major European
exchange such as Deutsche Börse or the London Stock Exchange, such publicly
traded common stock of Atlantic, the value of which will be determined [***]%
by the average closing price for the 15 trading days immediately preceding the
date the particular milestone event referenced in this Section 6.2
is achieved; or (b) if Atlantic does not have a class of publicly traded
stock, the equity securities of Atlantic issued in its most recent venture
capital financing occurring prior to the date the particular milestone event
referenced in this Section 6.2 is achieved, which will be issued to
Isis at the same price per share and with the same rights, preferences and
privileges as provided to the other investors in such financing.

 

Section 6.3            Sublicense Revenue.

 

6.3.1       In
the event that Atlantic enters into a Sublicense, Atlantic will pay Isis [***]%
of the Sublicense Revenue (which does not include payments based on
commercial sales of an Alicaforsen Product, including royalties or
profit-sharing) from
such sublicensing of any Alicaforsen Product by Atlantic or its Affiliates.

 

6.3.2       Any
payment to Isis for its portion of Sublicense Revenue due under this Section 6.3
will be due within 30 days of Atlantic receiving such Sublicense Revenue.

 

Section 6.4            Royalty Payments by Atlantic.

 

6.4.1       For
any Alicaforsen Product sold by Atlantic or its Affiliates, in consideration of
Isis’ collaborative efforts and the licenses granted hereunder, Atlantic will
pay Isis royalties on Net Sales of each Alicaforsen Product in accordance with
the following table:

 

	
  Cumulative
  Net Sales

  	
   

  	
  Royalty Rate

  	
   

  
	
  Less than US $[***]

  	
   

  	
  [***]

  	
  %

  
	
  US $[***] to US $[***]

  	
   

  	
  [***]

  	
  %

  
	
  Above US $[***]

  	
   

  	
  [***]

  	
  %

  

 

10

 

 

6.4.2       For
any Alicaforsen Products sold pursuant to a Sublicense, in consideration of
Isis’ collaborative efforts and the licenses granted hereunder, Atlantic will
pay Isis royalties on Net Sales as follows:

 

6.4.2.1           For Alicaforsen Products sold for [***]
indication, Atlantic will pay Isis royalties on Net Sales of each Alicaforsen
Product equal to the greater of (i) [***]% of the royalty Atlantic is
entitled to receive under such Sublicense, or (ii) [***]% of Net Sales;
and

 

6.4.2.2           For an Alicaforsen Product that is not
indicated for [***], Atlantic will pay Isis royalties on Net Sales of each
Alicaforsen Product as follows:

 

(a) If the royalty to Atlantic is less than
or equal to [***]% of Net Sales, then Isis receives [***]% of Net Sales of each
Alicaforsen Product;

 

(b) If the royalty to Atlantic is greater
than [***]% but less than [***]% of Net Sales, then Isis receives [***]% of Net
Sales of each Alicaforsen Product; or

 

(c) If the royalty to Atlantic is equal to or
greater than [***]% of Net Sales, then Isis receives [***]% of Net Sales of
each Alicaforsen Product.

 

6.4.3       Isis
will be responsible for payment of any Third Party royalty obligations related
to an Alicaforsen Product that exist as of the Effective Date (“Existing Royalties”), including Existing
Royalties due under the agreement with [***] dated [***].  Atlantic will be responsible for all other
Third Party royalties, fees and milestones that may arise related to the
development or commercialization of Alicaforsen Products.

 

Section 6.5            Term; Timing of Royalty
Payments.  Atlantic’s obligation to pay royalties on
each Alicaforsen Product will expire on a country-by-country basis upon the
later of: (i) [***] years from the date of First Commercial Sale of such
Alicaforsen Product in such country of sale, or (ii) the expiration of the
last to expire Valid Claim of Alicaforsen Patents and ICAM-1 Specific Patents
covering the making, using, or selling of such Alicaforsen Product in the
country of sale, or (iii) the expiration of the last to expire Valid
Composition of Matter Claim within Alicaforsen Patents or ICAM-1 Specific
Patents in the country of manufacture of that Alicaforsen Product. The
royalties due under Section 6.4 will become due and payable: (i) within
30 days of each respective Royalty Due Date with respect to Net Sales received
by Atlantic or its Affiliates, and (ii) with respect to royalties due
under Sublicenses, within 30 days of Atlantic itself receiving the royalty
payments due from its sublicensees.  In
each case royalties will be calculated in respect of the Net Sales in the
calendar quarter immediately preceding the applicable Royalty Due Date.

 

11

 

Section 6.6            Payment Method. 
Any amounts due to Isis under this Agreement will be paid in U.S.
dollars, by wire transfer in immediately available funds to an account
designated by Isis.  Any payments or
portions thereof due hereunder which are not paid on the date such payments are
due under this Agreement and the payment is not in dispute between the Parties,
or if disputed the dispute has not been resolved, will bear interest at a rate
equal to the prime rate as published in The Wall Street Journal,
Eastern Edition, on the first day of each calendar quarter in which such
payments are overdue, plus 1% calculated on the number of days such payment is
delinquent, compounded monthly.

 

Section 6.7            Currency; Foreign Payments. 
If any currency conversion will be required in connection with any
payment hereunder, such conversion will be made by using the exchange rate for
the purchase of U.S. dollars as published in The Wall
Street Journal, Eastern Edition, on the last business day of the
calendar quarter to which such payments relate. 
If at any time legal restrictions prevent the prompt remittance of any
payments in any jurisdiction, Atlantic may notify Isis and make such payments
by depositing the amount thereof in local currency in a bank account or other
depository in such country in the name of Isis or its designee, and Atlantic will
have no further obligations under this Agreement with respect thereto.  All payments under this Agreement shall be
made free and clear and without any set off, deduction, withholding or
deferment in respect of any taxes unless required by law or practice of any
relevant governmental authority.  The
Parties shall co-operate to minimize any deduction or withholding in relation
to any payments pursuant to this Agreement.

 

Section 6.8            Records Retention; Audit.

 

6.8.1       Record Retention.  Atlantic will maintain (and will ensure
that its Affiliates and sublicensees will maintain) complete and accurate
books, records and accounts that fairly reflect Net Sales with respect to each
Alicaforsen Product, in each case in sufficient detail to confirm the accuracy
of any payments required hereunder and in accordance with IFRS, which books,
records and accounts will be retained by Atlantic, its Affiliates or
sublicensees (as applicable) for the later of (i) 5 years after the end of
the period to which such books, records and accounts pertain, and (ii) the
expiration of the applicable tax statute of limitations (or any extensions
thereof), or for such longer period as may be required by Applicable Law.

 

6.8.2       Audit.  Isis will have the right to
have an independent certified public accounting firm of nationally recognized
standing, reasonably acceptable to Atlantic, have access during normal business
hours, and upon reasonable prior written notice, to Atlantic’s records (and its
Affiliates and sublicensees) as may be reasonably necessary to verify the
accuracy of Net Sales, Sublicense Revenue, as applicable, for any calendar
quarter or calendar year ending not more than [***] months prior to the date of
such request; provided, however, that Isis will
not have the right to conduct more than one such audit in any Calendar Year
except as provided below.  The accounting
firm will enter into appropriate obligations with Atlantic to treat all
information it receives during its inspection as confidential.  The accounting firm shall disclose to Isis
only whether the reported Net Sales and Sublicense Revenue are correct and
details of any discrepancies but no other information shall be disclosed to
Isis.  Isis will bear the cost of such
audit unless the audit reveals a variance of more than [***]% from the reported
results, in which case Atlantic will bear the cost of the audit.

 

12

 

6.8.3       Payment of Additional Amounts.  If, based on
the results of such audit, additional payments are owed by either party to the
other under this Agreement, the party due to make a payment will make such
additional payments, with interest as set forth in Section 6.6,
within 30 days after the date on which such accounting firm’s written report is
delivered to such Party.

 

6.8.4 Confidentiality. 
Isis will treat the financial information reported to it under Section 6.8.2
in accordance with the confidentiality provisions of Article 8; provided, however, that Isis may provide Third Parties to
which Isis owes Existing Royalties on Alicaforsen Products such information if
it exercises its audit rights concerning the Alicaforsen Products against
Isis and provided such Third Party is bound to keep such information
confidential.

 

Section 6.9            Isis
Payment to Atlantic.

 

6.9.1       Up-Front Payment by Isis. In
consideration for the Reverted Rights, Isis hereby provides Atlantic with a single US$[***] credit
that may be applied to the purchase of Alicaforsen API under Section 3.6.2
above.

 

ARTICLE
7 - 

PRESS RELEASES & PUBLICATIONS

 

Section 7.1            Press Releases

 

7.1.1 Press Releases -
Generally.  Each provision of this Section 7.1.1
is subject to Section 7.1.2 below. 
Press releases or other similar public communication by either Party
relating to this Agreement, will be approved in advance by the other Party,
which approval will not be unreasonably withheld or delayed, except (i) disclosures
made by Isis related to products covered by the Reverted Rights, or (ii) for
those communications required by Applicable Law, which are Authorized Disclosures
or disclosures of information for which consent has previously been obtained,
and information of a similar nature to that which has been previously disclosed
publicly with respect to this Agreement, each of which will not require advance
approval, but will be provided to the other Party as soon as practicable after
the release or communication thereof.

 

7.1.2 Press Releases —
Product Safety/Efficacy. Each
Party will immediately notify (and, if possible, provide as much advance notice
as possible to) the other of any event materially related to Alicaforsen
Products (including any regulatory approval) so that the Parties may analyze
the need to or desirability of publicly disclosing or reporting such event, and
Isis agrees to provide Atlantic with at least 3 days advance notice of Isis’
intention to publicly disclose any adverse safety information related to a
Follow-On Product.  Notwithstanding Section 7.1.1
above, any press release or other similar public communication by either Party
related an Alicaforsen Product’s efficacy or safety data and/or results, will
be submitted to the other Party for review and approval at least 72 hours in
advance of such proposed public disclosure, which approval will not be
unreasonably withheld or delayed.

 

Section 7.2            Publications. 
Each provision of this Section 7.2 is subject to Section 7.1.2
above.  At least [***] days prior to a
Party’s submission of any material related to the research or development
activities hereunder for publication or presentation, the publishing 

 

13

 

Party will provide to the other Party with a draft of
such material for its review and comment. 
The non-publishing Party will provide any comments to the publishing
Party within [***] days of receipt of such materials. Except for disclosures
made by Isis related to products covered by the Reverted Rights, no publication
or presentation with respect to the research or development activities
hereunder will be made unless and until the non-publishing Party’s comments on
the proposed publication or presentation have been discussed by the Parties. If
requested in writing by the non-publishing Party, the publishing Party will
withhold material from submission for publication or presentation for a reasonable
time to allow for the filing of a patent application.

 

ARTICLE
8 - 

CONFIDENTIALITY

 

Section 8.1            Disclosure and Use Restriction. 
Except pursuant to an Authorized Disclosure, the Parties agree that, for
the Term and for five years thereafter, each Party will keep completely
confidential and will not publish, submit for publication or otherwise
disclose, and will not use for any purpose except for the purposes contemplated
by this Agreement, any Confidential Information received from the other Party.

 

ARTICLE
9 - 

INTELLECTUAL PROPERTY

 

Section 9.1            Prosecution of Patents.

 

9.1.1       Solely Owned Patents. With the exception of the Alicaforsen Patents and the
ICAM-1 Specific Patents, which are addressed in Section 9.1.2, each
Party will have the sole right, at its cost and expense and at its sole
discretion, to obtain, prosecute, maintain and enforce throughout the world any
Patents solely owned or Controlled by such Party.

 

9.1.2       Alicaforsen Patents and ICAM-1 Specific Patents.  Subject to Section 9.1.4 below,  Isis will have the sole obligation at its expense, to
obtain, prosecute and maintain the Alicaforsen Patents and the ICAM-1 Specific
Patents in such countries as Isis is prosecuting such Patents on the
Restatement Date using Commercially Reasonable Efforts.  For clarity, Atlantic will not have the right
to review or comment on any applications or registrations to be filed by Isis
under this Section 9.1.2, and Isis may cease prosecuting or
maintaining particular applications or patents in the Alicaforsen Patents and
ICAM-1 Specific Patents in selected jurisdictions, if Isis determines that it
is not commercially reasonable to continue such efforts (in which case the
terms of Section 9.1.4 will apply).

 

9.1.3       [Not used]

 

9.1.4       Discontinued Patents.  If under Section 9.1.2
Isis elects to discontinue prosecution or maintenance of any particular
applications or patents in the Alicaforsen Patents or the ICAM-1 Specific
Patents (if applicable), as the case may be, in a selected jurisdiction, Isis
will give thirty (30) days advance written notice to Atlantic of any decision
to cease preparation, filing, prosecution and maintenance of that Patent right
(a “Discontinued Patent”).  In such case, Atlantic may elect at its sole
discretion to continue preparation, filing, prosecution or maintenance of the
Discontinued Patent in the select jurisdiction at its sole expense and
thereafter Atlantic will own any such patent application and patents maturing
therefrom and be 

 

14

 

solely responsible for all costs. Isis will execute
such documents and perform such acts as may be reasonably necessary for
Atlantic to continue prosecution or maintenance of the applicable Discontinued
Patent including assigning ownership of such Patent or application. Should
Atlantic elect to continue preparation, filing, prosecution and maintenance of
Discontinued Patents which are Alicaforsen Patents or ICAM-1 Specific Patents,
such Patents will no longer be deemed to be Alicaforsen Patents or ICAM-1 Specific
Patents for the purposes of this Agreement. 
Notwithstanding the foregoing, Atlantic’s right to continue the
preparation, filing, prosecution and maintenance of a Discontinued Patent that
is an ICAM-Specific Patent is limited solely to the extent such Patent claims
ICAM-1.

 

9.1.5       Cooperation.  Each Party will cooperate reasonably in
the preparation, filing, prosecution, and maintenance of the Alicaforsen
Patents and the ICAM-1 Specific Patents (if applicable), and the other Party’s
Patents which cover an Alicaforsen Product. Such cooperation includes (a) promptly
executing all papers and instruments and requiring employees to execute such
papers and instruments as reasonable and appropriate so as to enable such other
Party, to file, prosecute, and maintain its Patents in any country; and (b) promptly
informing such other Party of matters that may affect the preparation, filing,
prosecution, or maintenance of any such Patents.

 

9.1.6       Patent Term Extensions.  The Parties
agree to cooperate in an effort to avoid loss of any of the Patents forming
part of Alicaforsen Patents or ICAM-1 Specific Patents including by executing
any documents as may be reasonably required. 
In particular, the Parties shall cooperate with each other in obtaining
patent term extension or restoration or supplemental protection certificate (“Patent Term Extensions”) or their
equivalents in any country and region where applicable.  In particular but without limiting the
foregoing Isis shall provide reasonable assistance to Atlantic, including by
executing any required documents and providing any relevant patent information
to Atlantic, so that Atlantic, as Regulatory Approval applicant, may deal with
the applicable Regulatory Authority in connection with obtaining such Patent
Term Extension.

 

Section 9.2            Enforcement of Patents

 

9.2.1       Rights and Procedures.  If Isis or
Atlantic determines that any Patent licensed hereunder is being infringed by a
Third Party’s activities and that such infringement could affect the exercise
by the Parties of their respective rights and obligations under this Agreement,
it will promptly notify the other Party in writing.  Except for the Alicaforsen Patents and the
ICAM-1 Specific Patents which are discussed below, the Party controlling the
Patent(s) which are allegedly being infringed will have the sole right and
obligation to remove such infringement.

 

(a)           Alicaforsen
Patents and ICAM-1 Specific  Patents.  With respect to the Alicaforsen Patents and
the ICAM-1 Specific Patents (if applicable and solely to the extent infringed
by a Third Party with a product targeting ICAM-1), Atlantic will have the first
right, but not the obligation, at Atlantic’s expense, to remove such
infringement. In the event that Atlantic fails to take commercially appropriate
steps to remove any such infringement within 90 days following notice of such
infringement, or earlier notifies Isis in writing of its intent not to take
such steps, and such infringement is likely to have a material adverse effect
on 

 

15

 

the Alicaforsen Product,
so long as the infringement is not taking place in a Major Market and so long
as Atlantic does not inform Isis that Atlantic considers, in good faith, that
to take such proceeds would (x) be prejudicial to its litigation strategy
in a Major Market and (y) be commercially unreasonable under the
circumstances, (i) Isis will have the right to do so at its expense, (ii) Atlantic
will have the right, at its own expense, to be represented in any such action,
and (iii) the exclusive license(s) granted under Article 2
that pertain to such Alicaforsen Patent or ICAM-1 Specific Patent (if
applicable), will automatically convert into nonexclusive licenses. Isis will
have the right, at Isis’ own expense, to remove infringement of the Alicaforsen
Patents or ICAM-1 Specific Patents (if applicable) (i) if Isis is
unilaterally developing and commercializing an Alicaforsen Product pursuant to Section 11.2,
(ii) with respect to any products covered by the Reverted Rights, or (iii) if
a Third Party is infringing the ICAM-1 Specific Patents with any product that
does not target ICAM-1.

 

(b)           Cooperation. 
The Party not enforcing the applicable Patent will provide reasonable
assistance to the other Party (at the enforcing Party’s expense), including
providing access to relevant documents and other evidence, making its employees
available at reasonable business hours, and joining the action to the extent
necessary to allow the enforcing Party to maintain the action.  If Isis requests that Atlantic take action to
remove infringement of an Alicaforsen Patent or ICAM-1 Specific Patent (if
applicable) to the extent infringed by a Third Party with a product targeting
ICAM-1, and Atlantic believes it is not commercially appropriate to take such
actions, the Parties will meet and discuss in good faith such circumstances and
seek to reach agreement on what appropriate steps to take to cause such
infringement to end in a commercially appropriate manner.

 

9.2.2       Recovery.  Any amounts
recovered by Atlantic in connection with or as a result of any action
contemplated by Section 9.2.1(a), whether by settlement or
judgment, will be used to reimburse the Parties for their reasonable costs and
expenses in making such recovery (which amounts will be allocated pro rata if
insufficient to cover the totality of such expenses), with any remainder in
excess of the reasonable costs and expenses in making such recovery will be
treated as Net Sales of an Alicaforsen Product and royalties will be due in
respect of such Net Sales pursuant to this Agreement. Isis will retain all
amounts it recovers enforcing the Alicaforsen Patents and the ICAM-1 Specific
Patents.

 

ARTICLE
10 - 

TERM AND TERMINATION

 

Section 10.1         Term. 
The term of this Agreement (the “Term”)
commences upon the Restatement Date and, unless earlier terminated in
accordance with the provisions of this Article 10, will continue
until the expiration of all obligations to pay royalties on all Alicaforsen
Products to Isis.

 

Section 10.2         Rights in Bankruptcy or
Insolvency  If either Party becomes insolvent, files
a petition in bankruptcy, has such a petition filed against it, determines to
file a petition in bankruptcy, or receives notice of a Third Party’s intention
to file an involuntary petition in bankruptcy, such Party immediately shall
notify the other Party in writing.  In
addition to any other remedies available at law or in equity, the other Party
(i.e., the non-bankrupt Party) may immediately terminate this Agreement, in
whole or in part as the terminating Party may 

 

16

 

determine, upon learning of any of the foregoing
events; provided, however, that the financial
terms set forth in Article 6 above will remain in tact and will
survive any such termination.  The
terminating Party shall provide to the other Party a written notice regarding
the extent of termination. If a Party seeks (the “Filing
Party”) to be or is involuntarily placed under the protection of
the “Bankruptcy Code” (i.e., Title 11, U.S.
Code) or its equivalent outside the USA, and the trustee in bankruptcy, or the
Filing Party as a debtor-in-possession, rejects this Agreement, then the other
Party (the “Non-Filing Party”) hereby
elects, under Section 365(n) of the Bankruptcy Code, to retain all
licenses of rights to “intellectual property” (as defined under such Bankruptcy
Code) granted to it under this Agreement, to the extent permitted by law.  As of the commencement of a bankruptcy
proceeding by or against the Filing Party, the Non-Filing Party is entitled to
a complete duplicate of all embodiments of “intellectual property” licensed to
it hereunder.  To the extent such
embodiments are not already in the Non-Filing Party’s possession as of the
commencement of a bankruptcy, the Filing Party (or the trustee in bankruptcy)
shall deliver such embodiments to the Non-Filing Party (i) upon any such
commencement of a bankruptcy proceeding, unless the Filing Party elects to
continue to perform all of its obligations under this Agreement, or (ii) if
not delivered under (i), then upon a rejection of this Agreement (or the
equivalent) by or on behalf of the Filing Party.

 

Section 10.3         Material Breach.  Failure by a Party to comply with any of its material
obligations contained herein will entitle the Party not in default to give to
the defaulting Party notice specifying the nature of the material breach,
requiring the defaulting Party to make good or otherwise cure such default, and
stating its intention to invoke the provisions of Section 14.4 if
such default is not cured.  If such
default is not cured within 90 days after the receipt of such notice (or, if
such default cannot be cured within such 90-day period, if the Party in default
does not commence actions to cure such default within such period and thereafter
diligently continue such actions), the Party not in default will be entitled,
without prejudice to any of its other rights conferred on it by this Agreement,
to invoke the provisions of Section 14.4; provided,
however, that in the event of a good faith dispute with respect to
the existence of a material breach, the 90-day cure period will be stayed until
such time as the dispute is resolved pursuant to Section 14.4
hereof.

 

Section 10.4         Consequences of Expiration or
Termination.

 

10.4.1     Licenses.  Upon expiration of the Term or
upon termination of this Agreement in its entirety by either Party pursuant to Section 10.3,
or by Isis pursuant to Section 10.2 and upon payment of all amounts
owed pursuant to this Agreement, the licenses granted by Isis to Atlantic
hereunder will terminate.

 

10.4.2     Return of Information and Materials. 
Upon early termination of this Agreement in its entirety by either Party
pursuant to Section 10.3, or by Isis pursuant to Section 10.2,
Atlantic will return all data, files, records and other materials in its
possession or control relating to or containing or comprising Isis’
Confidential Information and, in each case (except one copy of which may be
retained for archival purposes).

 

17

 

Section 10.5         Accrued Rights; Surviving
Obligations.

 

10.5.1     Accrued Rights.  Termination or
expiration of this Agreement for any reason will be without prejudice to any
rights or financial compensation that will have accrued to the benefit of a Party
prior to such termination or expiration. 
Such termination or expiration will not relieve a Party from obligations
that are expressly indicated to survive the termination or expiration of this
Agreement.

 

10.5.2     Survival.  Articles 7, 8, 10,
11, 12, and 14, Section 1.2, and Section 6.8
of this Agreement will survive expiration or termination of this Agreement for
any reason.

 

ARTICLE
11

DISCONTINUED
DEVELOPMENT BY ATLANTIC

 

Section 11.1 
Discontinuances. In the event of a Discontinuance, Isis will have a reversion right as
further described in Section 11.2.

 

Section 11.2  Reversion Rights. Following the occurrence of a
Discontinuance, Isis may elect to continue to develop any Alicaforsen Product
that is the subject of such Discontinuance by notice in writing to Atlantic (an
“Election Notice”) that Isis is
exercising its rights under this Section 11.2, in which case this
Agreement will terminate (subject to the survival provisions set forth in Section 10.5.2).
Upon receipt of an Election Notice, Atlantic will (i) grant to Isis a
sublicensable, worldwide license or sublicense, as the case may be, to all
Patents controlled by Atlantic solely as they are necessary to make, have made,
use, sell, offer for sale, have sold and import the Alicaforsen Product and (ii) transfer
to Isis, for Isis’ unlimited use, any data, results, regulatory information and
files in the possession of Atlantic as of the date of the Election Notice that
relate to the Alicaforsen Product, subject to the negotiation in good faith of
a reasonable royalty payable to Atlantic that represents the value of the items
transferred to Isis.

 

18

 

ARTICLE
12 - 

INDEMNIFICATION AND INSURANCE

 

Section 12.1         Indemnification of Isis.  Atlantic will indemnify Isis and its Affiliates, and
each of their respective directors, officers, employees and agents, and defend
and hold each of them harmless, from and against any and all losses, damages,
liabilities, costs and expenses (including reasonable attorneys’ fees and
expenses) to the extent arising from or occurring as a result of any and all
liability suits, investigations, claims or demands by a Third Party
(collectively, “Losses”) arising from or
occurring as a result of or in connection with (a) the breach of any of
Atlantic’s representations, warranties, or covenants contained in Article 13
below, or (b) whether or not negligence is found or alleged, the
manufacture (except to the extent attributable to Isis’ negligence), use,
handling, storage, sale or other disposition of an Alicaforsen Product or other
compound that is developed or sold by Atlantic, its Affiliates, agents or
sublicensees, except to the extent Isis has an obligation to indemnify Atlantic
under Section 12.2 below.

 

Section 12.2         Indemnification of Atlantic. 
Isis will indemnify Atlantic, its Affiliates, and its sublicensees, and
each of their respective directors, officers, employees and agents, and defend
and hold each of them harmless, from and against any and all Losses arising
from or occurring as a result of or in connection with (a) the breach of
any of Isis’ representations, warranties, or covenants contained in Article 13
below, or (b) whether or not negligence is found or alleged, the
manufacture, use, handling, storage, sale or other disposition of a compound
that is developed or sold by Isis, its Affiliates, agents or sublicensees,
except to the extent Atlantic has an obligation to indemnify Isis under Section 12.1
above.

 

Section 12.3         Insurance. 
Each Party will have and maintain such types and amounts of liability
insurance as is reasonable and customary in the industry generally for parties
similarly situated, and will upon request provide the other with a certificate
of insurance.  Each Party will promptly
notify the other of any material change in insurance coverage or lapse in
coverage in that regard.

 

Section 12.4         Liability. Neither Party shall be liable to the
other in contract, tort, negligence, breach of statutory duty or otherwise for
any loss, damage, costs or expenses of any nature whatsoever incurred or
suffered by the other or its Affiliates:

 

12.4.1     of
a direct nature where the same is a loss of turnover, profits, business or
goodwill; or

 

12.4.2     of
an indirect or consequential or punitive nature, including any indirect or
consequential economic loss or other indirect or consequential loss of
turnover, profits, loss of enterprise value, business or goodwill or otherwise.

 

19

 

ARTICLE
13 - 

REPRESENTATIONS AND WARRANTIES

 

Section 13.1         Representations, Warranties and
Covenants.  Each Party hereby represents, warrants and
covenants to the other Party as of the Restatement Date as follows:

 

Section 13.2         Corporate Authority. 
Such Party (a) has the power and authority and the legal right to
enter into this Agreement and perform its obligations hereunder, and (b) has
taken all necessary action on its part required to authorize the execution and
delivery of this Agreement and the performance of its obligations
hereunder.  This Agreement has been duly
executed and delivered on behalf of such Party and constitutes a legal, valid
and binding obligation of such Party and is enforceable against it in
accordance with its terms subject to the effects of bankruptcy, insolvency or
other laws of general application affecting the enforcement of creditor rights
and judicial principles affecting the availability of specific performance and
general principles of equity, whether enforceability is considered a proceeding
at law or equity.

 

Section 13.3         Consents, Approvals, etc. 
All necessary consents, approvals and authorizations of all Regulatory
Authorities and other parties required to be obtained by such Party in
connection with the execution and delivery of this Agreement and the performance
of its obligations hereunder have been obtained.

 

Section 13.4         Conflicts. 
The execution and delivery of this Agreement and the performance of such
Party’s obligations hereunder (a) do not conflict with or violate any
requirement of Applicable Law or any provision of the articles of
incorporation, bylaws or any similar instrument of such Party, as applicable,
in any material way, and (b) do not conflict with, violate, or breach or
constitute a default or require any consent not already obtained under, any
contractual obligation or court or administrative order by which such Party is
bound.

 

Section 13.5         Intellectual Property. 
To each Party’s knowledge, as of the Effective Date, no additional Third
Party licenses are required to develop, use and sell the enema formulation of
Alicaforsen.

 

Section 13.6         Isis Representations, Warranties,
and Covenants.
Isis  hereby represents, warrants and
covenants to Atlantic as of the Effective Date as follows:

 

13.6.1     IP Ownership.  Isis has the
sufficient legal and/or beneficial title and ownership of the Alicaforsen
Patents and the ICAM-1 Specific Patents as is necessary to fulfill its
obligations under this Agreement and to grant the licenses (or sublicenses as
the case may be) to Atlantic pursuant to this Agreement; Isis has not
previously entered into any agreement, whether written or oral, with respect
to, or otherwise assigned, licensed, transferred, conveyed or otherwise
encumbered its right, title or interest in or to the Isis Data (“Isis Background Know How”) or the
Alicaforsen Patents and ICAM-1 Specific Patents licensed hereunder (including
by granting any covenant not to sue with respect thereto) (the Isis Background
Know How and such Alicaforsen Patents and ICAM-1 Specific Patents licensed
hereunder together being the “Isis Background IP”).   To the best of Isis’ knowledge, the
conception, development and reduction to practice of the Isis Background IP
existing as of the Effective Date have not constituted or involved the
misappropriation of trade secrets or other rights or property of any Third
Party; and

 

20

 

13.6.2     Patent Maintenance. True, complete and correct copies of the complete file
wrapper and other material correspondence with any patent office relating to
the prosecution, validity and enforceability of the Patents within the
Alicaforsen Patents and the ICAM-1 Specific Patents existing at the Effective
Date have been provided to or made available to Atlantic prior to the Effective
Date and, to the best of Isis’ knowledge, there is no material reason why any
of such Patents are invalid.  In respect
of the pending patent applications included within such Patents, Isis has
presented all relevant prior art of which it and the inventors are aware to the
relevant patent examiners at the relevant patent offices; and

 

13.6.3     Patent Prosecution.  The Alicaforsen
Patents and ICAM-1 Specific Patents licensed hereunder that are applications at
the Effective Date are being diligently procured from the respective patent
offices and the Patents within such Patents licensed hereunder that are granted
at the Effective Date have been maintained properly and correctly and all
applicable fees have been paid on or before the due date for payment; and

 

13.6.4     Third Party Actions.  To the best of
Isis’ knowledge,  no actions, suits, claims, disputes, or
proceedings concerning the Alicaforsen Patents or the ICAM-1 Specific Patents
licensed hereunder or the Alicaforsen Product are currently pending or are
threatened in writing, that if determined adversely to Isis would have a
material adverse effect on the Alicaforsen Product or would impair Isis’
ability to perform its obligations under this Agreement.

 

13.6.5     Alicaforsen.  As of the
Effective Date, Isis does not Control any Patents other than the Alicaforsen
Patents and the ICAM-1 Specific Patents that would be necessary to develop or
commercialize Alicaforsen Products or to manufacture Alicaforsen Product or
Alicaforsen API other than the Patents within Excluded Isis IP and, to the best
of Isis’ knowledge, Isis does not Control any know-how that would be necessary
to develop or commercialize Alicaforsen Products other than the Isis Data and
know-how transferred to Atlantic under Section 2.2.1.

 

Section 13.7         Enabled CMOs. Isis  hereby
represents and warrants, as of the Restatement Date, that each of Avecia
Biotechnology, Inc., Agilent Technologies, Inc., and Girindus America
Inc. is an Enabled CMO.

 

Section 13.8         Atlantic Representations,
Warranties, and Covenants.  Atlantic hereby represents, warrants and
covenants to Isis that:

 

13.8.1     Capabilities.   As of the
Effective Date, Atlantic has the requisite personnel, expertise, experience and
skill to perform its obligations under this Agreement; Atlantic’s sales
representatives will perform in a professional, timely, competent and efficient
manner; and Atlantic, its Affiliates, and its sublicensees will at all times
comply with all Applicable Laws.

 

21

 

13.8.2     Sublicenses.         As of
the Restatement Date, Atlantic has not granted any sublicenses (including
Sublicenses) under the Original Agreement, except that
certain Development and License Agreement with Sigma Pharmaceuticals (formerly
Orphan Australia Pty. Ltd.) executed on or about December 6, 2007, which
is in full compliance with, and remains subject to, the terms and conditions of
this Agreement.

 

13.8.3     Payment Obligations.  As of the
Restatement Date, no payment obligations have accrued under the Original
Agreement that have not been paid by Atlantic to Isis.

 

Section 13.9         DISCLAIMER OF WARRANTY.   EXCEPT FOR THE EXPRESS WARRANTIES SET FORTH IN THIS ARTICLE
13, ATLANTIC AND ISIS MAKE NO REPRESENTATIONS AND GRANT NO WARRANTIES,
EXPRESS OR IMPLIED, EITHER IN FACT OR BY OPERATION OF LAW, BY STATUTE OR
OTHERWISE, AND ATLANTIC AND ISIS EACH SPECIFICALLY DISCLAIM ANY OTHER
WARRANTIES, WHETHER WRITTEN OR ORAL, OR EXPRESS OR IMPLIED, INCLUDING ANY
WARRANTY OF QUALITY, MERCHANTABILITY OR FITNESS FOR A PARTICULAR USE OR PURPOSE
OR ANY WARRANTY AS TO THE VALIDITY OF ANY PATENTS OR THE NON-INFRINGEMENT OF
ANY INTELLECTUAL PROPERTY RIGHTS OF THIRD PARTIES.

 

ARTICLE
14 - 

MISCELLANEOUS

 

Section 14.1         Assignment. 
Without the prior written consent of the other Party hereto, neither
Party will sell, transfer, assign, delegate, pledge or otherwise dispose of,
whether voluntarily, involuntarily, by operation of law or otherwise, this
Agreement or any of its rights or duties hereunder; provided,
however, that (i) either Party hereto may assign or transfer
this Agreement or any of its rights or obligations hereunder without the
consent of the other Party to (a) any of its Affiliates, or (b) any
Third Party with which it has merged or consolidated, or to which it has
transferred all or substantially all of its assets to which this Agreement
relates provided always in the case where Isis is the assigning Party it also
transfers title to the Alicaforsen Patents or the ICAM-1 Specific Patents to
such Third Party, and if in any such event the Third Party assignee or
surviving entity assumes in writing all of the assigning Party’s obligations
under this Agreement, (ii) Atlantic may assign or transfer this Agreement,
without Isis’ consent, to Atlantic Healthcare, or (iii) Isis may assign or
transfer its rights under Article 6.4 (but no liabilities) to a
Third Party in connection with a royalty factoring transaction.  Any purported assignment or transfer in
violation of this Section 14.1 will be void ab initio and
of no force or effect.

 

Section 14.2         Severability. 
If any provision of this Agreement is held to be illegal, invalid or
unenforceable by a court of competent jurisdiction, such adjudication will not
affect or impair, in whole or in part, the validity, enforceability, or
legality of any remaining portions of this Agreement.  All remaining portions will remain in full
force and effect as if the original Agreement had been executed without the
invalidated, unenforceable or illegal part.

 

Section 14.3         Governing Law. 
This Agreement will be governed by and construed in accordance with the
laws of New York, USA without reference to any rules of conflicts of laws.

 

22

 

Section 14.4         Dispute
Resolution.

 

14.4.1     General.  Any dispute, controversy or claim arising from or related to this Agreement or the
breach thereof will first be referred to the attention of the Chief
Executive Officer of Atlantic and the Chief Operating Officer of Isis (the “Executive Officers”) by notice in
writing in accordance with the terms of this Agreement.  The Executive Officers (or their respective
designees) will meet as soon as reasonably possible thereafter, and use their
good faith efforts to mutually agree upon the resolution of the dispute,
controversy or claim.  If any dispute,
controversy or claim is not resolved by the designated officers of the Parties
(or their designees) within 30 days after such dispute is referred to them,
then the Parties agree that such dispute will be referred to mediation, and if
the dispute remains unresolved after mediation, either Party will have the
right to arbitrate such dispute in accordance with Section 14.4.3; provided, however, that any dispute relating to the
construction or validity of any Patent will not be subject to arbitration.

 

14.4.2     Mediation.  If the Parties pursue
mediation proceedings the Parties will attempt to resolve such dispute in
accordance with the Commercial Mediation Procedures of the American Arbitration
Association (“AAA”), before resorting to
arbitration in accordance with Section 14.4.3 below.  The mediation will be conducted by a single
mediator experienced in the business and technology that is the subject of this
Agreement.  The place of mediation will
be in New York, NY, USA.  Either Party
may apply to the mediator or to a court for interim injunctive relief until the
mediation decision is rendered or the dispute, controversy or claim is
otherwise resolved.

 

14.4.3     Arbitration. If the Parties do
not fully settle any dispute, controversy or claim pursuant to Section 14.4.1
or 14.4.2 and a Party wishes to pursue the matter further, each such
dispute, controversy or claim will be finally resolved by binding arbitration
in accordance with the Commercial Arbitration Rules of the AAA, and
judgment on the arbitration award may be entered in any court having
jurisdiction thereof. The arbitration will be conducted by a single arbitrator
agreeable by the Parties, if the Parties cannot agree upon an arbitrator, the
arbitrator will be appointed by the AAA. No individual will be appointed to arbitrate a dispute
pursuant to this Agreement unless he or she agrees in writing to be bound by
the provisions of this Section 14.4.  The place
of arbitration will be New York, NY, USA. Either Party may apply to the
arbitrator for interim injunctive relief until the arbitration award is
rendered or the controversy is otherwise resolved.

 

14.4.4     Disputes Regarding Material Breach.  If the Parties are in dispute as to whether
one party is in material breach of this Agreement, then the mediator or
arbitrators will first determine if material breach has in fact occurred, and
if so, will grant the defaulting Party the cure period provided pursuant to Section 10.3.  If the material breach is not cured within
the time period provided pursuant to Section 10.3, the mediation or
arbitration will continue and the mediator or arbitrators will, as part of the
same mediation or arbitration, award actual direct damages to the
non-defaulting Party.

 

23

 

14.4.5     Costs and Expenses.  Except as expressly provided herein, each
Party will bear its own costs and expenses and attorneys’ fees and an equal
share of the mediator’s and/or arbitrators’ and any administrative fees of
mediation and arbitration. Notwithstanding the foregoing, in the case of
arbitration, if a Party has been found to be in material breach of this
Agreement, the defaulting Party will be responsible for both Parties’ Third
Party costs and expenses (including the costs of the arbitrators and any
administrative fees of arbitration) and the reasonable attorneys’ fees of the
non-defaulting Party; provided, however,
that the total amount of such fees and expenses the defaulting Party is
required to reimburse the non-defaulting Party cannot exceed the total amount
of monetary damages awarded to the non-defaulting Party as a result of such
material breach.

 

14.4.6     Procedure. 
 Except to the extent necessary to
confirm an award or as may be required by law, neither a Party, a mediator, nor
an arbitrator may disclose the existence, content, or results of a mediation or
an arbitration without the prior written consent of both Parties. In no event
will arbitration be initiated after the date when commencement of a legal or
equitable proceeding based on the dispute, controversy or claim would be barred
by the applicable New York statute of limitations.

 

14.4.7     Speedy
Resolution.   The Parties intend,
and will take all reasonable action as is necessary or desirable to ensure,
that there be a speedy resolution to any dispute which becomes the subject of
mediation or arbitration, and the mediator and arbitrators will conduct the
mediation or arbitration so as to resolve the dispute as expeditiously as
possible.

 

14.4.8     Awards. In any mediation, a decision or opinion issued by the mediator
regarding the dispute between the Parties is non-binding. The arbitrators may award monetary damages and
injunctive relief, but may not order the granting or termination of licenses or
assign rights to an Alicaforsen Product to either of the Parties.  Monetary damages will be in the form of off-set royalties or otherwise, to account for
the damages to the non-defaulting Party from the breach, and to account for the
defaulting Party’s contribution to the Alicaforsen Product in view of the
breach.  All awards will be in
writing and will state reasons.  Executed
copies of all awards will be delivered by the arbitrators to the Parties as
soon as is reasonably possible.  All
awards of the arbitrators will be final and binding on the Parties, and there
will be no appeal of any such award whatsoever. 
The Parties undertake to satisfy any award without delay.

 

Section 14.5         Notices. 
All notices or other communications that are required or permitted
hereunder will be in writing and delivered personally with acknowledgement of
receipt, sent by facsimile (and promptly confirmed by personal delivery,
registered or certified mail or overnight courier as provided herein), sent by
nationally-recognized overnight courier or sent by registered or certified
mail, postage prepaid, return receipt requested, addressed as follows:

 

If to Atlantic, to:

Atlantic
Pharmaceuticals Limited

MoFo
Notices Limited

7th Floor

CityPoint

One
Ropemaker Street

London
EC2Y 9AW

Attention:   Chief Executive Officer

Facsimile:  +44 (0) 20 7496 8500

 

24

 

If to Isis, to:

Isis
Pharmaceuticals, Inc.

1896
Rutherford Road

Carlsbad,
California 92008

Attention:
Chief Operating Officer and CFO

Facsimile:
+1 (760) 603-4650

 

with a
copy to:

Attention:  General Counsel

Facsimile:
+1 (760) 268-4922

 

or to such other address
as the Party to whom notice is to be given may have furnished to the other
Party in writing in accordance herewith. 
Any such communication will be deemed to have been given (i) when
delivered, if personally delivered or sent by facsimile on a Business Day, (ii) on
the Business Day after dispatch, if sent by nationally-recognized overnight
courier, and (iii) on the third business day following the date of
mailing, if sent by mail.  It is
understood and agreed that this Section 14.5 is not intended to
govern the day-to-day business communications necessary between the Parties in
performing their duties, in due course, under the terms of this Agreement.

 

Section 14.6         Entire Agreement; Modifications. 
This Agreement (and the Subscription and Share Exchange Agreement) sets
forth and constitutes the entire agreement and understanding between the
Parties with respect to the subject matter hereof and all prior agreements
(including the Original Agreement), understandings, promises and
representations, whether written or oral, with respect thereto are superseded
hereby.  Each Party confirms that it is
not relying on any representations or warranties of the other Party except as
specifically set forth herein.  No
amendment, modification, release or discharge will be binding upon the Parties
unless in writing and duly executed by authorized representatives of both
Parties.

 

Section 14.7         Relationship of the Parties. 
It is expressly agreed that the Parties will be independent contractors
of one another and that the relationship between the Parties will not constitute
a partnership, joint venture or agency.

 

Section 14.8         Waiver. 
Any term or condition of this Agreement may be waived at any time by the
Party that is entitled to the benefit thereof, but no such waiver will be
effective unless set forth in a written instrument duly executed by or on
behalf of the Party waiving such term or condition.  Any such waiver will not be deemed a waiver
of any other right or breach hereunder.

 

Section 14.9         Counterparts. 
This Agreement may be executed in two or more counterparts, each of
which will be deemed an original, but all of which together will constitute one
and the same instrument.

 

25

 

Section 14.10       No Benefit to Third Parties. 
The provisions of this Agreement are for the sole benefit of the Parties
and their successors and permitted assigns. 
This Agreement shall not confer any rights or remedies upon any person
other than Isis and Atlantic and their respective successors and permitted
assigns except as otherwise expressly provided in Section 12.
Except as expressly provided in Section 12, no person who is not a
party to this Agreement (including any employee, officer, agent, representative
or subcontractor of either Party) shall have the right to enforce any terms of
this Agreement which expressly or by implication confers a benefit on that
person without the prior written agreement of the Parties which agreement must
refer to this Section 14.10.

 

Section 14.11       Further Assurance. 
Each Party will duly execute and deliver, or cause to be duly executed
and delivered, such further instruments and do and cause to be done such
further acts and things, including the filing of such assignments, agreements,
documents and instruments, as may be necessary to carry out the provisions and
purposes of this Agreement.

 

Section 14.12       Force Majeure. Neither Party shall be responsible to the
other for any failure or delay in performing any of its obligations under this
Agreement or for other non-performance hereunder if such delay or non-performance
is caused by strike, stoppage of labor, lockout or other labor trouble,
fire, flood, accident, war, act of terrorism, act of God or of the government
of any country or of any local government, or by cause unavoidable or beyond
the control of any Party hereto. In such event, the Party affected will use
Commercially Reasonable Efforts to resume performance of its obligations.

 

[SIGNATURES ON FOLLOWING PAGE]

 

26

 

IN
WITNESS WHEREOF,
the Parties hereto have caused this Agreement to be executed by their duly
authorized representatives as of the Restatement Date.

 

	
  ATLANTIC PHARMACEUTICALS
  LIMITED

  	
   

  	
  ISIS PHARMACEUTICALS, INC.

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
  Per: 

  	
  /s/ Toby Wilson Waterworth

  	
   

  	
  Per: 

  	
  /s/ B. Lynne Parshall

  
	
   

  	
   

  	
   

  
	
  Toby Wilson Waterworth

  	
   

  	
  B. Lynne Parshall

  
	
  Director

  	
   

  	
  Chief Operating
  Officer & CFO

  
					

 

27

 

APPENDIX
1

Definitions

 

“Affiliate”
of a Party means
any other party that, directly or indirectly, through one or more intermediaries,
controls, is controlled by, or is under common control with such Party. For
purposes of this definition only, “control” and,
with correlative meanings, the terms “controlled by”
and “under common control with” will mean the
possession, directly or indirectly, of the power to direct the management or
policies of a party, whether through the ownership of voting securities or by
contract relating to voting rights or corporate governance. Notwithstanding the
foregoing, Regulus Therapeutics Inc. will not be deemed an “Affiliate” of Isis for the purposes of this Agreement.

 

“Agreement”
has the meaning set forth in the Preamble.

 

“Alicaforsen” means the compound known by the USAN
name “Alicaforsen,” which is also known as
ISIS 2302.

 

“Alicaforsen  API” means Alicaforsen in bulk form
manufactured in accordance with cGMP for use in an Alicaforsen Product.

 

“Alicaforsen Patents” means (i) the
Patents listed on Appendix 2, and (ii) all Patents issuing from the
Patents in (i), and (iii) any other Patent Controlled by Isis during the
term of this Agreement which covers the composition, formulation or use of
Alicaforsen but excluding always the Patents within
Excluded Isis IP and the ICAM-1 Specific Patents.

 

“Alicaforsen Product” means a pharmaceutical preparation comprising
Alicaforsen.

 

“Applicable
Law”
means all applicable laws, rules, and regulations, including any rules,
regulations, guidelines, or other requirements of the Regulatory Authorities
that may be in effect from time to time.

 

“Atlantic
Equity Securities” has the meaning set forth in Section 6.2.2.

 

“Atlantic
Healthcare” means that company incorporated in England
and Wales with company registration no. 5878612 whose registered address is
Maple House, Birdbrook, Halstead, Essex CO9 4BB.

 

“Authorized Disclosure” means a disclosure of Confidential
Information by the receiving Party to the extent that such disclosure is:

 

(i)  made in response to a
valid order of a court of competent jurisdiction; provided, however, that such receiving Party will first have
given notice to such other Party and given such other Party a reasonable
opportunity to quash such order and to obtain a protective order requiring that
the Confidential Information and documents that

 

 

Confidential — Execution Version

 

are the subject of such order be held in confidence
by such court or agency or, if disclosed, be used only for the purposes for
which the order was issued; and provided
further that if a disclosure order is not quashed or a protective
order is not obtained, the Confidential Information disclosed in response to
such court or governmental order will be limited to that information which is
legally required to be disclosed in response to such court or governmental
order;

 

(ii)           otherwise
required to comply with Applicable Laws, including to the extent such
disclosure is required in publicly filed financial statements or other public
statements under rules governing a stock exchange (e.g., the rules of
the United States Securities and Exchange Commission, NASDAQ, NYSE, UKLA or any
other stock exchange or which securities of either Party may be listed) provided, however, to the extent possible
bearing in mind such Applicable Laws and subject to the next subsequent
sentence of this paragraph, the receiving Party shall provide the other Party
with a copy of the proposed text of such statements or disclosure five (5) Business
Days in advance of the date on which the disclosure is to be made to enable the
other Party to review and provide comments, unless a shorter review time is
agreed.  If the compliance with an
Applicable Law requires filing of this Agreement, the filing Party shall to the
extent possible seek confidential treatment of portions of this Agreement from
the relevant competent authority and shall provide the other Party with a copy
of the proposed filings at least ten (10) Business Days prior to filing
for the other Party to review any such proposed filing.  Each Party agrees that it will obtain its own
legal advice with regard to its compliance with Applicable Laws and will not
rely on any statements made by the other receiving Party relating to such laws;

 

(iii)          made by such receiving Party to the Regulatory Authorities
as necessary for (a) the development or commercialization of a Alicaforsen
Product in a particular country, or (b) as required in connection with any
filing, application or request for Regulatory Approval in a particular country
and in either case to the extent consistent with the licenses granted under the
terms of this Agreement;

 

(iv)          made
by the receiving Party, in connection with the performance of this Agreement,
to Affiliates sublicensees, licensors, licensees, directors, officers,
employees, consultants, representatives or agents, each of whom prior to
disclosure must be bound by obligations of confidentiality and non-use at least
equivalent in scope to those set forth in this Agreement;

 

(v)           made
by the receiving Party to existing or potential acquirers; existing or
potential pharmaceutical collaborators (to the extent contemplated hereunder);
investment bankers; existing or potential investors, merger candidates,
partners, venture capital firms or other financial institutions or investors
for purposes of obtaining financing; or, bona fide strategic potential
partners; each of whom prior to disclosure must be bound by obligations of
confidentiality and non-use at least equivalent in scope to those set forth in
this Agreement; or

 

(vi)          made by the receiving Party to its
legal advisers for the purpose of seeking advice.

 

 

“Business Day” means 9.00am to 5.00pm local time on any day, other than Saturday, Sunday
or any statutory holiday or public holiday in the United States or England and
Wales.

 

“Calendar Year” means each successive period of 12 months
commencing on January 1 and ending on December 31.

 

“cGMP” means
current Good Manufacturing Practices as specified in ICH Guideline Q7A, the
United States Code of Federal Regulations, or equivalent laws, rules, or
regulations of an applicable Regulatory Authority at the time of manufacture.

 

“Commercially Reasonable Efforts”
(i) in respect of Atlantic means efforts and resources commonly used in
the biotechnology industry by companies at a similar stage of development for
products of similar commercial potential to develop and commercialize a product
owned by such a company or to which it has rights, which product is at a
similar stage in its development or product life and is of similar market
potential to the Alicaforsen Product in question and taking into account the
patent and other proprietary position of the product; and (ii) in respect
of Isis means efforts and resources commonly used by biotechnology companies of
a similar size to Isis based on market capitalization to develop a product
owned by such a company or to which it has rights, which product is at a
similar stage in its development or product life and is of similar market
potential to the Alicaforsen Product in question and taking into account the
patent and other proprietary position of the product.  If Atlantic is commercializing Alicaforsen in
a given Major Market in accordance with the Development Plan, such
commercialization will be deemed to be an example of using Commercially
Reasonable Efforts; provided, however,
that a failure to so commercialize in such a Major Market will not be dispositive
of a failure to use Commercially Reasonable Efforts.

 

“Committee Members”
has the meaning
set forth in Section 3.2.

 

“Confidential Information”
means all
information and know-how and any tangible embodiments thereof provided by or on
behalf of one Party to the other Party either in connection with the
discussions and negotiations pertaining to this Agreement or the Original
Agreement, or in the course of performing this Agreement or the Original
Agreement, including data; knowledge; practices; processes; ideas; research
plans; engineering designs and drawings; research data; manufacturing processes
and techniques; scientific, manufacturing, marketing and business plans; and
financial and personnel matters relating to the disclosing Party or to its present
or future products, sales, suppliers, customers, employees, investors or
business.

 

Exceptions. Notwithstanding the foregoing, information or
know-how of a Party will not be deemed Confidential Information for purposes of
this Agreement if such information or know-how:

 

(a)           was already known to the receiving Party,
other than under an obligation of confidentiality or non-use, at the time of
disclosure to such receiving Party;

 

 

(b)           was generally available or known to
parties reasonably skilled in the field to which such information or know-how
pertains, or was otherwise part of the public domain, at the time of its
disclosure to, or, with respect to know-how, discovery or development by, such
receiving Party;

 

(c)           became generally available or known to
parties reasonably skilled in the field to which such information or know-how
pertains, or otherwise became part of the public domain, after its disclosure
to such receiving Party through no fault of the receiving Party;

 

(d)           was disclosed to such receiving Party,
other than under an obligation of confidentiality or non-use, by a Third Party
who had no obligation to the disclosing Party not to disclose such information
or know-how to others; or

 

(e)           was independently discovered or developed
prior to disclosure by such receiving Party, as evidenced by their written
records, without the use of Confidential Information belonging to the
disclosing Party.

 

“Control” means, with respect to any Patent or
other intellectual property right, possession of the right (whether by
ownership, license or otherwise), to assign, or grant a license, sublicense or
other right to or under, such Patent or right as provided for herein without
violating the terms of any agreement or other arrangement with any Third Party
or incurring any additional financial or other obligation to a Third Party
except the obligations specifically described in Section 6.7.

 

“Cumulative
Net Sales” means the total cumulative amount of Net Sales calculated separately
for each of the Alicaforsen Products, from the first date that each such
product was approved for commercialization by a Regulatory Authority.

 

“Development
Plan” means a written plan for the development of an Alicaforsen
Product which describes the planned activities and timelines including:

 

a)              Pre-clinical studies

b)             Formulation development

c)              Clinical studies

d)             Regulatory activities

e)              Manufacturing process development and
scale up

f)                Pharmacovigilance plans

g)             Commercialization plans

 

The term “Development Plan” includes the Initial
Development Plan approved by Isis and Atlantic and attached to this Agreement
as Appendix 4.

 

“Discontinuance” means
the occurrence of any one of the following:

 

 

1. Atlantic voluntarily elects
to abandon researching, developing and/or commercializing all Alicaforsen
Products, as evidenced by a written communication from an authorized officer of
Atlantic to Isis; or

 

2.     Atlantic
fails to use Commercially Reasonable Efforts and the Quality Standard to
develop and commercialize at least one Alicaforsen Product.

 

“Discontinued Patent” has the meaning set forth in Section 9.1.4.

 

“Effective Date”
means March 7, 2007.

 

“EMEA” means
the European Regulatory Authority known as the European Medicines Agency and
any successor agency thereto.

 

“Enabled CMO”
means a Third Party engaged in the business of contract manufacturing to which
Isis has granted a license to certain of Isis’ manufacturing intellectual
property for the manufacture of oligonucleotides, including Alicaforsen API.

 

“Enema Delivery”
means a route of delivery directly into an ostomy or the rectum to achieve a
local effect in the gastrointestinal tract or a systemic therapeutic effect.

 

“Equity Cap” means [***]% of the issued and outstanding
share capital of Atlantic (on an as-issued, post financing basis).

 

“Excluded
Isis IP” means
all know how and Patents Controlled by Isis on the Effective Date and at any
time during the term of the Agreement other than (A) Alicaforsen
Patents, (B) ICAM-1 Specific Patents, (C) Isis Data, and (D) Isis
Manufacturing Know How.  For clarity,
Excluded Isis IP includes any know how and Patents Controlled by Isis which
cover Isis’ (i) formulation and delivery technology (save as expressly
claimed in the Alicaforsen Patents, ICAM-1 Specific Patents and Isis
Manufacturing Know How), (ii) RNAi technologies, (iii) microRNA
technologies, and (iv) chemical modifications and motifs, and (v) the
Excluded Manufacturing IP.

 

“Excluded
Manufacturing IP” means all Patents and know how
(including any and
all information directly relating to manufacturing methods (including related
analytical methods) of Alicaforsen API) Controlled by Isis on
the Effective Date and at any time during the term of the Agreement which claim
the manufacturing process by which Isis manufactures Alicaforsen API.

 

“Existing
Royalties” has the meaning set forth in Section 6.4.3.

 

“FDA” means the United States Food and Drug
Administration and any successor agency thereto.

 

“First
Commercial Sale” means the first sale of an Alicaforsen Product by
Atlantic, its Affiliates or a sublicensee to a Third Party in a particular
country after Regulatory Approval has been obtained.

 

 

“Follow-On Product”
means a pharmaceutical composition, formulation, dosage form, delivery system
and presentation discovered and developed by Isis after the Restatement Date
that contains a nucleic acid that hybridizes to a nucleic acid molecule
encoding ICAM-1 (alone or with other active ingredients) that has a different
chemistry than Alicaforsen.

 

“IBD” means a chronic disorder of the [***],
including without limitation, [***] or [***].

 

“ICAM-1” means intercellular adhesion molecule-1
(also called CD54).

 

“ICAM-1
Specific Patents” means (i) the Patents listed on Appendix 3 (ii) all Patents issuing therefrom, and (iii) any
other Patents Controlled by Isis during the term of this Agreement which cover
the composition, formulation or use of Alicaforsen Products, but excluding always the Alicaforsen Patents and the Patents
within Excluded Isis IP.

 

“IFRS”
means
International Financial Reporting Standards established by the International
Accounting Standards Board, as amended from time to time.

 

“IND” means
an Investigational New Drug Application (as defined in the Food, Drug and Cosmetic
Act, as amended) filed with the FDA or its foreign counterparts.

 

“IND-Supporting Toxicology
Studies” means the pharmacokinetic and toxicology studies
required to meet the requirements for filing an IND.

 

“[***]”
means a route of delivery into the human body by [***] directly into the [***]
of a human being.

 

“Initiation of a Phase I
Clinical Trial” means the first visit by the first human patient
in a Phase I Clinical Trial during which
dosing of an Alicaforsen Product or placebo occurs.

 

“Initiation
of a Pivotal Quality Clinical Trial” means the first visit by the
first patient in a Pivotal Quality Clinical Trial during which dosing of an
Alicaforsen Product or placebo occurs.

 

“Intramuscular Injection”
means an injection directly into muscle of a human being.

 

“Intravenous Injection”
means an injection directly into a vein of a human being.

 

“Isis
Background IP” has the meaning set forth in Section 13.6.1.

 

“Isis
Background Know How” has the meaning set forth in Section 13.6.1.

 

“Isis Data” has the meaning set forth in Section 2.2.1.

 

“Isis
Database” has the meaning set forth in Section 3.3.1.

 

 

“Isis
Manufacturing Know How” has the meaning set forth in Section 2.2.1.

 

“JDC” has the meaning set forth in Section 3.2.

 

“Losses” has the meaning set forth in Section 12.1.

 

“Major Market” means the [***] and [***].

 

“NDA” means a New Drug
Application filed with the FDA after completion of clinical trials to obtain
Regulatory Approval for commercial product in the United States or an
equivalent application for regulatory approval in other Major Market countries.

 

“NDA Filing” means the acceptance by
the FDA or other Regulatory Authority of the filing of an NDA for the
applicable Alicaforsen Product.

 

“Net Sales”
means the gross invoiced price charged by Atlantic or its Affiliates or
sublicensees, as appropriate, for the sale of an Alicaforsen Product to a Third
Party by Atlantic, its Affiliates or its sublicensees, as appropriate, less the
following deductions:

 

(i)            Trade and quantity discounts
actually granted;

 

(ii)           Credits for returns or allowances;

 

(iii)          Actual uncollectible amounts for
Alicaforsen Product where collectibility is determined in accordance with IFRS
consistently applied to all of Atlantic’s products;

 

(iv)          Freight, shipping insurance and other
transportation expenses directly related to the sale of the Alicaforsen Product
(if actually borne by Atlantic, its Affiliates or sublicensees without
reimbursement from any Third Party);

 

(v)           The amount of any sales tax or other
taxes assessed directly on the sale of such Alicaforsen Product which is not
refunded; and

 

(vi)          Charge back payments or rebates
granted to managed health care organizations or federal, state and local
governments, their agencies, purchasers and reimburses.

 

The transfer of Alicaforsen
Product by Atlantic or one of its Affiliates to another Affiliate shall not be
considered a sale.  Upon the sale or
other disposal of Alicaforsen Product for other than monetary consideration ,
which sales price is either customary or is reasonably expected in the country
in which such sale is made, such sale or other disposal shall be deemed to be a
sale with the consideration for such sale constituting Net Sales hereunder  at the average sales price during the
applicable reporting period generally achieved (or as achieved by similar
products) for such Alicaforsen Product in the country in which such sale or
other disposal occurred when such Alicaforsen Product is sold

 

 

alone and not with other products. Disposal of
Alicaforsen Product for or use of Alicaforsen Product in clinical trials or as
free samples shall not be deemed a sale under this definition.  Such amounts shall be determined from the
books and records of Atlantic maintained in accordance with IFRS, consistently
applied.

 

Where Alicaforsen Product
contains Alicaforsen and is sold in combination with one or more other active
ingredient(s) that are sold either as a fixed dose or as separate doses in
a single package  for a single price (a “Combination Product”), Net Sales
will be determined as follows:

 

(X divided by Y)
multiplied by Z

 

where X is the average
sales price during the applicable reporting period generally achieved for the
Alicaforsen Product in the country in which such sale or other disposal
occurred when such Alicaforsen Product is sold alone and not as a Combination
Product; Y is the sum of the average sales price during the applicable
reporting period generally achieved in that country, when sold alone, by each
product (including the Alicaforsen Product) included in the Combination Product
that is sold for the single price; and Z equals the single price at which the
Combination Product represented in Y was actually sold.  In the event one or more of the products in
the Combination Product are not sold separately, the Parties shall confer in
good faith to determine a fair market price that shall be equitable for the
value of the Alicaforsen Product within the Combination Product.

 

“Oral Delivery”
means a route of delivery using a tablet or capsule into the alimentary canal
of a human being to achieve a local effect in the gastrointestinal tract or a
systemic therapeutic effect.

 

“Patents” will include (x) all U.S. patents
and patent applications, (y) any substitutions, divisions, continuations,
reissues, renewals, registrations, confirmations, re-examinations, extensions,
supplementary protection certificates and the like, and any provisional
applications, of any such patents or patent applications, and (z) any
foreign or international equivalent of any of the foregoing.

 

“Patent Term
Extensions” has the meaning set forth in Section 9.1.6.

 

“Phase I Clinical Trial”
means the initial clinical testing of an Alicaforsen Product in humans
(first-in-humans study).

 

“Pivotal Quality Clinical Trial” means a human clinical trial of an Alicaforsen Product
designed to be of a size and statistical power to support an NDA Filing alone
or in combination with other studies.  If
it is unclear whether or not a study design will be sufficient to support an
NDA Filing (other than by virtue of the uncertainty of safety and efficacy data
from that trial) the study will be deemed to be a Pivotal Quality Clinical
Trial on the initiation of activities to support an NDA Filing.  A Phase III clinical study will be deemed to
be a Pivotal Quality Clinical Trial.

 

 

“Positive Pouchitis Clinical Trial” means a clinical
study of an Alicaforsen Product in humans conducted by Atlantic in accordance
with this Agreement that is directed to the treatment of Pouchitis, which meets
the study’s primary endpoint(s).

 

“Pouchitis”
means inflammation of the mucosa, or of the full thickness, of the intestinal
wall of an ileal or ileoanal reservoir.

 

“Quality Standard” means, with respect to research, development, manufacture or
commercialization of an Alicaforsen Product, the standard of care, quality, and
professional competence commonly used in the biotechnology industry for
products of similar commercial potential at a similar stage in its lifecycle.

 

“Regulatory
Approval”
means (a) in the United States, approval by the FDA of an NDA, or similar
application for marketing approval, and satisfaction of any related applicable
FDA registration and notification requirements (if any), and (b) in a
Major Market other than the United States, approval by Regulatory Authorities
having jurisdiction over such country of a single application or set of
applications comparable to an NDA and satisfaction of any related applicable
regulatory and notification requirements (if any).

 

“Regulatory
Authority” means any applicable government entities regulating or otherwise
exercising authority with respect to the development and commercialization of
an Alicaforsen Product.

 

“Regulatory
Documentation” means all applications, registrations, licenses, authorizations and
approvals (including all Regulatory Approvals), all correspondence submitted to
or received from Regulatory Authorities (including minutes and official contact
reports relating to any communications with any Regulatory Authority), all
supporting documents and all clinical studies and tests, including the
manufacturing batch records, relating to an Alicaforsen Product, and all data
contained in any of the foregoing, including all regulatory drug lists,
advertising and promotion documents, adverse event files and complaint files.

 

“Reverted Rights”
has the meaning set forth in Section 1.2.1.

 

“Royalty Due
Dates”
means the last working days of March, June, September and December of
each and every year during which this Agreement remains in full force and
effect.

 

“Subcutaneous Injection”
means an injection directly into the subcutaneous tissue of the human body
between the skin and the muscle of a human being.

 

“Sublicense”
means a
sublicense from Atlantic to a Third Party under the Alicaforsen Patents or the
ICAM-1 Patents to develop, use, sell, offer for sale, have sold and/or import
any Alicaforsen Product.

 

 

“Sublicense
Revenue” means
any consideration that Atlantic receives from a sublicensee in consideration
for a grant of any Sublicense, including, but not limited to, license fees,
milestone payments, and license maintenance fees, but excluding: (i) royalties
on Net Sales of Alicaforsen Products, (ii) payments made in consideration
of equity or debt securities of Atlantic at fair market value and (iii) payments
specifically committed to reimburse Atlantic for the direct cost of research
and development.  If Atlantic receives
any non-cash Sublicense Revenue, Atlantic will pay Isis, at Isis’ election,
either (x) a cash payment equal to the fair market value of Isis’
appropriate portion of the Sublicense Revenue or (y) the in-kind portion,
if practicable, of the Sublicense Revenue. 
For purposes of calculating Sublicense Revenue, a series of Sublicenses
to the same sublicensee or related sublicensees will be aggregated to constitute
a single Sublicense.

 

“Subscription
and Share Exchange Agreement” has the meaning set forth in Section 1.2.1.

 

“Systemic Delivery”
means a route of delivery directly into the bloodstream to reach and affect
cells in all areas of the body, which includes by Intravenous Injection,
Intramuscular Injection, Subcutaneous Injection and Oral Delivery.  “Systemic Delivery”
does not include [***].

 

“Term” has the meaning set
forth in Section 10.1.

 

“Third Party” means any party other than Isis or
Atlantic or their respective Affiliates.

 

“Valid Claim” means a claim of a Patent which (i) in
the case of any granted, unexpired United States or foreign Patent, shall not
have been donated to the public, disclaimed or held invalid or unenforceable by
a court of competent jurisdiction in an unappealed or unappealable decision, or
(ii) in the case of any United States or foreign patent application, is
being prosecuted in good faith and shall not have been permanently cancelled, withdrawn,
or abandoned provided that no more than eight (8) years have
passed since the earliest priority date for such application.

 

“Valid
Composition of Matter Claim” means a Valid Claim of a Patent in a given country
that covers the structure of the compound comprising the active pharmaceutical
ingredient in the Alicaforsen Product as opposed to its process of manufacture,
use or method of treatment.

 

 

APPENDIX
2

 

ALICAFORSEN
PATENTS

 

[***]

 

 

APPENDIX
3

 

ICAM-1
SPECIFIC PATENTS

 

[***]

 

 

Confidential
— Execution Version

 

APPENDIX
4

 

INITIAL
DEVELOPMENT PLAN

 

[Attached]

 

[***]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00169-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00169-of-00352.parquet"}]]